Matrix-bound nanovesicles encapsulated in hydrogels
By binding ECM hydrogels and matrix binding nanovesicles (MBVs) that do not express CD63 and CD81, the problem of insufficient activity of existing ECM hydrogels is solved, effective treatment of inflammatory diseases is achieved, and M2-like macrophages are activated. Cells enhance tissue repair ability.
Patent Information
- Application Number
- CN202380032308.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-08
- Filing Date
- 2023-04-07
- Publication Date
- 2024-12-03
AI Technical Summary
Existing extracellular matrix (ECM) hydrogels lack the complex biochemical properties of native tissues and are not active enough to effectively treat inflammatory diseases.
A composition including ECM hydrogel and matrix-bound nanovesicles (MBV) was developed, which does not express CD63 and CD81 and does not contain alkaline phosphatases, for synergistic action to reduce inflammation. The composition has an energy storage modulus of 50 Pa to 200 Pa at 37°C, a loss modulus of 5 Pa to 20 Pa, a G' to G" ratio of 4:1 to 15:1, and degraded by 50% within 24 hours to 14 days .
Through synergistic action, the composition significantly reduces inflammation, activates M2-like macrophages, regulates immune response, improves tissue repair ability, and is effectively used to treat inflammatory diseases such as ulcerative colitis.
Smart Images

Figure CN119072301A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 329,319, filed on April 8, 2022, which is incorporated herein by reference in its entirety. Technical Field
[0003] This relates to the field of extracellular matrix (ECM) compositions, in particular compositions comprising ECM hydrogels and matrix-bound nanovesicles (MBVs), and uses of these compositions.
[0004] References to Electronic Sequence Listings
[0005] The electronic Sequence Listing (Sequences.xml; size: 3,955 bytes; creation date: April 6, 2023) is incorporated herein by reference in its entirety. Background Art
[0006] Hydrogels composed of purified ECM components (e.g., collagen, hyaluronic acid, silk fibroin, laminin, and fibronectin) have been widely used in tissue engineering applications. However, these purified single-component ECM biomaterials lack the complex biochemistry of native tissue ECM. Decellularization of whole tissues or organs provides an alternative method to obtain ECM that retains the biochemistry of native tissue ECM. A major advance in the use of decellularized ECM is the ability to form hydrogels, thereby expanding the clinical applicability of decellularized ECM. However, there is still a need to enhance the activity of ECM hydrogels. Summary of the invention
[0007] Disclosed herein are compositions comprising ECM hydrogels and MBVs. These compositions provide synergistic effects, such as synergistic effects for reducing inflammation.
[0008] In some aspects, disclosed are compositions comprising an ECM hydrogel comprising a) a dissolved extracellular matrix and b) exogenous MBV derived from the extracellular matrix, wherein the MBV does not express CD63 and CD81 or is CD63 lo CD81 lo , and wherein the MBV does not contain alkaline phosphatase. The exogenous MBV is present in the ECM hydrogel at a concentration of at least about 1×10 5 Up to 1×10 20The composition may be: i) shear thinning; ii) having a storage modulus (G') of about 50 Pa to about 200 Pa and a loss modulus (G") of about 5 Pa to about 20 Pa at 37°C and a G' to G" ratio of about 4:1 to about 15:1, and iii) a degradation rate of 50% from 24 hours to 14 days.
[0009] In other aspects, a composition is disclosed, comprising: an acidic solution comprising an exogenous acid protease and dissolved extracellular matrix, such as intact ECM; and exogenous MBV derived from the extracellular matrix, wherein the MBV does not express CD63 and CD81 or is CD63 lo CD81 lo , and wherein the MBV does not contain alkaline phosphatase. The exogenous MBV is present in the composition at a concentration of at least about 1×10 5 Up to 1×10 20 particles / mL, and when the acidic solution is neutralized to a pH of about 7.0 to about 7.8, a gel is formed at a temperature above 25°C.
[0010] In further aspects, compositions are disclosed, comprising dissolved extracellular matrix, such as intact ECM; inactivated or inactivated exogenous acid proteases; and exogenous MBV derived from the extracellular matrix. The MBV does not express CD63 and CD81 or is CD63 lo CD81 lo , and does not contain alkaline phosphatase. These exogenous MBVs are present in the composition at a concentration of at least about 1×10 5 Up to 1×10 20 The composition enters a liquid phase at a temperature below 25°C and a gel phase at a temperature above 25°C, with a pH between about 7 and about 7.8. The ECM may have been dissolved by an acid protease.
[0011] The above and other features and advantages of the present invention will become apparent from the following detailed description of several aspects made with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 A schematic overview of a study in which ulcerative colitis was induced in study animals and a treatment regimen was provided. The animals were given 5.5% DSS water for 6 days and then normal water until day 4. Treatment was given on days 0 to 4, either daily by enema or by injection on days 0 and 2. Colon tissue was removed from the test animals on day 4.
[0013] Figures 2A-2C A series of photographs illustrating exemplary enema delivery preparation and process. Figure 2AA method for performing an enema is shown. Cutting site for winged infusion catheter and needle removal. Figure 2B The needle is shown cut from the catheter and two marks are made (black arrows), one at 8 cm from the end to ensure consistent enema depth and another at 4 cm to ensure even withdrawal of the catheter as material is injected. Figure 2C The digital image shows how the catheter is inserted through the anus of the test animal and into the colon and slowly delivers 5 mL of enema material.
[0014] Figure 3 Graphs are provided showing food consumption (right) and water consumption (left) measured daily for each animal during the study.
[0015] Figure 4 The graph shows the initial body weight fraction of the animals during the study. The body weight of each animal was measured daily and normalized to the initial body weight of the animal on day -6.
[0016] Figure 5 A graph of the stool consistency scores (left) and stool blood content scores (right) obtained for each animal each day is provided. The ES Lab Pack fecal occult blood test measured fecal blood content and was scored [0 = no blood, 2 = occult blood, 4 = heavy bleeding]. Fecal consistency was scored [0 = normal, 2 = loose, 4 = diarrhea]. The score was determined by normalizing the score of an individual rat to the score given on day 0.
[0017] Figure 6 The bar graphs provided are colon length (left) and gross anatomical scores of the removed colons (right). For the bar graph on the left, the length of each colon from the cecum to the rectum was measured after removal. All groups given DSS appeared to have short colons compared to the healthy groups. For the bar graph on the right, the removed colons were scored for macroscopic evidence of ulceration and inflammation by a blinded investigator. All treated groups had lower scores (less severe disease) compared to the sick controls.
[0018] Figures 7A-7G Provides images of histological analysis of H&E stained rat colon tissue sections from experimental animals, Fig. 7A -F provides the image Figure 7G Magnified view of a larger tissue sample section shown in . Fig. 7A and 7G (i) is an image of a healthy animal. Figure 7B and 7G (ii) is an image of a sick animal. Figure 7C and 7G (vi) is an image of a sick animal receiving MBV saline enema. Fig.7D and 7G (iii) is an image of a diseased animal that received ECM hydrogel enema. Fig. 7E and 7G (v) is an image of a diseased animal receiving MBV-injected ECM hydrogel enema. Figure 7F and 7G (iv) is an image of a sick animal that received MBV via intravenous injection.
[0019] Figures 8A-8B Surface markers of exosomes, bone microvesicles (MVs), and MBVs were compared. TM The Exosome Antibody Kit (System Biosciences) compared the results of the levels of various markers of interest in mouse exosomes, mouse bone matrix vesicles (bone MVs), and mouse matrix-bound nanovesicles (MBVs). Fig. 8A A digital image of the kit is provided, Figure 8B The graphs show the relative expression of each marker of interest in exosomes, bone MVs, and MBVs. The data show that MBVs are distinct from exosomes and bone microvesicles (MVs) based on their profile of surface markers. As shown in the bar graphs in the lower panel, MBVs express no or low levels of CD63, EpCAM, ANXA5, TSG101, GM130, FLOT1, ICAM1, ALIX, and CD81 compared to the levels of these markers in bone MVs or exosomes.
[0020] Fig. 9 Western blots show that the bone MV markers Annexin V and tissue non-specific alkaline phosphatase (TNAP) are expressed by bone MVs. Lysates prepared from 1711A cells were used as positive controls. The results of this experiment show that matrix-bound nanovesicles (MBVs) lack any expression of the bone microvesicle markers TNAP and Annexin V. Plasma exosomes do express Annexin V, but not TNAP. These results clearly distinguish MBVs from exosomes and bone microvesicles. It is worth noting that the MBVs used were isolated from muscle tissue.
[0021] Fig.10The bar graph shows the different effects of exosomes, MVs, and MBVs on gene expression for macrophage activation. MBVs have different immunomodulatory effects compared to exosomes or bone MVs that do not have such effects, i.e., they increase M2 macrophages. Bone marrow-derived macrophages (BMDMs) obtained from mice were either untreated (M0) or treated for 24 h with the following test articles: IFNγ+LPS to induce an M1 phenotype (M1), IL-4 to induce an M2-like phenotype (M2), plasma-derived exosomes, 17A cell-derived bone MVs, or MBVs isolated from muscle. After treatment, the fold changes in the expression of the indicated genes (Arg, CD206, Fixx, IL-6, INOS, and TNF) were assessed by qPCR. Fig.10 It was shown that MBV's downregulation of proinflammatory markers IL-6 and TNF-α was clearly distinct from the downregulation of the same two inflammatory mediators by exosomes and bone MVs. MBV had a potent anti-inflammatory effect; whereas exosomes and bone MVs did not.
[0022] Figures 11A-11E are high magnification views showing histological (hematoxylin and eosin) images of the colon in each treatment group (Disease: Fig.11A ; ECM hydrogel enema: Fig. 11B MBV+PBS enema: Fig. 11C ;MBV-injected ECM hydrogel enema; Fig.11D ; Double MV intravenous injection: Fig.11E ). These represent the results for each group.
[0023] Fig. 12A -E Bar graph showing quantification of the ratio of M2:M1 macrophages in the following layers of the treated samples: Colon ( Fig. 12A )、mucosal( Fig. 12B ), muscularis ( Fig. 12C ) and submucosa ( Fig.12D ).exist Fig.12E Quantification of CD68+ cells for each treatment is shown in . DETAILED DESCRIPTION
[0024] MBV is an indispensable component of the ECM, different from exosomes, and effectively redirects excessive inflammation in preclinical models (Hussey GS, et al. (2020) Lipidomics and RNA sequencing reveal a novel subpopulation of nanovesicles within extracellular matrix biomaterials. Sci Adv 6(12):eaay4361; van der Merwe Y, et al. (2019) Matrix-bound nanovesicles preventischemia-induced retinal ganglion cell axon degeneration and death andpreserve visual function. Sci Rep 9(1):3482). In some aspects, MBV contains immunomodulatory miRNAs, proteins, and lipids and is rapidly taken up by macrophages, thereby triggering signaling cascades and regulating gene expression necessary for phenotypic switching, a phenomenon that has been well studied in the context of ECM-based biomaterials (Hussey GS, et al. (2019) Matrix bound nanovesicle-associated IL-33activates a pro-remodeling macrophage phenotype via a non-canonical, ST2-independent pathway. J Immunol Regen Med 3: 26-35; Huleihel L, et al. (2017) Macrophage phenotype in response to ECM bioscaffolds. Semin Immunol 29: 2-13). In addition, in some aspects, MBV administration results in the activation of regulatory T cells (T REG) upregulation, a phenomenon that has been previously characterized in the context of ECM-based biomaterials. MBV rapidly and effectively induces restorative immune responses in hostile environments including rheumatoid arthritis, traumatic muscle injury, ulcerative colitis, and esophageal cancer (Huleihel L, et al. (2017) Matrix-Bound Nanovesicles Recapitulate Extracellular Matrix Effects on Macrophage Phenotype. Tissue Eng Part A 23(21-22): 1283-1294; Dziki JL, et al. (2016) Immunomodulation and Mobilization of progenitor cells by Extracellular Matrix Bioscaffolds for Volumetric Muscle Loss Treatment. Tissue Eng Part A 22(19-20): 1129-1139; Keane TJ, et al. (2017) Restoring Mucosal Barrier Function and Modifying Macrophage Phenotype with an Extracellular Matrix Hydrogel: Potential Therapy for Ulcerative Colitis. J Crohns Colitis 11(3):360-368; Saldin LT, et al. (2019) Extracellular Matrix Degradation Products Downregulate Neoplastic EsophagealCell Phenotype.Tissue Eng Part A 25(5-6):487-498.)
[0025] Cytokine cargo stored within MBV supports reparative and regulatory M2 macrophages and controls bacterial infection and inflammation after acute lung injury (Liu Q, et al. (2019) IL-33-mediated IL-13secretion by ST2+T REGcontrols inflammation after lung injury. JCI Insight 4 (6)). ECM bioscaffolds can be used in various clinical applications involving musculoskeletal tissue, gastrointestinal tissue, urogenital tissue and CNS tissue (Badylak SF (2007) The extracellular matrix as a biologic scaffold material. Biomaterials. 28 (25): 3587-3593). ECM is composed of structural and functional molecules secreted by each tissue's intrinsic cells, which define tissue identity. This xenogeneic scaffold does not cause adverse innate or adaptive immune responses, but supports anti-inflammatory and reparative innate and adaptive immune responses (Brown BN, et al. (2009) Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials. 30 (8): 1482-1491). The use of these natural biomaterials is often associated with (at least) partial restoration of functional, site-appropriate tissue; a process known as "constructive remodeling" (Badylak SF (2007) The extracellular matrix as a biologic scaffold material. Biomaterials. 28(25): 3587-3593). ECM bioscaffolds or degradation products of ECM bioscaffolds have been shown to direct tissue repair by recruiting anti-inflammatory M2-like macrophages and helper T cell type 2 (Th2) cell responses, which are often associated with reduced local inflammation and constructive crosstalk with progenitor cells.
[0026] Matrix-bound nanovesicles (MBVs) activate M2-like reparative and anti-inflammatory macrophage phenotypes. Studies have shown that MBVs are a unique class of extracellular vesicles that are distinguished from exosomes found in body fluids (Hussey GS, et al. (2020) Lipidomics and RNA sequencing reveal a novel subpopulation of nanovesicles within extracellular matrix biomaterials. Sci Advances. 6 (12): eaay4361). Because MBVs can survive even harsh tissue decellularization processes, they can play a fundamental role in tissue and organ development and homeostasis across species and play a regulatory role in tissue responses to injury. MBVs can be derived from a variety of different tissue sources. MBVs are abundant, can be lyophilized, have high stability, and can be easily administered by tracheal instillation or nebulization.
[0027] MBV can reproduce the effects of ECM on enhancing the pro-remodeling macrophage phenotype. Macrophage gene and protein expression, cell surface markers, and functional capacity determined by phagocytic activity, nitric oxide (NO) production, and observed antimicrobial activity best represent the regulatory / anti-inflammatory phenotype after MBV treatment, which is consistent with previous reports describing the effects of ECM-based bioscaffolds on macrophage phenotype and function. (See, e.g., PCT Publication No. WO 2017 / 151862A1). MBV has been shown to exert immunomodulatory effects through a combination of miRNA, protein, and phospholipid cargo. For example, compared to exosomes present in body fluids, MBV is highly enriched in pro-resolving lipid mediators activated by different phospholipases, which depend on the pro- / anti-inflammatory background of the extracellular environment (Hussey GS, et al. (2020) Lipidomics and RNA sequencing reveal a novel subpopulation of nanovesicle within extracellular matrix biomaterials. Sci Adv 6 (12): eaay4361). In addition, MBVs are a rich and stable source of IL-33, which signals immune cells toward a reparative M2-like phenotype while also stimulating T cells in the injured lung. REG Repair and regulatory functions (Liu Q, et al. (2019) IL-33-mediated IL-13secretion by ST2+T REGcontrols inflammation after lung injury. JCI Insight 4(6)). IL-33 delivery reduces bacterial superinfection after H1N1 infection by improving bacterial clearance (Robinson KM, et al. (2018) Novel protective mechanism for interleukin-33 at the mucosal barrier during influenza-associated bacterial superinfection. Mucosal immunology. 11(1): 199-208). In addition, MBV enriches miRNA 125b-5p, 143-3p, and 145-5p. Inhibition of these miRNAs in macrophages is associated with gene and protein expression profiles that are more consistent with a pro-inflammatory phenotype rather than an anti-inflammatory / regulatory phenotype (Huleihel L, et al. (2017) Matrix bound nanovesicles recapitulate extracellular matrix effects on macrophage phenotype. Tissue Eng Part A). Disclosed herein is a composition comprising both MBV and an ECM hydrogel.
[0028] Disclosed herein are compositions comprising an extracellular matrix (ECM) hydrogel and matrix-bound nanovesicles (MBVs). These compositions provide synergistic effects and can be used to treat a subject.
[0029] the term
[0030] Unless otherwise indicated, technical terms are used in conventional usage. Definitions of many common terms in molecular biology can be found in Krebs et al. (eds.), Lewin's genes XII, published by Jones & Bartlett Learning, 2017. The following explanations of terms and methods are provided to better describe the present disclosure and guide those of ordinary skill in the art to implement the present disclosure. The singular forms "a", "an" and "the" refer to one or more, unless the context clearly stipulates otherwise. For example, the term "comprising MBV" includes a single or more MBVs and is considered equivalent to the phrase "comprising at least one MBV". The term "or" refers to a single element or a combination of two or more elements of the alternative elements, unless the context clearly indicates otherwise. As used herein, "comprises" means "includes". Therefore, "comprising A or B" means "including A, B, or A and B", without excluding other elements. It should also be understood that, unless otherwise stated, any and all molecular weight or molecular mass values or ratios given for compositions are approximate and are for description purposes. The term "or" refers to a single element or a combination of two or more elements of the alternative elements, unless the context clearly indicates otherwise. Accession number dates are sequences available as of at least April 5, 2021. All references, patent applications, and publications cited herein and Accession numbers are incorporated herein by reference. Unless otherwise specified, "about" means within 5%. In the event of a conflict, the present specification (including term explanations) shall prevail. For ease of reference to various aspects of this disclosure, specific terms are explained as follows:
[0031] Acidic protease: An enzyme that cleaves peptide bonds, wherein the activity of the enzyme in cleaving peptide bonds is enhanced at acidic pH. For example, but not limited to, acidic proteases may include pepsin and trypsin.
[0032] Administration: Introducing a composition (e.g., MBV or a pharmaceutical formulation comprising MBV) into a subject via a selected route. The route can be local or systemic. For example, if the selected route is intravenous, the composition is administered by introducing the composition into a vein of the subject. If the selected route is local, the composition can be administered by introducing the composition directly into a tissue of the subject.
[0033] Animal: A living multicellular vertebrate organism, a class that includes, for example, mammals and birds. The term "mammal" includes both human and non-human mammals. Likewise, the term "subject" includes both human and animal subjects.
[0034] Biocompatible: Any material that, when implanted into a mammalian subject, does not cause an adverse reaction in said subject. A biocompatible material is able to perform its intended function when introduced into an individual, is not toxic or harmful to said individual, and does not induce an immune rejection reaction to said material in said subject.
[0035] Centrifugation: The process of applying centrifugal force to a mixture, causing the denser components of the mixture to move away from the centrifuge axis relative to the less dense components of the mixture. The force exerted on the mixture is a function of the speed of the centrifuge rotor and the radius of rotation. In most applications, the force of rotation causes the sediment (pellet) to collect at the bottom of the centrifuge tube, and the remaining solution is properly called the "supernatant" or "supernatant". In other similar applications, density-based separation or "gradient centrifugation" techniques are used to separate specific species from a mixture that contains components that are more and less dense than the desired component.
[0036] During the circular motion of a centrifuge rotor, the force applied is the product of the radius of rotation and the angular velocity, where the force is conventionally expressed as an acceleration relative to "g", the standard acceleration due to gravity at the surface of the earth. The applied centrifugal force is called the "relative centrifugal force" (RCF) and is expressed in multiples of "g".
[0037] Comminution (comminution and comminuting): The process of reducing larger particles to smaller particles, including but not limited to by grinding, blending, chopping, slicing, grinding or cutting. ECM can be comminuted in any form, including but not limited to hydrated form, frozen form, air-dried form, lyophilized form, powder form or sheet form. "Comminuted ECM" includes intact collagen. Comminuted ECM has not been digested by ultrasound or enzymatic digestion, such as without digestion by a protease (e.g., an acid protease).
[0038] Contact: Arranged in direct physical contact (either solid or liquid).
[0039] Cytokine: The term "cytokine" is used as a general term for a diverse group of soluble proteins and peptides that function as humoral regulators at nanomolar to picomolar concentrations, modulating the functional activities of individual cells and tissues under normal or pathological conditions. These proteins also directly mediate interactions between cells and regulate processes occurring in the extracellular environment. Examples of cytokines include, but are not limited to, tumor necrosis factor-α, interleukin (IL)-6, IL-10, IL-12, transforming growth factor, and interferon-γ.
[0040] Diagnosis: The process of identifying a disease through its signs, symptoms, and the results of various tests. The conclusion reached through this process is also called "diagnosis." Common forms of diagnostic testing include, but are not limited to, blood tests, medical imaging, and biopsies.
[0041] Enrichment: A process in which the ratio of the amount of a component of interest (eg, nanovesicles) in a mixture to the amounts of other components in the mixture increases after the enrichment process compared to before the enrichment process.
[0042] Extracellular matrix (ECM): A complex mixture of structural and functional biomolecules and / or biomacromolecules, including but not limited to structural proteins, specific proteins, proteoglycans, glycosaminoglycans and growth factors, which surround and support cells within tissues and are acellular unless otherwise specified. ECM preparations can be considered "decellularized" or "acellular", meaning that the cells have been removed from the source tissue by the processes described herein and known in the art. The so-called "ECM-derived materials", such as "ECM-derived nanovesicles", "matrix-bound nanovesicles", "MBVs" or "ECM-derived nanovesicles", refer to nanovesicles prepared from natural ECM or in vitro sources, wherein the ECM is produced by cultured cells. "Intact extracellular matrix" and "intact ECM" refer to an extracellular matrix (such as but not limited to the pulverized ECM described herein) that retains its structural and non-structural biomolecule activity, including but not limited to collagen, elastin, laminin, glycosaminoglycans, proteoglycans, antimicrobial agents, chemical attractants, cytokines and growth factors. The activity of the biomolecules within the ECM can be removed chemically or mechanically, for example by crosslinking and / or by dialysis of the ECM. An intact ECM is substantially free of crosslinking and / or dialysis, meaning that the ECM has not been subjected to conditions other than dialysis and / or crosslinking processes or processes that occur naturally during storage and handling of the ECM prior to preparation of the enzymatic ECM hydrogel dissolution. Thus, an ECM that is substantially crosslinked and / or dialyzed (except in a negligible manner that does not materially affect the gelation and functional characteristics of the ECM for use as described herein) is not considered to be "intact".
[0043] Exogenous: Derived from a different source. Exogenous MBVs are separately generated, e.g., extracted from an ECM source, and added to an ECM hydrogel, where endogenous MBVs may or may not be present. Exogenous MBVs may be derived from the same tissue as the ECM used to make the ECM hydrogel, or from a different tissue. Exogenous MBVs may be derived from the same species as the ECM used to make the ECM hydrogel, or from a different species.
[0044] Gel: A state of matter intermediate between liquid and solid, generally defined as a cross-linked polymer network swollen in a liquid medium. In general, a gel is a two-phase colloidal dispersion containing a solid and a liquid in which the amount of solid is greater than that in the two-phase colloidal dispersion known as a "sol." Thus, a "gel" has some properties of a liquid (i.e., elasticity and deformability of shape) and some properties of a solid (e.g., discrete shapes sufficient to maintain three-dimensional dimensions on a two-dimensional surface). "Gelation time," also called "gel time," is the time required for a composition to become nonflowable under moderate stress.
[0045] Gelation: Formation of gel from sol.
[0046] Hydrogel: A network of hydrophilic polymer chains, sometimes in the form of a colloidal gel, in which water is the dispersion medium. A hydrogel is a natural or synthetic polymer network that is highly absorbent. A hydrogel also has a flexibility similar to that of natural tissue. "Acoustic" hydrogels, such as acoustic ECM hydrogels, are produced using ultrasonic energy. Characteristics of these hydrogels are disclosed herein. For hydrogels, G' (storage modulus) is typically an order of magnitude greater than G" (loss modulus). "Enzymatic" ECM hydrogels, produced by enzymatic digestion of ECM. The viscosity of enzymatic hydrogels increases when heated to a physiological temperature close to 37°C. For example, enzymatic hydrogels are formed from injectable solutions at temperatures below 37°C, and the injectable solutions form gels at a physiological temperature of 37°C.
[0047] Inflammation: Inflammation is a local protective response caused by tissue damage that serves to isolate inflammatory factors. Inflammation is caused by a complex biological response of vascular tissue to harmful stimuli (such as pathogens, damaged cells, or irritants). This is an organism's protective attempt to remove harmful stimuli and initiate the tissue healing process. The inflammatory response is characterized by the accumulation of leukocytes throughout the body or locally at the site of inflammation. The inflammatory response can be measured by many methods, including but not limited to measuring the number of leukocytes, the number of polymorphonuclear neutrophils (PMNs), measures of the degree of PMN activation (such as luminol-enhanced chemiluminescence), or measures of the amount of cytokines present. C-reactive protein is a marker of systemic inflammatory response.
[0048] Inflammatory disorders are disorders in which inflammation disrupts normal or routine physiological functions. Inflammatory disorders can include a variety of conditions, such as autoimmune disorders (inappropriate inflammatory responses to endogenous antigens), and disorders caused by inflammation from traumatic injury or exogenous antigens. Primary inflammatory disorders are diseases or disorders caused by inflammation itself. Secondary inflammatory disorders are inflammation caused by another disorder. Inflammation can lead to inflammatory disorders, such as acute respiratory distress syndrome (ARDS).
[0049] In some aspects, anti-inflammatory drugs are administered to treat inflammatory diseases or conditions, such as ARDS. Anti-inflammatory drugs include, but are not limited to, nonsteroidal anti-inflammatory drugs (NSAIDs, such as aspirin, ibuprofen, and naproxen), anti-leukotrienes, immunoselective anti-inflammatory derivatives (ImSAIDs), biologically active compounds, steroids (e.g., corticosteroids), and opioids.
[0050] Isolated: An "isolated" biological component (e.g., nucleic acid, protein cell, or nanovesicle) has been substantially separated or purified from the cells of the organism in which the component naturally occurs or from other biological components in the ECM. Nucleic acids and proteins that have been "isolated" include nucleic acids and proteins purified by standard purification methods. Isolated MBVs are removed from the fibrous material of the ECM. The term also encompasses nucleic acids and proteins prepared by recombinant expression in a host cell and chemically synthesized nucleic acids.
[0051] Isotonic Buffer Solution: A solution buffered to a pH between 7.2 and 7.8 with a balanced salt concentration to promote an isotonic environment.
[0052] Lysine oxidase (Lox): A copper-dependent enzyme that catalyzes the formation of aldehydes from lysine residues in collagen and elastin precursors. These aldehydes are highly reactive and react spontaneously with other lysine oxidase-derived aldehyde residues or unmodified lysine residues. In vivo, this allows collagen and elastin to crosslink, thereby contributing to the stability of collagen fibrils and the integrity and elasticity of mature elastin. Complex crosslinks with different structures are formed in collagen (pyridoline derived from three lysine residues) and elastin (descones derived from four lysine residues). Genes encoding Lox enzymes have been cloned from a variety of organisms (Hamalainen et al., Genomics 11:508, 1991; Trackman et al., Biochemistry 29:4863, 1990; incorporated herein by reference). Residues 153-417 and residues 201-417 of the human lysine oxidase sequence have been shown to be important for catalytic function. There are four Lox-like subtypes, called LoxL1, LoxL2, LoxL3 and LoxL4.
[0053] Macrophage: A white blood cell that engulfs and degrades cellular debris, foreign material, microorganisms, and cancer cells. In addition to their role in phagocytosis, these cells play important roles in development, tissue maintenance and repair, and innate and adaptive immunity because they recruit and influence other cells, including immune cells (e.g., lymphocytes). Macrophages can exist in a variety of phenotypes, including those known as M1 and M2. Macrophages that primarily perform pro-inflammatory functions are known as M1 macrophages (CD86 + / CD68 + ), while macrophages that reduce inflammation and promote and regulate tissue repair are called M2 macrophages (CD206 + / CD68 + ). Markers that define various phenotypes of macrophages vary from species to species. It should be noted that macrophage phenotypes are represented by a spectrum ranging between the extremes of M1 and M2. F4 / 80 (encoded by the adhesion G protein-coupled receptor E1 (ADGRE1) gene) is a macrophage marker, see Accession Nos. NP_001243181.1, April 6, 2018 and NP_001965, March 5, 2018, both of which are incorporated herein by reference. Without wishing to be bound by theory, it is believed that MBV has the ability to modulate macrophage phenotype, resulting in an increase in M2-like, regulatory, or pro-remodeling macrophages. The effects of MBV on macrophages are further characterized in PCT Publication No. WO 2017 / 151862A1, which is incorporated herein by reference in its entirety. In some aspects, the MBV of the present invention can be used to induce an M2 phenotype in macrophages and inhibit M1 macrophages in a subject.
[0054] MicroRNA: A small non-coding RNA of about 17 to about 25 nucleotide bases in length that regulates gene expression post-transcriptionally, usually by inhibiting translation of target mRNA. MicroRNA ("miRNA" or "miR") can act as a negative regulator, so the higher the amount of a specific miRNA, the lower the target gene expression level. There are three forms of miRNA, primary miRNA (pri-miRNA), precursor miRNA (pre-miRNA) and mature miRNA. Primary miRNA (pri-miRNA) is expressed in the form of a stem-loop structure transcript of about a few hundred bases to more than 1 kb. The pri-miRNA transcript is cleaved in the nucleus by an RNase II endonuclease called Drosha, which cleaves the two strands of the stem near the base of the stem loop. Drosha cleaves the RNA duplex in a staggered cleavage manner, leaving a 5' phosphate and a 2-nucleotide overhang at the 3' end. The cleavage product, the precursor miRNA (pre-miRNA), is about 60 to about 110 nucleotides long and has a hairpin structure formed in a folded manner. Pre-miRNA is transported from the nucleus to the cytoplasm by Ran-GTP and exportin-5. Pre-miRNA is further processed in the cytoplasm by another RNase II endonuclease called Dicer. Dicer recognizes 5' phosphate and 3' overhangs and cleaves the loop at the stem-loop junction to form a miRNA duplex. The miRNA duplex binds to the RNA-induced silencing complex (RISC), wherein the antisense strand is preferentially degraded, and the mature miRNA of the sense strand guides RISC to its target site. Mature miRNA is the miRNA in biologically active form, with a length of about 17 to about 25 nucleotides.
[0055] Nanovesicle: Extracellular vesicle, i.e., nanoparticles with a diameter of about 10 to about 1,000 nm. Nanovesicles are lipid membrane-bound particles that carry biologically active signaling molecules (e.g., microRNAs, proteins) and other molecules. Typically, the nanovesicles are limited by a lipid bilayer, and the biomolecules are enclosed and / or can be embedded in the bilayer. Therefore, nanovesicles include a lumen surrounded by a plasma membrane. Different types of vesicles can be distinguished based on diameter, subcellular origin, density, shape, deposition rate, lipid composition, protein markers, nucleic acid content, and source (e.g., from the extracellular matrix region or secreted). Nanovesicles can be identified by their source (e.g., matrix-bound nanovesicles of ECM (see above)), protein content, and / or miR content.
[0056] "Exosomes" or "fluid-phase extracellular vesicles (EVs)" are membranous vesicles secreted by cells, ranging in diameter from 10 to 150 nm. Typically, late endosomes or multivesicular bodies contain intraluminal vesicles, which are formed by budding inward from the limited endosomal membrane and fragmentation of vesicles into these enclosed vesicles. These intraluminal vesicles are then released from the multivesicular body lumen into the extracellular environment, usually body fluids (such as blood, cerebrospinal fluid or saliva) during exocytosis after fusion with the plasma membrane. Exosomes are produced inside cells when a segment of the membrane is invaginated and endocytosed. The internalized fragments are broken down into smaller vesicles and eventually excreted from the cell, containing proteins and RNA molecules, such as mRNA and miRNA. Plasma-derived exosomes mainly lack ribosomal RNA. Extracellular matrix-derived exosomes include specific miRNA and protein components and have been shown to be present in almost all body fluids, such as blood, urine, saliva, semen and cerebrospinal fluid. Exosomes may express CD11c, CD63, CD81 and / or CD9 and may therefore be CD11c + and / or CD63 + and / or C81 + and / or CD9 + . There is no high level of lysine oxidase on the surface of exosomes.
[0057] "ECM-derived nanovesicles," "matrix-bound nanovesicles," "MBVs," or "ECM-derived nanovesicles" all refer to the same membrane-bound particles present in the extracellular matrix, ranging in size from 10 nm to 1000 nm, containing bioactive signaling molecules such as proteins, lipids, nucleic acids, growth factors, and cytokines that influence cell behavior. These terms are interchangeable and refer to the same vesicles. These nanovesicles are embedded within and bound to the ECM, rather than simply attached to surfaces or freely circulating in body fluids. These nanovesicles tolerate harsh isolation conditions, such as freeze-thaw and digestion with proteases (e.g., pepsin, elastase, hyaluronidase, proteinase K, and collagenase), as well as digestion with detergents. MBVs are distinct from other extracellular vesicles, including exosomes, and have a different phospholipid composition than exosomes. MBVs, unlike bone matrix vesicles, do not express alkaline phosphatase. In some cases, MBVs can also be distinguished from exosomes based on the fact that exosomes generally lack certain markers.
[0058] In some aspects, MBV is characterized by one or more of the following protein expression or lipid content characteristics:
[0059] (i) Compared to other vesicles (e.g., exosomes), MBVs may not express one or more of CD63 and / or CD81 and / or CD9, or have low or barely detectable levels of CD63 and / or CD81 and / or CD9 (CD63 lo and / or CD81 lo and / or CD9 lo ) (See, e.g., Example 1). Low, barely detectable, or absent expression of CD63 and / or CD81 and / or CD9 in MBV can be distinguished using a variety of methods, such as antibody-based methods, such as Western blot or flow cytometry (see, e.g., Bashashati and Brinkman, Adv Bioinformatics, 2009: 584603). In some aspects, MBV expression of CD63 and / or CD81 and / or CD9 is considered low or barely detectable if the expression of CD63 and / or CD81 and / or CD9 in MBV is at least one standard deviation lower or at least two standard deviations lower than the mean expression of other vesicles (e.g., exosomes) compared to other vesicles;
[0060] (ii) the MBV has a phospholipid content wherein at least 55% of the total phospholipids comprise combined phosphatidylcholine (PC) and phosphatidylinositol (PI);
[0061] (iii) MBV has a phospholipid content in which 10% or less of the total phospholipids comprises sphingomyelin (SM);
[0062] (iv) the MBV has a phospholipid content in which 20% or less of the total phospholipids comprise phosphatidylethanolamine (PE);
[0063] (v) MBV has a phospholipid content in which 15% or more of the total phospholipid content comprises phosphatidylinositol (PI), the percentage representing the percentage of lipid concentration.
[0064] In some aspects, MBV is characterized by all of the following features:
[0065] (i) does not express one or more of CD63 and / or CD81 and / or CD9, or has low or almost undetectable levels of CD63 and / or CD81 and / or CD9 (CD63 lo and / or CD81 lo and / or CD9 lo ) (as described above);
[0066] (ii) a phospholipid content wherein at least 55% of the total phospholipids comprises phosphatidylcholine (PC) and phosphatidylinositol (PI) combined;
[0067] (iii) a phospholipid content in which 10% or less of the total phospholipids comprises sphingomyelin (SM);
[0068] (iv) a phospholipid content in which 20% or less of the total phospholipids comprises phosphatidylethanolamine (PE); and
[0069] (v) A phospholipid content wherein 15% or more of the total phospholipid content is phosphatidylinositol (PI).
[0070] In some aspects, MBV is characterized by all of the following features:
[0071] (i) a phospholipid content wherein at least 55% of the total phospholipids comprises phosphatidylcholine (PC) and phosphatidylinositol (PI) combined;
[0072] (ii) a phospholipid content in which 10% or less of the total phospholipids comprises sphingomyelin (SM);
[0073] (iii) a phospholipid content in which 20% or less of the total phospholipids comprises phosphatidylethanolamine (PE); and
[0074] (iv) a phospholipid content wherein 15% or more of the total phospholipid content is phosphatidylinositol (PI).
[0075] In some aspects, the MBV is characterized by one or more of the following features:
[0076] (i) a phospholipid content wherein at least 55% of the total phospholipids comprises phosphatidylcholine (PC) and phosphatidylinositol (PI) combined;
[0077] (ii) a phospholipid content in which 10% or less of the total phospholipids comprises sphingomyelin (SM);
[0078] (iii) a phospholipid content in which 20% or less of the total phospholipids comprises phosphatidylethanolamine (PE); and
[0079] (iv) a phospholipid content wherein 15% or more of the total phospholipid content is phosphatidylinositol (PI).
[0080] In some aspects, the MBV is characterized by one or more of the following features:
[0081] (i) does not contain detectable levels of alkaline phosphatase;
[0082] (ii) does not contain detectable levels of osteopontin;
[0083] (iii) does not contain detectable levels of osteoprotegerin;
[0084] (iv) does not contain detectable levels of complement C5; and / or
[0085] (v) Contains no detectable levels of C-reactive protein.
[0086] In some aspects, MBV contains IL33 and is IL33 + .
[0087] The ECM from which the MBVs are isolated may be tissue ECM, may be produced by cells in culture, or may be purchased from a commercial source.
[0088] Pharmaceutically acceptable carriers: Pharmaceutically acceptable carriers used in the claimed pharmaceutical formulations are conventional. Remington's Pharmaceutical Sciences, by EW Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975) describes compositions and formulations suitable for drug delivery of the fusion proteins disclosed herein.
[0089] In general, the character of the carrier will depend on the specific mode of administration adopted. For example, parenteral formulations generally include injectable fluids, which include pharmaceutically and physiologically acceptable fluids, such as water, physiological saline, balanced salt solution, aqueous glucose solution, glycerol, etc. as vehicles. For solid compositions (for example, powders, pills, tablets or capsule forms), conventional non-toxic solid carriers can include, for example, mannitol, lactose, starch or magnesium stearate of pharmaceutical grade. In addition to biological neutral carriers, the pharmaceutical preparations to be used can also contain a small amount of non-toxic auxiliary substances, such as wetting agents or emulsifiers, preservatives and pH buffers, such as sodium acetate or sorbitan monolaurate.
[0090] Pharmaceutical agent: A compound or composition capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject or cell.
[0091] Phospholipids: A class of lipids whose structure consists of two hydrophobic fatty acid tails and a hydrophilic head (composed of a phosphate group). The main classes of phospholipids include phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylinositol (PG), sphingomyelin (SM), cardiolipin (CL), phosphatidic acid (PA) and dimonoacylglycerophosphate (BMP). Phospholipids can be measured in a variety of ways. For example, global lipidomics and redox lipidomics based on liquid chromatography-mass spectrometry (LC-MS) can be used. In some aspects, the content of a specific phospholipid is expressed as a percentage concentration of total phospholipids (e.g., total phospholipids in MBV), where the percentage concentration is weight / weight (w / w).
[0092] Polynucleotide: A nucleic acid sequence (e.g., a linear sequence) of any length. Thus, polynucleotides include oligonucleotides, and also include gene sequences found in chromosomes. An "oligonucleotide" is a plurality of linked nucleotides linked by natural phosphodiester bonds. An oligonucleotide is a polynucleotide between 6 and 300 nucleotides in length. An oligonucleotide analog refers to a portion that functions similarly to an oligonucleotide but has a non-naturally occurring portion. For example, an oligonucleotide analog may contain a non-naturally occurring portion, such as an altered sugar moiety or intersugar linkage, such as a phosphorothioate oligodeoxynucleotide. Functional analogs of naturally occurring polynucleotides can bind to RNA or DNA, and include peptide nucleic acid (PNA) molecules.
[0093] Prophylactic: As used herein refers to drugs or treatments designed and used to prevent a disease or condition from occurring. As used herein, the terms "prophylactic" and "prevention" are used interchangeably.
[0094] Purification: The term "purification" does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified preparation of nucleic acid molecules refers to a preparation in which the referenced nucleic acid is purer than it is in its natural environment within a cell. For example, a nucleic acid preparation is purified such that the nucleic acid accounts for at least 50% of the total protein content of the preparation. Similarly, a purified MBV preparation is one in which the exosomes are purer than in an environment including cells, in which microvesicles and exosomes are present. A purified nucleic acid or MBV population is greater than about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% pure, respectively, or is free of other nucleic acids or cellular components.
[0095] Preventing or treating a disease: "Preventing" a disease means inhibiting the development of a disease, such as inhibiting the development of a disease in a person known to be susceptible to the disease. Examples of people with known susceptibility are people with a family history of the disease, or people who are exposed to factors that predispose the subject to the condition. "Treatment" refers to therapeutic intervention to ameliorate the signs or symptoms of a disease or pathological condition after it has begun to develop.
[0096] Solubilized ECM: ECM that has been subjected to ultrasonic cavitation or enzymatic digestion such that the microstructure is altered, for example, by physical disruption of protein aggregates or digestion, respectively.
[0097] Subject: Human and non-human animals, including all vertebrates, such as mammals and non-mammals, such as non-human primates, mice, rabbits, sheep, dogs, cats, horses, cows, chickens, amphibians and reptiles. In certain aspects of the described methods, the subject is a human. "Subject" can be used interchangeably with the term "patient". A subject can be an individual diagnosed with a high risk of having a disease or condition (e.g., an infectious disease or condition) (e.g., an immunocompromised individual, a healthcare professional), a person who has been diagnosed with a disease or condition (e.g., an infectious disease or condition), a person who has previously had a disease or condition (e.g., an infectious disease or condition), or an individual being evaluated for symptoms or signs of a disease or condition (e.g., an infectious disease or condition).
[0098] Therapeutically effective amount: The amount of a particular substance (e.g., MBV) sufficient to achieve the desired effect in the subject being treated. When administered to a subject, a dose that achieves target tissue concentrations (e.g., in the lungs) that have been shown to achieve the desired effect in vitro will generally be used.
[0099] Thermoreversible hydrogel: A hydrogel formed due to the entanglement of polymer chains, where the viscosity changes at a characteristic temperature of gelation. The disclosed acoustic ECM hydrogel is a thermoreversible hydrogel, where gelation (sol to gel transition) occurs upon cooling.
[0100] Topical application: Topically applied agents are applied only to a specific area, rather than to the entire body. In certain instances, the composition is applied to the skin or eye in an area where hemostasis is desired. For example, the pharmaceutical composition can be applied to a wound, such as an epithelial wound or defect, such as a traumatic wound or a surgical wound, such as a skin or corneal abrasion or a surgical incision, in the form of a topical formulation.
[0101] Total phospholipid content: As used herein, "total phospholipids" or "total phospholipid content", with respect to MBV, refers to the sum of all phospholipids present in a given amount of isolated MBV (i.e., MBV isolated from the ECM). MBV can be isolated by, for example, enzymatic digestion of decellularized ECM and differential centrifugation. Total phospholipid content can be determined by methods such as LC-MS-based global lipidomics and redox lipidomics. Total phospholipid content is measured by weight. Percentages of total phospholipid content refer to percentage concentrations on a weight / weight basis.
[0102] Implantation: The implantation of a biocompatible matrix (eg, MBV) into a subject in need thereof.
[0103] Treating, treatment, and therapy: Any success or indication of success in alleviating or ameliorating an injury, pathology, or condition, including any objective or subjective parameter, such as reduction, alleviation, relief of symptoms, or making the condition more tolerable to the patient, slowing the rate of degeneration or decline, making the terminal point of degeneration less debilitating, or improving the physical or mental health of the subject. Treatment may be assessed by objective or subjective parameters; including the results of a physical examination, neurological examination, or psychiatric evaluation.
[0104] Ultrasonication: The process of exposure to ultrasound with a frequency higher than 20kHz.
[0105] Overview
[0106] In some aspects, a composition is disclosed, comprising an extracellular matrix (ECM) hydrogel, the hydrogel comprising a) dissolved extracellular matrix; and b) exogenous matrix-bound nanovesicles (MBVs) derived from the extracellular matrix, wherein the MBVs do not express CD63 and CD81 or are CD63 lo CD81 lo , and wherein the MBV does not contain alkaline phosphatase. The exogenous MBV is present in the ECM hydrogel at a concentration of less than 1 mg / mL. For example, the MBV is present in the ECM hydrogel at a concentration of at least about 1×10 5 About 1×10 20 In another example, the MBV is present in the ECM hydrogel at a concentration of about 1×10 6 About 1×10 12 Particles / mL.
[0107] In some aspects, a composition is disclosed, comprising an extracellular matrix (ECM) hydrogel, the hydrogel comprising a) dissolved extracellular matrix; and b) exogenous matrix-bound nanovesicles (MBVs) derived from the extracellular matrix, wherein the MBVs do not express CD63 and CD81 or are CD63 lo CD81 lo , and wherein the MBV does not contain alkaline phosphatase. The exogenous MBV is present in the ECM hydrogel at a concentration of less than 1 mg / mL. For example, the MBV is present in the ECM hydrogel at a concentration of at least about 1×10 5 About 1×10 20In some aspects, the composition has one or more of the following characteristics: i) is shear thinning; ii) has a storage modulus (G') of about 50 Pa to about 200 Pa and a loss modulus (G") of about 5 Pa to about 20 Pa at 37°C and a G' to G" ratio of about 4:1 to about 15:1, and / or iii) has a degradation rate of 50% in 24 hours to 14 days.
[0108] In some aspects, a composition is disclosed, comprising an extracellular matrix (ECM) hydrogel, the hydrogel comprising a) dissolved extracellular matrix; and b) exogenous matrix-bound nanovesicles (MBVs) derived from the extracellular matrix, wherein the MBVs do not express CD63 and CD81 or are CD63 lo CD81 lo , and wherein the MBV does not contain alkaline phosphatase. The exogenous MBV is present in the ECM hydrogel at a concentration of less than 1 mg / mL. For example, the MBV is present in the ECM hydrogel at a concentration of at least about 1×10 5 About 1×10 20In some aspects, the composition i) is shear thinning; ii) has a storage modulus (G') of about 50 Pa to about 200 Pa and a loss modulus (G") of about 5 Pa to about 20 Pa at 37°C and a G' to G" ratio of about 4:1 to about 15:1, and iii) has a degradation rate of 50% in 24 hours to 14 days. In certain aspects, the amount of dissolved ECM in the ECM hydrogel is between 1 mg / mL and 500 mg / mL. In certain aspects, the amount of ECM dissolved in the ECM hydrogel is 1 mg / mL to 400 mg / mL, or 1 mg / mL to 350 mg / mL, or 1 mg / mL to 300 mg / mL, or 1 mg / mL to 250 mg / mL, or 1 mg / mL to 200 mg / mL, or 1 mg / mL to 150 mg / mL, or 1 mg / mL to 100 mg / mL, or 1 mg / mL to 50 mg / mL, or 5 mg / mL to 250 mg / mL, or 20 mg / mL to 200 mg / mL, or 5 mg / mL to 200 mg / mL, or 5 mg / mL to 100 mg / mL. In more aspects, the amount of dissolved ECM in the ECM hydrogel is between about 5 mg / ml to about 50 mg / ml, for example, about 10 mg / ml to about 50 mg / ml, about 20 mg / ml to about 50 mg / mL, about 30 mg / ml to about 50 mg / ml, about 40 mg / ml to about 50 g / ml, about 5 mg / ml to about 40 mg / ml, about 5 mg / ml to about 30 mg / ml, about 5 mg / mL to about 20 mg / ml, or about 5 mg / mL to about 10 mg / ml. The ECM hydrogel can contain a concentration of about 5 mg / ml, 10 mg / ml, 15 mg / ml, 20 mg / ml, 25 mg / ml, 30 mg / ml, 35 mg / ml, 40 mg / ml, 45 mg / ml, 50 mg / ml, 60 mg / ml, 65 mg / ml, 70 mg / ml, 75 mg / ml, 80 mg / ml, 85 mg / ml, 90 mg / ml, 95 mg / ml, 100 mg / ml, 150 mg / ml, 200 mg / ml, 250 mg / ml, 300 mg / ml, 350 mg / ml, 400 mg / ml, 450 mg / ml or 500 mg / ml dissolved ECM. In a non-limiting example, the amount of dissolved ECM in the ECM hydrogel is between 10 mg / ml and 30 mg / ml. In one non-limiting example, the amount of dissolved ECM in the ECM hydrogel is between 4 mg / mL and 50 mg / mL.In some aspects, the ECM or dissolved ECM in the ECM hydrogel is present at a concentration of about 5 to about 100 mg / mL, such as 50 to 100 mg / mL, 25 to 75 mg / mL, 60 to 80 mg / mL, 40 to 60 mg / mL, 50 to 80 mg / mL, or about 30 to about 60 mg / mL.
[0109] In some aspects, the exogenous MBV is present in the ECM hydrogel at a concentration of about 1×10 5 About 1×10 18 Particles / mL, for example, about 1×10 5 About 1×10 16 Particles / mL, for example, about 1×10 5 About 1×10 14 particles / mL, or for example about 1×10 5 About 1×10 12 In some aspects, the exogenous MBV is present in the ECM hydrogel at a concentration of about 1×10 6 About 1×10 20 Particles / mL, for example, about 1×10 6 About 1×10 18 Particles / mL, for example, about 1×10 6 About 1×10 16 Particles / mL, for example, about 1×10 6 About 1×10 14 Particles / mL, for example, about 1×10 6 Up to 1×10 12 Particles / mL, for example, about 1×10 7 About 1×10 12 Particles / mL, for example, about 1×10 7 About 1×10 11 Particles / mL, for example, about 1×10 8 About 1×10 12 Particles / mL, for example, about 1×10 8 About 1×10 11 Particles / mL, for example, about 1×10 9 About 1×10 12 Particles / mL, for example, about 1×10 9 About 1×10 11 Particles / mL, for example, about 1×10 10 About 1×10 12 Particles / mL, for example, about 1×10 10 About 1×10 11 Particles / mL, for example, about 1×10 11 About 1×10 12In one non-limiting example, the exogenous MBV is present in the ECM hydrogel at a concentration of about 1×10 8 Up to 1×10 11 In one non-limiting example, the exogenous MBV is present in the ECM hydrogel at a concentration of about 1×10 5 Up to 1×10 12 In one non-limiting example, the exogenous MBV is present in the ECM hydrogel at a concentration of about 1×10 6 Up to 1×10 12 In some aspects, the exogenous MBV is present in the ECM hydrogel at a concentration of about 1×10 6 Particles / mL, 1×10 7 Particles / mL, 1×10 8 Particles / mL, 1×10 9 Particles / mL, 1×10 10 Particles / mL, 1×10 11 Particles / mL, 1×10 12 Particles / mL, 1×10 14 Particles / mL, 1×10 16 Particles / mL, 1×10 18 Particles / mL or about 1×10 20 In other aspects, the exogenous MBV is present in the ECM hydrogel at a concentration of about 5×10 6 Particles / mL, 5×10 7 Particles / mL, 5×10 8 Particles / mL, 5×10 9 Particles / mL, 5×10 10 Particles / mL, 5×10 11 Particles / mL or about 5×10 12 In a specific non-limiting example, the exogenous MBV is present in the ECM hydrogel at a concentration of about 1×10 11 In another non-limiting example, the exogenous MBV is present in the ECM hydrogel at a concentration of about 1×10 12 In another non-limiting example, the exogenous MBV is present in the ECM hydrogel at a concentration of about 1×10 10 Particles / mL or about 1×10 9 In some aspects, the exogenous MBV is present in the ECM hydrogel at a concentration of about 1×10 6 Up to 1×10 18 Particles / mL, for example, about 1×106 Up to 1×10 14 Particles / mL, about 1×10 10 Up to 1×10 14 Particles / mL, 1×10 12 Up to 1×10 18 Particles / mL, 1×10 14 Up to 1×10 18 Particles / mL or 1×10 10 Up to 1×10 18 In another non-limiting example, the exogenous MBV is present in the ECM hydrogel at a concentration of less than 1 mg / mL, such as ≤0.9 mg / mL, ≤0.8 mg / mL, ≤0.7 mg / mL, ≤0.6 mg / mL, ≤0.5 mg / mL, ≤0.4 mg / mL, ≤0.3 mg / mL, ≤0.2 mg / mL, ≤0.1 mg / mL, ≤90 μg / mL, ≤80 μg / mL, ≤70 μg / mL, ≤60 μg / mL, ≤50 μg / mL, ≤40 μg / mL, ≤30 μg / mL, ≤20 μg / mL or ≤10 μg / mL, but greater than 0 μg / mL, such as greater than 0.1 μg / mL, or greater than 0.5 μg / mL or greater than 1 μg / mL.
[0110] In some aspects, the storage modulus (G') of the composition is about 50 Pa to about 200 Pa, e.g., about 75 Pa to about 200 Pa, about 100 Pa to about 200 Pa, about 125 Pa to about 200 Pa, about 150 Pa to about 200 Pa, about 175 Pa to about 200 Pa, about 50 Pa to about 75 Pa, about 50 to about 100 Pa, about 50 to about 125 Pa, about 50 to about 150 Pa, or about 50 to about 175 Pa. The storage modulus of the composition can be about 50 Pa, 60 Pa, 70 Pa, 80 Pa, 90 Pa, 100 Pa, 110 Pa, 120 Pa, 130 Pa, 140 Pa, 150 Pa, 160 Pa, 170 Pa, 180 Pa, 190 Pa, or 200 Pa. The storage modulus of the composition may be about 50-60 Pa, 60-70 Pa, 70-80 Pa, 80-90 Pa, 90-100 Pa, 100-110 Pa, 110-120 Pa, 120-130 Pa, 130-140 Pa, 150-150 Pa, 150-160 Pa, 160-170 Pa, 170-180 Pa, 180-190 Pa, or 190-200 Pa.
[0111] In more aspects, the loss modulus (G") of the composition is from about 5 Pa to about 20 Pa, e.g., from about 10 Pa to about 20 Pa, from about 15 Pa to about 20 Pa, from about 5 Pa to about 10 Pa, from about 5 Pa to about 15 Pa. The loss modulus of the composition can be about 5 Pa, 6 Pa, 7 Pa, 8 Pa, 9 Pa, 10 Pa, 11 Pa, 12 Pa, 13 Pa, 14 Pa, 15 Pa, 16 Pa, 17 Pa, 18 Pa, 19 Pa or 20 Pa.
[0112] In other aspects, the composition has a G' to G" ratio of about 4:1 to about 15:1 at 37°C. In some aspects, the composition can have a G' to G" ratio of about 4:1 to about 5:1, about 4:1 to about 6:1, about 4:1 to about 7:1, about 4:1 to about 8:1, about 4:1 to about 9:1, about 4:1 to about 10:1, about 4:1 to about 11:1, about 4:1 to about 12:1, about 4:1 to about 13:1, or about 4:1 to about 14:1. In other aspects, the composition can have a G' to G" ratio of about 5:1 to about 15:1, about 6:1 to about 15:1, about 7:1 to about 15:1, about 8:1 to about 15:1, about 9:1 to about 15:1, about 10:1 to about 15:1, about 11:1 to about 15:1, about 12:1 to about 15:1, about 13:1 to about 15:1, or about 14:1 to about 15:1. The composition can have a G' to G" ratio of about 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1 or 15:1.
[0113] In other aspects, the composition is shear-thinning, so as the injection rate (e.g., ml / sec) increases, delivery by injection becomes easier. In some non-limiting examples, as the shear rate (expressed in 1 / sec) increases, the viscosity (expressed in Pa*sec) decreases.
[0114] In more aspects, the degradation rate of the composition within 24 hours to 14 days is 50%. The degradation rate of the composition can be 50% at the following time: about 1 to about 13 days, about 1 to about 12 days, about 1 to about 11 days, about 1 to about 10 days, about 1 to about 9 days, about 1 to about 8 days, about 1 to about 7 days, about 1 to about 6 days, about 1 to about 5 days, about 1 to about 4 days, about 1 to about 3 days, about 1 to about 2 days. The degradation rate of the composition can be 50% at the following time: about 2 to about 14 days, about 3 to about 14 days, about 4 to about 14 days, about 5 to about 14 days, about 6 to about 14 days, about 7 to about 14 days, about 8 to about 14 days, about 9 to about 14 days, about 10 to about 14 days, about 11 to about 14 days, about 12 to about 14 days or about 13 to about 14 days. The composition can have a degradation rate of 50% in about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days or 14 days. The rate of release of MBV from the hydrogel after delivery to the anatomical site can depend on the degradation of the hydrogel, the anatomical site and the degree of inflammation of the tissue.
[0115] In some aspects, the ECM hydrogel can be an acoustic ECM hydrogel. Acoustic hydrogels suitable for use according to the present application are disclosed, for example, in PCT Publication No. WO2020 / 186082, which is incorporated herein by reference. In other aspects, the ECM hydrogel can be an enzymatic ECM hydrogel. Enzymatic ECM hydrogels suitable for use according to the present application are disclosed, for example, in U.S. Patent No. 8,361,503, which is incorporated herein by reference in its entirety.
[0116] In other aspects, a composition is disclosed, comprising: an acidic solution comprising an exogenous acidic protease and dissolved extracellular matrix, such as dissolved intact ECM; and exogenous MBV derived from the extracellular matrix, wherein the MBV does not express CD63 and CD81 or is CD63 lo CD81 lo , and wherein the MBV does not contain alkaline phosphatase. The exogenous MBV is present in the composition at a concentration of less than 1 mg / mL. For example, the MBV is present in the composition in an amount of about 1×10 5 About 1×10 20 In some aspects, the acidic solution forms a gel at a temperature above 25° C. when neutralized to a pH of about 7.0 to about 7.8. In some aspects, the acidic protease is pepsin and / or trypsin. In some aspects, the pH of the composition is less than 7.0.
[0117] In further aspects, compositions are disclosed, comprising dissolved extracellular matrix (e.g., intact ECM) that has been digested with an acidic protease; inactivated exogenous acidic protease; and exogenous MBV derived from the extracellular matrix. The MBV does not express CD63 and CD81, or is CD63 lo CD81 lo , and does not contain alkaline phosphatase. These exogenous MBVs are present in the composition at a concentration of less than 1 mg / mL. For example, the MBV is present in the composition in an amount of about 1×10 5 About 1×10 20 Particles / ml. The composition enters a liquid phase at a temperature below 25°C and a gel phase at a temperature above 25°C, with a pH between 7 and 7.8, such as about 7.2 to about 7.8, about 7.3 to 7.8, 7.4 to 7.8, or about 7.5 to 7.8. The pH of the composition can be, for example, about 7.2, about 7.3, about 7.4, about 7.5, or about 7.6. In some aspects, the acidic protease is pepsin and / or trypsin. In other aspects, the pH of the composition is about 7.2. In more aspects, the pH range of the composition is within 7.2 to 7.4, such as about 7.2, 7.3, or 7.4.
[0118] In some aspects, the amount of ECM dissolved in the disclosed composition is between 1 mg / mL and 500 mg / mL. In some aspects, the amount of ECM dissolved in the disclosed composition is 1 mg / mL to 400 mg / mL, or 1 mg / mL to 350 mg / mL, or 1 mg / mL to 300 mg / mL, or 1 mg / mL to 250 mg / mL, or 1 mg / mL to 200 mg / mL, or 1 mg / mL to 150 mg / mL, or 1 mg / mL to 100 mg / mL, or 1 mg / mL to 50 mg / mL, or 5 mg / mL to 250 mg / mL, or 20 mg / mL to 200 mg / mL, or 5 mg / mL to 200 mg / mL, or 5 mg / mL to 100 mg / mL. In more aspects, the amount of dissolved ECM in the disclosed compositions is between about 5 mg / ml to about 50 mg / ml, e.g., about 10 mg / ml to about 50 mg / ml, about 20 mg / ml to about 50 mg / ml, about 30 mg / ml to about 50 mg / ml, about 40 mg / ml to about 50 mg / ml, about 5 mg / ml to about 40 mg / ml, about 5 mg / ml to about 30 mg / ml, about 5 mg / ml to about 20 mg / ml, or about 5 mg / ml to about 10 mg / ml. The dissolved ECM concentration contained in the disclosed composition can be about 5mg / ml, 10mg / ml, 15mg / ml, 20mg / ml, 25mg / ml, 30mg / ml, 35mg / ml, 40mg / ml, 45mg / ml, 50mg / ml, 60mg / ml, 65mg / ml, 70mg / mL, 75mg / ml, 80mg / ml, 85mg / ml, 90mg / ml, 95mg / ml, 100mg / ml, 150mg / ml, 200mg / ml, 250mg / ml, 300mg / ml, 350mg / ml, 400mg / mL, 450mg / mL or 500mg / mL. In a non-limiting example, the amount of dissolved ECM in the disclosed composition is between 10mg / mL and 30mg / mL. In a non-limiting example, the amount of dissolved ECM in the disclosed composition is between 4mg / mL and 50mg / mL. In certain aspects, the ECM or solubilized ECM in the disclosed compositions is present at a concentration of about 5 to about 100 mg / mL, e.g., 50 to 100 mg / mL, 25 to 75 mg / mL, 60 to 80 mg / mL, 40 to 60 mg / mL, 50 to 80 mg / mL, or about 30 to about 60 mg / mL.
[0119] In some aspects, the exogenous MBV is present in the disclosed compositions at a concentration of about 1×10 5 About 1×10 20 Particles / mL, for example, about 1×105 About 1×10 18 Particles / mL, for example, about 1×10 5 About 1×10 16 Particles / mL, for example, about 1×10 5 About 1×10 14 particles / mL, or for example about 1×10 5 About 1×10 12 In some aspects, the exogenous MBV is present in the disclosed composition at a concentration of about 1×10 6 About 1×10 20 Particles / mL, for example, about 1×10 6 About 1×10 18 Particles / mL, for example, about 1×10 6 About 1×10 16 Particles / mL, for example, about 1×10 6 About 1×10 14 Particles / mL, for example, about 1×10 6 About 1×10 12 Particles / mL, for example, about 1×10 7 About 1×10 12 Particles / mL, for example, about 1×10 7 About 1×10 11 Particles / mL, for example, about 1×10 8 About 1×10 12 Particles / mL, for example, about 1×10 8 About 1×10 11 Particles / mL, for example, about 1×10 9 About 1×10 12 Particles / mL, for example, about 1×10 9 About 1×10 11 Particles / mL, for example, about 1×10 10 About 1×10 12 Particles / mL, for example, about 1×10 10 About 1×10 11 Particles / mL, for example, about 1×10 11 About 1×10 12 In one non-limiting example, the exogenous MBV is present in the disclosed composition at a concentration of about 1×10 8 Up to 1×10 11 In one non-limiting example, the exogenous MBV is present in the disclosed composition at a concentration of about 1×10 5 Up to 1×10 12In one non-limiting example, the exogenous MBV is present in the disclosed composition at a concentration of about 1×10 6 Up to 1×10 12 In some aspects, the exogenous MBV is present in the disclosed composition at a concentration of about 1×10 6 Particles / mL, 1×10 7 Particles / mL, 1×10 8 Particles / mL, 1×10 9 Particles / mL, 1×10 10 Particles / mL, 1×10 11 Particles / mL, 1×10 12 Particles / mL, 1×10 14 Particles / mL, 1×10 16 Particles / mL, 1×10 18 Particles / mL or about 1×10 20 In other aspects, the exogenous MBV is present in the disclosed composition at a concentration of about 5×10 6 Particles / mL, 5×10 7 Particles / mL, 5×10 8 Particles / mL, 5×10 9 Particles / mL, 5×10 10 Particles / mL, 5×10 11 Particles / mL or about 5×10 12 In a specific non-limiting example, the exogenous MBV is present in the disclosed composition at a concentration of about 1×10 11 In another non-limiting example, the exogenous MBV is present in the disclosed composition at a concentration of about 1×10 12 In yet another non-limiting example, the exogenous MBV is present in the disclosed composition at a concentration of about 1×10 10 Particles / mL is about 1×10 9 In some aspects, the exogenous MBV is present in the disclosed composition at a concentration of about 1×10 6 Particles / mL to 1×10 18 Particles / mL, for example, about 1×10 6 Up to 1×10 14 Particles / mL, about 1×10 10 Up to 1×10 14 Particles / mL, 1×10 12 Up to 1×10 18 Particles / mL, 1×10 14 Up to 1×10 18 Particles / mL or 1×1010 Up to 1×10 18 In another non-limiting example, the exogenous MBV is present in the ECM hydrogel at a concentration of less than 1 mg / mL, for example, ≤0.9 mg / mL, ≤0.8 mg / mL, ≤0.7 mg / mL, ≤0.6 mg / mL, ≤0.5 mg / mL, ≤0.4 mg / mL, ≤0.3 mg / mL, ≤0.2 mg / mL, ≤0.1 mg / mL, ≤90 μg / mL, ≤80 μg / mL, ≤70 μg / mL, ≤60 μg / mL, ≤50 μg / mL, ≤40 μg / mL, ≤30 μg / mL, ≤20 μg / mL, or ≤10 μg / mL, but greater than 0 μg / mL, for example, greater than 0.1 μg / mL, or greater than 0.5 μg / mL, or greater than 1 μg / mL.
[0120] In some aspects, the ECM hydrogel or dissolved ECM of the disclosed composition is derived from the extracellular matrix of bladder, small intestine, heart, dermis, liver, kidney, uterus, brain, blood vessel, lung, bone, muscle, pancreas, placenta, stomach, spleen, colon, adipose tissue or esophagus. In more aspects, the ECM hydrogel or dissolved ECM of the disclosed composition is derived from bladder matrix (UBM), small intestinal submucosa (SIS) or bladder submucosa (UBS). In other aspects, the ECM hydrogel or dissolved ECM of the disclosed composition is derived from mammalian vertebrates, and the mammalian vertebrates are selected from humans, monkeys, pigs, cattle or sheep. In other aspects, the ECM hydrogel or dissolved ECM of the disclosed composition is derived from non-human mammals. In some aspects, the ECM hydrogel or dissolved ECM of the disclosed composition is non-derived from UBM.
[0121] In some aspects, the MBV does not express CD63 and CD81, or expresses CD63 lo CD81 lo , and the MBV does not contain detectable alkaline phosphatase. In some aspects, expression of CD63, CD81 and / or CD9 cannot be detected on the MBV. Thus, in some aspects, the MBV does not express CD63 and / or CD81 and / or CD9. In a specific example, CD63, CD81 and CD9 cannot be detected on the nanovesicles. In other aspects, the MBV has almost undetectable levels of CD63, CD81 and CD9, such as levels detectable by Western blot. These MBV are CD63 lo CD81 lo CD9 loIn other aspects, the MBV does not express detectable levels of one or more of CD63, CD81, or CD9. In other aspects, the MBV does not contain detectable alkaline phosphatase, osteopontin, osteoprotegerin, complement C5, and / or c-reactive protein.
[0122] In more aspects, the MBV (e.g., the exogenous MBV) is derived from the extracellular matrix of the bladder, small intestine, heart, dermis, liver, kidney, uterus, brain, blood vessels, lungs, bones, muscles, pancreas, placenta, stomach, spleen, colon, adipose tissue and / or esophagus. In more aspects, the MBV (e.g., the exogenous MBV) is derived from the extracellular matrix of the bladder, small intestine, dermis, liver, kidney, uterus, brain, blood vessels, lungs, muscles, pancreas, placenta, stomach, spleen, colon, adipose tissue and / or esophagus. In specific non-limiting examples, the MBV (e.g., the exogenous MBV) is derived from bladder matrix (UBM), small intestinal submucosa (SIS) or bladder submucosa (UBS). In one aspect, the MBV (e.g., the exogenous MBV) is derived from the dermis. In another aspect, the MBV (e.g., the exogenous MBV) is derived from UBM. In other aspects, the MBV (e.g., the exogenous MBV) is derived from the extracellular matrix of a mammalian vertebrate selected from humans, monkeys, pigs, cows or sheep. In specific non-limiting examples, the MBV (e.g., the exogenous MBV) is derived from a non-human mammal. In some aspects, the MBV (e.g., the exogenous MBV) is not derived from bone ECM. In some aspects, the MBV (e.g., the exogenous MBV) is not derived from heart (cardiac) ECM. In some aspects, the MBV (e.g., the exogenous MBV) is not derived from heart (cardiac) ECM or bone ECM.
[0123] In some aspects, the composition can include pulverized ECM. In other aspects, the composition can include trehalose.
[0124] The disclosed compositions can be formulated for topical administration. These topical compositions can be used to treat inflammation. For example, the disclosed compositions can be used to treat inflammation in the esophagus, such as esophagitis or esophageal ulcers. In one aspect, the compositions described herein are topically applied to coat esophageal tissue. The disclosed compositions can be used to treat anal fistulas. The disclosed compositions can be used as submucosal linings.
[0125] Disclosed herein are methods for treating a subject suffering from inflammatory bowel disease or esophageal inflammation. These methods include topically administering an effective amount of the disclosed composition to the affected organ of the subject, thereby treating the inflammatory bowel disease or esophageal inflammation of the subject. In certain aspects, the subject suffers from inflammatory bowel disease, and the affected organ is the intestine. In other aspects, the subject suffers from ulcerative colitis, and therefore the affected organ is the colon. In more aspects, the subject suffers from esophageal inflammation, and therefore the affected organ is the esophagus. In some non-limiting examples, the subject is human.
[0126] The compositions disclosed herein can also be used to treat inflammation of the throat or stomach or promote wound healing by topically applying the compositions disclosed herein to the throat or stomach of a subject suffering from throat or stomach inflammation or wounds (e.g., gastric ulcers or throat ulcers). The compositions can be applied enterally (e.g., by mouth), or by surgical operation (e.g., with a catheter or endoscope), or by topical application by injection to achieve local application at the site of inflammation, ulcers or wounds.
[0127] Matrix-bound nanovesicles derived from the extracellular matrix (ECM)
[0128] Nanovesicles derived from ECM (also referred to as matrix-bound nanovesicles, "MBVs") are generally described in PCT Publication Nos. WO 2017 / 151862, WO 2018 / 204848, and WO 2019 / 213482, which are incorporated herein by reference. It is disclosed that MBVs are embedded in the extracellular matrix. These MBVs can be isolated and have biological activity. MBVs do not express CD63 and CD81, or are CD63 lo CD81 lo , and does not contain alkaline phosphatase. The MBV may contain IL-33. These MBVs can be used for therapeutic purposes. In some aspects, the MBV does not contain alkaline phosphatase, osteopontin, osteoprotegerin, complement C5 and / or c-reactive protein.
[0129] The extracellular matrix is a complex mixture of structural and functional biomolecules and / or biomacromolecules, including but not limited to structural proteins, specific proteins, proteoglycans, glycosaminoglycans, and growth factors, that surrounds and supports cells within mammalian tissues and is acellular unless otherwise specified. In general, the disclosed MBVs are embedded in any type of extracellular matrix (ECM) and can be isolated from that location. Thus, the MBVs are not detachably present on the surface of the ECM and are not exosomes (also known as extracellular vesicles or EVs).
[0130] Extracellular matrices are disclosed, for example, but not limited to, in the following U.S. Patent Nos.: 4,902,508; 4,956,178; 5,281,422; 5,352,463; 5,372,821; 5,554,389; 5,573,784; 5,645,860; 5,771,969; 5,753,267; 5,762,966; 5,866,414; 6,099,567; 6,485, 723, 6,576,265, 6,579,538, 6,696,270, 6,783,776, 6,793,939, 6,849,273, 6,852,339, 6,861,074, 6,887,495, 6,890,562, 6,890,563, 6,890,564; and 6,893,666, each of which is incorporated herein by reference in its entirety. However, ECM can be produced by any tissue, or by any in vitro source, wherein the ECM is produced by cultured cells and comprises one or more polymer components (ingredients) of natural ECM. ECM preparations can be considered to be "decellularized" or "cell-free," meaning that the cells have been removed from source tissue or culture.
[0131] In some aspects, the ECM is separated from a vertebrate, such as a mammalian vertebrate (including but not limited to humans, monkeys, pigs, cattle, sheep, etc.). The ECM can be derived from any organ or tissue, including but not limited to bladder, intestinal tract (such as small intestine or large intestine), heart, dermis, liver, kidney, uterus, brain, blood vessel, lung, bone, muscle, pancreas, placenta, stomach, spleen, colon, adipose tissue or esophagus. In a specific non-limiting example, the extracellular matrix is separated from esophageal tissue, bladder (such as bladder matrix or bladder submucosa), small intestinal submucosa, dermis, umbilical cord, pericardium, heart tissue or skeletal muscle. The ECM can include any part or tissue obtained from an organ, including but not limited to submucosa, epithelial basement membrane, lamina propria, etc. In a non-limiting aspect, the ECM is separated from the bladder. In some aspects, the ECM is from a human subject. In other aspects, the ECM is from a pig subject. In some aspects, the ECM is not a pig ECM. In some aspects, the ECM is not a pig UBM.
[0132] The ECM may or may not include a basement membrane. In another non-limiting aspect, the ECM includes at least a portion of the basement membrane. The ECM material may or may not retain some cell elements that constitute the original tissue, such as capillary endothelial cells or fibroblasts. In some aspects, the ECM contains a basement membrane surface and a non-basement membrane surface.
[0133] In some aspects, the ECM is obtained from a porcine bladder (also referred to as a bladder matrix or UBM). In short, the ECM is prepared by removing bladder tissue from a mammal (such as a pig) and trimming the remaining external connective tissue (including adipose tissue). All residual urine is removed by repeatedly rinsing with tap water. The tissue is stripped by first soaking the tissue in a de-epithelialization solution (such as, but not limited to, a hypertonic saline solution (such as 1.0N saline)) for a period of 10 minutes to 4 hours. Exposure to a hypertonic saline solution will remove epithelial cells from the basement membrane below. Optionally, a calcium chelator can be added to the saline solution. The tissue remaining after the initial stripping process includes an epithelial basement membrane and a tissue layer abluminal to the epithelial basement membrane. The relatively fragile epithelial basement membrane is always damaged and removed by any mechanical wear on the luminal surface. Next, the tissue is further processed to remove most of the abluminal tissue, but retain the epithelial basement membrane and the lamina propria. The outer serosal, adventitial, tunica muscularis mucosa, submucosa, and most of the muscularis mucosa are removed from the remaining de-epithelialized tissue by mechanical abrasion or in combination with enzymatic treatment (e.g., using trypsin or collagenase), followed by hydration and abrasion. Mechanical removal of these tissues is accomplished by removing mesenteric tissue using, for example, but not limited to, Adson-Brown forceps and Metzenbaum scissors, and using a scalpel handle or other hard object wrapped in moist gauze to perform longitudinal wiping motions to wipe away the muscularis and submucosa. Automated robotic procedures involving cutting blades, lasers, and other tissue separation methods are also contemplated. After removing these tissues, the resulting ECM is primarily composed of the epithelial basement membrane and the underlying lamina propria.
[0134] On the other hand, the ECM is prepared by abrading porcine bladder tissue with a scalpel handle and moistened gauze in a longitudinal wiping motion to remove the outer layer (including the serosa and muscular layer). After the tissue segment is everted, the luminal portion of the mucosa is peeled off from the underlying tissue using the same wiping motion. Care is taken to prevent perforation of the submucosal layer. After removing these tissues, the resulting ECM is primarily composed of the submucosal layer (see FIG. 2 of U.S. Patent No. 9,277,999, incorporated herein by reference).
[0135] ECM can also be made into powder. Such powder can be prepared according to the method of Gilbert et al., Biomaterials 26 (2005) 1431-1435, which is incorporated herein by reference in its entirety. For example, UBM flakes can be freeze-dried and then cut into small pieces for immersion in liquid nitrogen. The rapidly frozen material can then be pulverized to make the particles small enough to be placed in a rotary knife mill and the ECM powdered. Similarly, by precipitating NaCl within the ECM tissue, the material will be broken into particles of uniform size, which can be rapidly frozen, freeze-dried and powdered.
[0136] In one non-limiting aspect, the ECM is derived from the small intestinal submucosa or SIS. Commercially available preparations include but are not limited to SURGISIS TM 、SURGISISES TM 、STRATASIS TM and STRATASIS-ES TM (Cook Urological Inc.; Indianapolis, Ind.) and GRAFTPATCH TM (Organogenesis Inc.; Canton Mass.). In another non-limiting aspect, the ECM is derived from the dermis. Commercially available preparations include, but are not limited to, PELVICOL TM (Permacol TM For sale; Bard, Covington, Ga.), REPLIFORM TM (Microvasive; Boston, Mass.) and ALLODERM TM (LifeCell; Branchburg, NJ). In another aspect, the ECM is derived from the bladder. Commercially available preparations include, but are not limited to, UBM (ACell Corporation; Jessup, Md.).
[0137] MBV can be derived from (released from) the extracellular matrix using the methods disclosed below. For example, MBV can be obtained from the extracellular matrix according to the methods disclosed in U.S. Patent Application Publication No. 2019 / 0117837, the contents of which are incorporated herein by reference for all purposes. In some aspects, the ECM is digested with an enzyme (e.g., pepsin, collagenase, elastase, hyaluronidase, and / or proteinase K), and the MBV is separated. In other aspects, the MBV is released and separated from the ECM by changing the pH with a solution (e.g., glycine HCL, citric acid, ammonium hydroxide), using a chelating agent (e.g., but not limited to EDTA, EGTA), by using the ionic strength and / or chaotropic effect of a salt (e.g., but not limited to potassium chloride (KCl), sodium chloride, magnesium chloride, sodium iodide, sodium thiocyanate), or by exposing the ECM to denaturing conditions (e.g., guanidine hydrochloride or urea).
[0138] The MBV can be derived from the extracellular matrix of the bladder, small intestine, heart, dermis, liver, kidney, uterus, brain, blood vessels, lungs, bones, muscles, pancreas, placenta, stomach, spleen, colon, adipose tissue and / or esophagus. In a specific non-limiting example, the MBV is derived from the bladder matrix (UBM), the small intestine submucosa (SIS) or the bladder submucosa (UBS). In one aspect, the MBV is derived from the dermis. In another aspect, the MBV is derived from the UBM. In other aspects, the MBV is derived from the extracellular matrix of a mammalian vertebrate selected from humans, monkeys, pigs, cattle or sheep. In a specific non-limiting example, the MBV is from a non-human mammal. In some aspects, the MBV is not derived from bone ECM. In some aspects, the MBV is not derived from heart (heart) (cardiac) ECM. In some aspects, the MBV is not derived from heart (heart) (cardiac) ECM or bone ECM. In particular aspects, the MBV is prepared after digestion of the ECM with an enzyme (eg, pepsin, elastase, hyaluronidase, proteinase K, saline and / or collagenase, or a combination thereof). The ECM may be freeze-thawed, or subjected to mechanical degradation.
[0139] In some aspects, expression of CD63, CD81 and / or CD9 cannot be detected on the MBV. Thus, in some aspects, the MBV does not express CD63 and / or CD81 and / or CD9. In a specific example, CD63, CD81 and CD9 cannot be detected on the nanovesicles. In other aspects, the MBV has almost undetectable levels of CD63, CD81 and CD9, such as levels detectable by Western blot. These MBV are CD63 lo CD81lo CD9 lo In other aspects, MBV does not express detectable levels of one or more of CD63, CD81, or CD9. In other aspects, MBV expresses barely detectable levels of one or more of CD63, CD81, or CD9. One skilled in the art can readily identify CD63 using, for example, antibodies that specifically bind to CD63, CD81, and CD9. lo and / or CD81 lo and / or CD9 lo MBVs. Low levels of these markers can be determined using procedures such as fluorescence activated cell sorting (FACS) and fluorescently labeled antibodies to determine low and high thresholds for CD63, CD81, and CD9. The disclosed MBVs are different from nanovesicles (e.g., exosomes), which can temporarily attach to the surface of the ECM due to their presence in biological fluids, while MBVs in vivo are bound to the ECM and are therefore not found in biological fluids.
[0140] For example, MBV has a unique phospholipid content compared to exosomes. In some aspects, the total phospholipid content of the MBV is at least 50%, 55%, 60%, 65%, 70%, 75%, 85%, or 90%, or about 50%-90%, 50%-65%, 50%-60%, 50%-70%, 60%-70%, 60%-90%, or 70%-90% of the combined phosphatidylcholine (PC) and phosphatidylinositol (PI). In specific aspects, the total phospholipid content of the MBV is at least 55% of the combined phosphatidylcholine (PC) and phosphatidylinositol (PI). In specific aspects, the total phospholipid content of the MBV is at least 60% of the combined phosphatidylcholine (PC) and phosphatidylinositol (PI). In some aspects, the phospholipid content of the MBV comprises a ratio of phosphatidylcholine (PC) to phosphatidylinositol (PI) of less than 8:1 (e.g., less than 7:1, less than 6:1, less than 5:1, less than 4:1, less than 3:1, or less than 2:1). In some aspects, the phospholipid content of the MBV comprises a ratio of phosphatidylcholine (PC) to phosphatidylinositol (PI) in the range of 0.5-1:1, or 1:0.5-1, or 0.5-1:2, or 2:0.5-1, or 0.8-1:1, or 1:0.8-1. In one aspect, the phospholipid content of the MBV comprises a ratio of phosphatidylcholine (PC) to phosphatidylinositol (PI) of about 1:1. In a specific aspect, the phospholipid content of the MBV comprises a ratio of phosphatidylcholine (PC) to phosphatidylinositol (PI) of about 0.9:1.
[0141] In some aspects, the total phospholipid content of the MBV is 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4% or less, or about 5%-10%, 5%-15%, 10%-15% or 8%-12% sphingomyelin (SM). In specific aspects, the total phospholipid content of the MBV is 10% or less sphingomyelin (SM). In some aspects, the total phospholipid content of the MBV is 15% or less sphingomyelin (SM), 14% or less sphingomyelin, 13% or less sphingomyelin, 12% or less sphingomyelin, 11% or less sphingomyelin, 10% or less sphingomyelin, 9% or less sphingomyelin, 8% or less sphingomyelin, 7% or less sphingomyelin, 6% or less sphingomyelin, 5% or less sphingomyelin or 4% or less sphingomyelin.
[0142] In some aspects, the total phospholipid content of the MBV is 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11% or 10% or less, or about 10%-20%, 15%-20%, 14%-18% or 12%-16% phosphatidylethanolamine (PE). In specific aspects, the total phospholipid content of the MBV is 20% or less phosphatidylethanolamine (PE).
[0143] In some aspects, the total phospholipid content of the MBV is 5%, 10%, 12%, 15%, 18%, 20%, 25%, or 30% or more, or about 5%-30%, 10%-20%, 10%-25%, 15%-25%, or 12%-18% phosphatidylinositol (PI). In specific aspects, the MBV includes a phospholipid content of 15% or more phosphatidylinositol (PI).
[0144] In particular aspects, the total phospholipid content of the MBV comprises 15% or more phosphatidylinositol, 20% or less phosphatidylethanolamine, and 10% or less sphingomyelin. In particular aspects, the total phospholipid content of the MBV is 15% or more phosphatidylinositol and 20% or less phosphatidylethanolamine. In particular aspects, the total phospholipid content of the MBV is 15% or more phosphatidylinositol and 10% or less sphingomyelin. In particular aspects, the total phospholipid content of the MBV comprises 20% or less phosphatidylethanolamine and 10% or less sphingomyelin. In particular aspects, the total phospholipid content of the MBV is greater than 15% phosphatidylinositol, 20% or less phosphatidylethanolamine, 10% or less sphingomyelin, and at least 55% combined phosphatidylinositol and phosphatidylcholine. In one aspect, the total phospholipid content of the MBV is at least 55% of combined phosphatidylcholine (PC) and phosphatidylinositol (PI) and 10% or less sphingomyelin (SM). In a specific aspect, the total phospholipid content of the MBV is at least 55% of combined phosphatidylinositol and phosphatidylcholine and more than 15% phosphatidylinositol. In a specific aspect, the total phospholipid content of the MBV is 55% of combined phosphatidylinositol and phosphatidylcholine and 20% or less phosphatidylethanolamine.
[0145] The MBV may also contain lysine oxidase (Lox). Typically, nanovesicles derived from the ECM have a higher Lox content than exosomes. Lox is expressed on the surface of MBV. Nano-LC MS / MS proteomics analysis can be used to detect Lox proteins. Quantification of Lox can be performed (see, e.g., Hill RC, et al., Mol Cell Proteomics. 2015; 14(4): 961-73, incorporated herein by reference in its entirety).
[0146] In certain aspects, the MBV comprises one or more miRNAs. In a specific non-limiting example, the MBV comprises one, two or all three of miR-143, miR-145 and miR-181. MiR-143, miR-145 and miR-181 are known in the art.
[0147] The miR-145 nucleic acid sequence is provided in MiRbase Accession No. MI0000461 (incorporated herein by reference). The miR-145 nucleic acid sequence is CACCUUGUCCUCACGGUCCAGUUUUCCCAGGAAUCCCUUAGAUG CUAAGAUGGGAUUCCUGGAAAUACUGUUCUUGAGGUCAUGGUU (SEQ ID NO: 1). The miR-181 nucleic acid sequence is provided in miRbase Accession No. MI0000269 (incorporated herein by reference). The miR-181 nucleic acid sequence is: AGAAGGGCUAUCAGGCCAGCCUUCAGAGGACUCCAAGGAACAUUC AACGCUGUCGGUGAGUUUGGGAUUUGAAAAAACCACUGACCGUUGACUGUACCUUGGGGUCCUUA (SEQ ID NO: 2). The miR-143 nucleic acid sequence is provided in NCBI Accession No. NR_029684.1 on March 30, 2018 (incorporated herein by reference). The DNA encoding the miR-143 nucleic acid sequence is: GC GCAGCGCCCTGTCTCCCA GCCTGAGGTG CAGTGCTGCA TCTCTGGTCA GTTGGG AGTC TGAGATGAAG CACTGTAGCTCAGGAAGAGA GAAGTTGTTC TGCAGC (SEQ ID NO: 3).
[0148] After administration, the MBV maintained the expression of F4 / 80 (macrophage marker) and CD-11b on the subject's macrophages. Nanovesicle-treated macrophages were predominantly F4 / 80+Fizz1+, indicating an M2 phenotype.
[0149] The MBV disclosed herein can be formulated into a composition for drug delivery. MBV is further disclosed and described in PCT Publication No. WO 2017 / 151862, which is incorporated herein by reference.
[0150] Separation of MBV from the ECM
[0151] To produce MBV, the ECM can be produced by any cell of interest, or can be used from a commercial source as described above. The MBV can be produced by the same species as the subject being treated or a different species. In some aspects, these methods include digesting the ECM with an enzyme to produce a digested ECM. In a specific aspect, the ECM is digested with one or more of pepsin, elastase, hyaluronidase, collagenase, metalloproteinase and / or proteinase K or a combination thereof. In a specific non-limiting example, the ECM is digested only with elastase and / or metalloproteinase. In another non-limiting example, the ECM is not digested with collagenase and / or trypsin and / or proteinase K. In other aspects, the ECM is treated with a detergent. In other aspects, the method does not include the use of an enzyme. In a specific non-limiting example, the method utilizes a chaotropic agent or ionic strength to separate MBV, such as a salt (e.g., potassium chloride). In another aspect, the ECM can be treated to increase the MBV content before separating the MBV. For example, techniques for separating MBV from ECM are described in U.S. Patent Application Publication No. 2019 / 0117837, the contents of which are incorporated herein by reference for all purposes. Techniques for separating MBV are also disclosed in Quijano et al., Tissue Eng Part C Methods. 2020 Oct; 26(10): 528-540, which is also incorporated herein by reference.
[0152] In certain aspects, the ECM is digested with an enzyme. The ECM can be digested with an enzyme for about 12 to about 48 hours, for example, about 12 to about 36 hours. The ECM can be digested with an enzyme for about 12 hours, about 24 hours, about 36 hours, or about 48 hours. In a specific non-limiting example, the ECM is digested with an enzyme at room temperature. However, the digestion can be performed at any temperature between about 4°C or about 4°C to 25°C. Typically, the ECM is digested with the enzyme for an unlimited time and temperature sufficient to remove collagen fibrils. The digestion process can vary depending on the tissue source. Optionally, the ECM is treated by freezing and thawing before or after digestion with the enzyme. The ECM can be treated with a detergent, including an ionic detergent and / or a non-ionic detergent.
[0153] Then, for example, by centrifugation of the ECM digested, to separate the supernatant without fibrils. In some aspects, the ECM digested is for example centrifuged in the first step at about 300 to about 1000 g. Therefore, the ECM digested can be centrifuged at about 400 g to about 750 g, for example, about 400 g, about 450 g, about 500 g or about 600 g. This centrifugation can be carried out for about 10 to about 15 minutes, for example, about 10 to 12 minutes, for example, about 10 minutes, about 11 minutes, about 12 minutes, about 13 minutes, about 14 minutes or about 15 minutes. Collect the supernatant comprising the ECM digested.
[0154] In some aspects, the MBV comprises Lox. In some aspects, the method of isolating such MBV comprises digesting the extracellular matrix with an elastase and / or a metalloprotease to produce a digested extracellular matrix, centrifuging the digested extracellular matrix to remove collagen fibril remnants, thereby producing a fibril-free supernatant, centrifuging the fibril-free supernatant to separate solid material, and suspending the solid material in a carrier.
[0155] In some aspects, the digested ECM can also be subjected to a second step of centrifugation at about 2000 g to about 3000 g. Therefore, the digested ECM can be centrifuged at about 2,500 g to about 3,000 g, for example, at about 2,000 g, 2,500 g, 2,750 g or 3,000 g. This centrifugation can be carried out for about 20 to about 30 minutes, for example, about 20 to 25 minutes, for example, about 20 minutes, about 21 minutes, about 22 minutes, about 23 minutes, about 24 minutes, about 25 minutes, about 26 minutes, about 27 minutes, about 28 minutes, about 29 minutes or about 30 minutes. The supernatant comprising the digested ECM is collected.
[0156] In other aspects, the digested ECM can be centrifuged in the third step at about 10,000 to about 15,000g. Therefore, the digested ECM can be centrifuged at about 10,000g to about 12,500g, such as about 10,000g, 11,000g or 12,000g. This centrifugation can be carried out for about 25 to about 40 minutes, such as about 25 to 30 minutes, such as about 25 minutes, about 26 minutes, about 27 minutes, about 28 minutes, about 29 minutes, about 30 minutes, about 31 minutes, about 32 minutes, about 33 minutes, about 34 minutes, about 35 minutes, about 36 minutes, about 37 minutes, about 38 minutes, about 39 minutes or about 40 minutes. Collect the supernatant including the digested ECM. One, two or all three of these centrifugation steps can be used independently. In some aspects, all three centrifugation steps are used. The centrifugation step can be repeated, such as repeated 2 times, 3 times, 4 times or 5 times. In one aspect, all three centrifugation steps are repeated three times.
[0157] In some aspects, the digested ECM is centrifuged at about 500g for about 10 minutes, at about 2,500g for about 20 minutes, and / or at about 10,000g for about 30 minutes. These steps (e.g., all three steps) are repeated 2, 3, 4, or 5 times, for example, three times. Therefore, in a non-limiting example, the digested ECM is centrifuged at about 500g for about 10 minutes, at about 2,500g for about 20 minutes, and at about 10,000g for about 30 minutes. These three steps are repeated three times. Thus, a fibril-free supernatant is produced. The fibril-free supernatant is then centrifuged to separate the MBV. In some aspects, the fibril-free supernatant is centrifuged at about 100,000g to about 150,000g. Thus, the fibril-free supernatant is centrifuged at about 100,000 g to about 125,000 g, for example, at about 100,0000 g, about 105,000 g, about 110,000 g, about 115,000 g, or about 120,000 g. This centrifugation can be performed for about 60 to about 90 minutes, for example, about 70 to about 80 minutes, for example, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, or about 90 minutes. In a non-limiting example, the fibril-free supernatant is centrifuged at about 100,000 g for about 70 minutes. Solid material, i.e., MBV, is collected. These MBVs can then be resuspended in any carrier of interest, such as, but not limited to, a buffer.
[0158] In other aspects, the ECM is not enzymatically digested. In these methods, the ECM is suspended in an isotonic saline solution, such as phosphate buffered saline. Salt is then added to the suspension so that the final concentration of the salt is greater than about 0.1M. The concentration can be, for example, up to about 3M, for example, about 0.1M to about 3M, or about 0.1M to about 2M. The salt can be, for example, about 0.1M, 0.15M, 0.2M, 0.3M, 0.4M, 0.5M, 0.6M, 0.7M, 0.8M, 0.9M, 1.0M, 1.1M, 1.2M, 1.3M, 1.4M, 1.5M, 1.6M, 1.7M, 1.8M, 1.9M or 2M. In some non-limiting examples, the salt is potassium chloride, sodium chloride or magnesium chloride. In other aspects, the salt is sodium chloride, magnesium chloride, sodium iodide, sodium thiocyanate, a sodium salt, a lithium salt, a cesium salt, or a calcium salt.
[0159] In some aspects, the ECM is suspended in the saline solution for about 10 minutes to about 2 hours, for example, about 15 minutes to about 1 hour, about 30 minutes to about 1 hour, or about 45 minutes to about 1 hour. The ECM can be suspended in the saline solution for about 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes, 65 minutes, 70 minutes, 75 minutes, 80 minutes, 85 minutes, 90 minutes, 95 minutes, 100 minutes, 105 minutes, 110 minutes, 115 minutes or 120 minutes. The ECM can be suspended in the saline solution at a temperature of 4°C to about 50°C (for example, but not limited to about 4°C to about 25°C or about 4°C to about 37°C). In a specific non-limiting example, the ECM is suspended in the saline solution at about 4°C. In other specific non-limiting examples, the ECM is suspended in the saline solution at about 22°C or about 25°C (room temperature). In other non-limiting examples, the ECM is suspended in the saline solution at about 37°C.
[0160] In some aspects, the method comprises incubating an extracellular matrix at a salt concentration greater than about 0.4 M; centrifuging the digested extracellular matrix to remove collagen fibril remnants and separating the supernatant; centrifuging the supernatant to separate the solid material; and suspending the solid material in a carrier, thereby separating MBV from the extracellular matrix.
[0161] After cultivating in the saline solution, the ECM is centrifuged to remove collagen fibrils. In some aspects, the digested ECM can also be centrifuged at about 2000g to about 5000g. Therefore, the digested ECM can be centrifuged at about 2,500g to about 4,500g, such as about 2,500g, about 3,000g, 3,500g, about 4,000g or about 4,500g. In a specific non-limiting example, centrifuged at about 3500g. This centrifugation can be carried out for about 20 to about 40 minutes, such as about 25 to about 35 minutes, such as about 20 minutes, about 21 minutes, about 22 minutes, about 23 minutes, about 24 minutes, about 25 minutes, about 26 minutes, about 27 minutes, about 28 minutes, about 29 minutes, about 30 minutes, about 31 minutes, about 32 minutes, about 33 minutes, about 34 minutes or about 35 minutes. Then collect the supernatant.
[0162] In other aspects, the supernatant can then be subjected to a third centrifugation step at about 100,000 to about 150,000 g. Thus, the digested ECM can be centrifuged at about 100,000 g to about 125,000 g, such as about 100,000 g, 110,000 g, or 120,000 g. This centrifugation can be performed for about 30 minutes to about 2.5 hours, such as about 1 hour to about 3 hours, such as about 30 minutes, about 45 minutes, about 60 minutes, about 90 minutes, or about 120 minutes (2 hours). The solid material is collected and suspended in a solution, such as a buffered saline, thereby isolating the MBV.
[0163] In other aspects, the ECM is suspended in an isotonic buffered saline solution, such as, but not limited to, phosphate buffered saline. Centrifugation or other methods can be used to remove large particles (see below). Ultrafiltration is then used to separate MBV from the ECM, with particles between about 10 nm and about 10,000 nm, such as between about 10 and about 1,000 nm, such as between about 10 nm and about 300 nm.
[0164] In a specific non-limiting example, the isotonic buffered saline solution has a total salt concentration of about 0.164 mM and a pH of about 7.2 to about 7.4. In some aspects, the isotonic buffered saline solution comprises 0.002 M KCl to about 0.164 M KCl, such as about 0.0027 M KCl (concentration of KCl in phosphate buffered saline). The suspension is then processed by ultracentrifugation.
[0165] After cultivating in the isotonic buffered saline solution, the ECM is centrifuged to remove collagen fibrils. In some aspects, the ECM digested can also be centrifuged at about 2000g to about 5000g. Therefore, the ECM digested can be centrifuged at about 2,500g to about 4,500g, such as about 2,500g, about 3,000g, about 3,500g, about 4,000g or about 4,500g. In a specific non-limiting example, centrifuged at about 3500g. This centrifugation can be carried out for about 20 to about 40 minutes, such as about 25 to about 35 minutes, such as about 20 minutes, about 21 minutes, about 22 minutes, about 23 minutes, about 24 minutes, about 25 minutes, about 26 minutes, about 27 minutes, about 28 minutes, about 29 minutes, about 30 minutes, about 31 minutes, about 32 minutes, about 33 minutes, about 34 minutes or about 35 minutes.
[0166] Microfiltration and centrifugation can be used and combined to remove large molecular weight materials from the suspension. In one aspect, microfiltration is used to remove large size (e.g., greater than 200 nm) molecular materials. In another aspect, large size materials are removed by using centrifugation. In a third aspect, microfiltration and ultracentrifugation are both used to remove large molecular weight materials. Large molecular weight materials, such as materials greater than about 10,000 nm, greater than about 1,000 nm, greater than about 500 nm, or greater than about 300 nm, are removed from the suspended ECM.
[0167] The effluent or supernatant of the microfiltration is then subjected to ultrafiltration. Thus, the effluent comprising particles less than about 10,000 nm, less than about 1,000 nm, less than about 500 nm, or less than about 300 nm is collected and utilized. The effluent is then subjected to ultrafiltration using a membrane having a molecular weight cutoff (MWCO) of 3,000 to 100,000.
[0168] Preparation of extracellular matrix hydrogels
[0169] Any type of extracellular matrix can be used to produce mammalian ECM hydrogels (see U.S. Patent Nos. 4,902,508; 4,956,178; 5,281,422; 5,352,463; 5,372,821; 5,554,389; 5,573,784; 5,645,860; 5,771,969; 5,753,267; 5,762,966; 5,866, In certain aspects, the ECM is isolated from a vertebrate, such as, but not limited to, a mammal (including, but not limited to, humans, monkeys, horses, pigs, cattle, and sheep). In a specific non-limiting example, the ECM is a porcine ECM.
[0170] ECM can be derived from any organ or tissue, including but not limited to bladder, intestine (such as small intestine or large intestine), heart, kidney, uterus, brain, blood vessels, lungs, bones, muscles, pancreas, stomach, spleen, adipose tissue, liver, esophagus and dermis. The ECM can be obtained from cell culture. In one aspect, the ECM is separated from the bladder. On the other hand, the ECM is separated from the esophagus. On the other hand, the ECM is separated from the dermis. On the other hand, the ECM is separated from the small intestinal submucosa (SIS). The ECM may or may not include the basement membrane portion of the ECM. In certain aspects, the ECM includes at least a portion of the basement membrane. Tissues can be decellularized, such as to remove cells and cell material from source tissues or organs, thereby producing ECM. It is desirable to use decellularized materials to prevent immune responses, such as when ECM is implanted in a subject, such as as a component of a hydrogel disclosed herein. Removing cell material (such as when using ECM to form a hydrogel) can prevent such immune responses.
[0171] U.S. Pat. No. 8,361,503 (incorporated herein by reference in its entirety for all purposes) discloses the preparation of bladder ECM, for example, porcine bladder ECM is prepared by abrading bladder tissue with a scalpel handle and moistened gauze in a longitudinal wiping motion to remove the outer layers including the serosa and muscularis. After eversion of the tissue segment, the luminal portion of the mucosa is peeled away from the underlying tissue using the same wiping motion. In certain aspects, perforation of the submucosal layer can be prevented. After removal of these tissues, the resulting ECM consists primarily of the submucosal layer.
[0172] The production of hydrogels from dermal ECM is disclosed in Wolf et al., Biomaterials 33:7028-7038, 2012, which is incorporated herein by reference. For example, the production of ECM from esophageal tissue is disclosed in Badylak et al. J Pediatr Surg. 35(7):1097-103, 2000 and Badylak et al., J Surg Res. 2005 September; 128(1):87-97, 2005, both of which are incorporated herein by reference. U.S. Pat. No. 6,893,666 (incorporated herein by reference) discloses the production of ECM from bladder, skin, esophagus, and small intestine. ECM can be produced by any of these tissues.
[0173] Commercially available ECM preparations may also be used. In one aspect, the ECM is derived from the small intestinal submucosa or SIS. Commercially available preparations include, but are not limited to, SURGISIS TM 、SURGISIS-ES TM 、STRATASIS TMand STRATASIS-ES TM (CookUrological Inc.; Indianapolis, Ind.) and GRAFTPATCH TM (Organogenesis Inc.; Canton Mass.). In another aspect, the ECM is derived from the dermis. Commercially available preparations include, but are not limited to, PELVICOL TM (Permacol TM For sale; Bard, Covington, Ga.), REPLIFORM TM (Microvasive; Boston, Mass.) and ALLODERM TM (LifeCell; Branchburg, NJ). In another aspect, the ECM is derived from the bladder. Commercially available preparations include, but are not limited to, UBM (Acell Corporation; Jessup, Md.).
[0174] Tissue for preparing ECM can be obtained in a variety of ways, and once obtained, multiple parts of the obtained tissue can be used. ECM has also been prepared from the esophagus and small intestine, see, for example, Keane et al., Tissue Eng. Part A, 21 (17-18): 2293-2300, 2015, which is incorporated herein by reference. Esophageal ECM can be prepared by mechanically separating the mucosa and submucosa from the muscularis externa, digesting the mucosa in a buffer including trypsin, and then exposing to sucrose, TRITON-x The SIS can be prepared by mechanically removing the superficial mucosa, superficial serosa and superficial muscularis externa from the intact small intestine, leaving the submucosa, muscularis mucosa and basal dense layer intact. The SIS is then treated with peracetic acid. Keane et al provides an exemplary protocol. For example, as disclosed in Wolf et al, J Biomed Mater Res A. 2013. 35 (25): 6838–49. PMID: 23873846. PMCID: 3808505 (incorporated herein by reference), a dermal hydrogel can be produced.
[0175] In one aspect, the ECM is separated from the obtained pig bladder to prepare bladder matrix (UBM). Excess connective tissue and residual urine are removed from the bladder. Serosa, outer muscularis, submucosa and most of the muscularis mucosa can be removed by mechanical abrasion or enzymatic treatment, hydration and abrasion combination. Mechanical removal of these tissues can be achieved by using longitudinal wiping motion to remove outer layer (particularly distal luminal smooth muscle layer), or even the luminal part (epithelial layer) of mucosa. Mechanical removal of these tissues is by excising mesenteric tissue with, for example, Adson-Brown forceps and Metzenbaum scissors, and using a scalpel handle or other hard objects wrapped in moist gauze to wipe longitudinally, thereby wiping off muscularis and submucosa to complete. The epithelial cells of mucosa can also be dissociated by soaking the tissue in a de-epithelialization solution (such as, but not limited to, hypertonic saline). The resulting UBM comprises the basement membrane of the mucosa and adjacent lamina propria, which is further treated with peracetic acid, lyophilized and powdered as described in US Pat. No. 8,361,503, incorporated herein by reference.
[0176] Dermis slices can be used to prepare the ECM hydrogels described in PCT Application No. 2015 / 15164728, incorporated herein by reference. In a specific non-limiting example, dermis can be treated with 0.25% trypsin / 1% TRITON- -100 (i.e., without SDS) were decellularized on a vortex shaker at 300 RPM in the following solutions: 0.25% trypsin for 6 hours, 1×; deionized water, 15 minutes, 3×; 70% ethanol, 10 to 12 hours, 1×; 3% H 2 O 2 , 15 min, 1×, deionized water, 15 min, 2×; 1% TRITON- -100 0.26% EDTA / 0.69% Tris solution, 6 hours, 1×, then overnight, 1×; deionized water, 15 minutes, 3×; 0.1% peracetic acid / 4% ethanol, 2 hours, 1×; PBS, 15 minutes, 2×; and finally deionized water, 15 minutes, 2×. The dermal sheets were then freeze-dried and subsequently granulated using a Waring blender and a Wiley Mill with a #20 mesh screen.
[0177] In some aspects, epithelial cells can first be stripped by soaking the tissue in a de-epithelialization solution (e.g., hypertonic saline, such as, but not limited to, 1.0N saline) for 10 minutes to 4 hours. Exposure to a hypertonic saline solution can effectively remove epithelial cells from the basement membrane below. The tissue remaining after the initial stripping process comprises the tissue layer of the epithelial basement membrane and the epithelial basement membrane abaxial cavity. Next, the tissue is further processed to remove most of the abaxial cavity tissue, but the epithelial basement membrane is not removed. By the combination of mechanical abrasion or enzymatic treatment, hydration and abrasion, outer serosal (outer serosal), adventitial (adventitial), smooth muscle tissue, submucosal layer and most of muscularis mucosa are removed from the remaining de-epithelialization tissue.
[0178] In some aspects, the ECM itself can be sterilized by many standard techniques, including but not limited to exposure to peracetic acid, low-dose gamma radiation, gas plasma sterilization, ethylene oxide treatment or electron beam treatment. More generally, the sterilization of the ECM is carried out by soaking in 0.1% (v / v) peracetic acid, 4% (v / v) ethanol and 95.9% (v / v) sterile water for two hours. The peracetic acid residue is removed by washing twice with PBS (pH=7.4) for 15 minutes and washing twice with sterile water for 15 minutes. The ECM material can be sterilized by propylene oxide or ethylene oxide treatment, gamma radiation treatment (0.05 to 4mRad), gas plasma sterilization, peracetic acid sterilization or electron beam treatment. The ECM can also be sterilized by glutaraldehyde treatment, which will cause the protein material to be cross-linked, but this treatment will greatly change the material, making it slowly absorbed or not absorbed at all, and triggering a different type of host remodeling, which is more similar to the formation or encapsulation of scar tissue rather than constructive remodeling. The cross-linking of the protein material can also be induced by carbodiimide or dehydrogenation heat method or photooxidation method. As disclosed in U.S. Pat. No. 8,361,503, the ECM is sterilized by immersion in 0.1% (v / v) peracetic acid (a), 4% (v / v) ethanol and 96% (v / v) sterile water for 2 hours. The ECM material is then washed twice with PBS (pH=7.4) for 15 minutes, and twice with deionized water for 15 minutes.
[0179] Typically, after the tissue of interest is isolated, decellularization is performed by various methods, such as, but not limited to, exposure to hypertonic saline, peracetic acid, TRITON- Or other detergents. Sterilization and decellularization can be performed simultaneously. For example, but not limited to, the above-mentioned sterilization with peracetic acid can also be used for decellularization. Then, the ECM can be dried by freeze drying (freeze drying) or air drying. The dried ECM can be pulverized by methods including but not limited to tearing, grinding, cutting, grinding and shearing. The pulverized ECM can also be further processed into a powder form by methods such as, but not limited to, grinding or grinding in a frozen or freeze-dried state.
[0180] Mammalian ECM is also commercially available. This includes AVITENE TM , and XENMATRIX TM These commercially available products can also be used to produce mammalian acoustic ECM hydrogels.
[0181] Acoustic ECM hydrogel
[0182] In some aspects, the crushed ECM (e.g., mammalian ECM) is diluted in a liquid to prepare an acoustic ECM hydrogel. The ECM may be freeze-dried before crushing, or may not be freeze-dried. The ECM may be crushed, for example, by grinding, chopping or cutting the ECM. The crushed ECM should have a fragment range of about 10 μm to about 5000 μm, about 10 μm to about 4000 μm, about 10 μm to about 3000 μm, about 10 μm to about 2000 μm, about 10 μm to about 1000 μm, about 10 μm to about 500 μm, about 30 μm to about 300 μm, about 40 μm to about 400 μm, about 25 μm to about 500 μm, about 50 μm to about 500 μm, about 100 μm to about 300 μm, about 10 μm to about 50 μm, or about 10 μm to about 100 μm. In one aspect, the fragment range of the ECM is from about 10 μm to about 1000 μm. In another preferred aspect, the fragment range of the ECM is from about 10 μm to about 2000 μm. In a non-limiting example, the fragment range is about 30 μm to about 300 μm. The liquid can be a buffer of neutral pH, for example, pH is about 7.0 to about 7.6, for example, about 7.1 to about 7.5, for example, about 7.2 to about 7.4, for example, about 7.0 to 7.2, for example, about 7.0 to 7.4, for example, about 7.1, 7.2, 7.3, 7.4, 7.5 or 7.6. The ECM can be diluted in an isotonic buffered saline solution, for example, but not limited to phosphate buffered saline (PBS) or Tris buffered saline. In some aspects, the osmotic pressure of the buffered saline solution is about 290 mOsm / L. The liquid can be water. In some aspects, the isotonic buffer, including but not limited to phosphate buffered saline (PBS), can be used to bring the solution to a target pH, or to help maintain the pH and ionic strength of the gel at target levels, such as physiological pH and ionic conditions. This forms a liquid ECM solution.
[0183] The preparation method of acoustic hydrogels generally does not involve the use of acidic proteases, including pepsin, trypsin or hyaluronidase, or enzymatic digestion of the ECM tissue. See PCT application number WO 2015 / 164728, which is incorporated herein by reference. Typically, the ECM dissolved in the liquid is not in contact with an acidic protease.
[0184] The method for preparing extracellular matrix hydrogel by applying acoustic technology (such as ultrasonic frequency) can be found in U.S. Patent Application Publication No. 2022 / 0143265, which is incorporated herein by reference for all purposes. In some aspects, the concentration of the ECM used in the liquid is greater than about 25mg / ml. The concentration of the ECM used in the liquid (such as buffer) can be about 25mg / ml to about 600mg / ml. Suitable concentrations also include about 25mg / ml to about 300mg / ml, about 25mg / ml to about 200mg / ml and about 25mg / ml to about 150mg / ml. The concentration of the ECM used in the liquid (such as buffer) can be about 50mg / ml to 600mg / ml. Suitable concentrations also include about 50mg / ml to about 300mg / ml, about 50mg / ml to about 200mg / ml and about 50mg / ml to about 150mg / ml. Suitable concentrations include about 25 mg / ml, 30 mg / ml, 35 mg / ml, 40 mg / ml, 45 mg / ml, 50 mg / ml, 55 mg / ml, 60 mg / ml, 65 mg / ml, 70 mg / ml, 75 mg / ml, 80 mg / ml, 85 mg / ml, 90 mg / ml, 95 mg / ml, 100 mg / ml, 105 mg / ml, 110 mg / ml, 115 mg / ml, 120 mg / ml, 125 mg / ml, 130 mg / ml, 135 mg / ml, 140 mg / ml, 150 mg / ml, 155 mg / ml, 160 mg / ml, 165 mg / ml, 170 mg / ml, 175 mg / ml, 180 mg / ml, 185 mg / ml, 190 mg / ml, 195 mg / ml and 200 mg / ml. Exemplary concentrations include about 25 mg / ml, 100 mg / ml, and 150 mg / ml. In one non-limiting example, the concentration of the ECM in the liquid is about 25 mg / ml to about 150 mg / ml. In one non-limiting example, the concentration of the ECM in the liquid is 100 mg / ml.
[0185] The liquid (e.g., buffered saline solution) solution of the ECM described in ultrasonic frequency treatment. In one aspect, the ultrasonic frequency is about 20kHz to about 100kHz. The liquid solution of the ECM can be about 20kHz to about 30kHz, about 20Hz to about 40kHz, about 20kHz to about 50kHz, about 20kHz to about 60kHz, about 20kHz to about 70kHz, about 20kHz to about 80kHz, or about 20kHz to about 90kHz ultrasonic treatment with a frequency of about 20kHz, 30kHz, 40kHz, 50kHz, 60kHz, 70kHz, 80kHz, 90kHz or 100kHz. In a non-limiting example, the liquid solution of the ECM can be about 20kHz with a frequency of about 20kHz ultrasonic treatment.
[0186] The liquid (e.g., buffered saline) solution of the ECM is sonicated for at least 20 seconds, for example, at least 30 seconds. The liquid (e.g., buffered saline) solution of the ECM is sonicated for at least 60 seconds. In some aspects, the liquid solution of the ECM is sonicated for at least 60 seconds to about one hour. In other aspects, the liquid solution of the ECM is sonicated for at least 60 seconds to about 30 minutes. In other aspects, the liquid solution of the ECM is sonicated for at least 30 seconds to about 30 minutes. In more aspects, the liquid solution of the ECM is sonicated for at least 60 seconds to about 15 minutes. In more aspects, the liquid solution of the ECM is sonicated for at least 30 seconds to about 15 minutes. In some aspects, the liquid solution of the ECM is sonicated for at least 60 seconds to about 10 minutes. In some aspects, the liquid solution of the ECM is sonicated for at least 30 seconds to about 10 minutes. In some aspects, the liquid solution of the ECM is sonicated for at least 60 seconds to about 5 minutes. In some aspects, the liquid solution of the ECM is sonicated for at least 30 seconds to about 5 minutes. The liquid solution of the ECM can be sonicated for about 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 11 minutes, 12 minutes, 13 minutes, 14 minutes, 15 minutes, 16 minutes, 17 minutes, 18 minutes, 19 minutes, 20 minutes, 21 minutes, 22 minutes, 23 minutes, 24 minutes, 25 minutes, 26 minutes, 27 minutes, 28 minutes, 29 minutes, 30 minutes, 31 minutes, 32 minutes, 33 minutes, 34 minutes, 35 minutes, 36 minutes, 37 minutes, 38 minutes, 39 minutes, 40 minutes, 41 minutes, 42 minutes, 43 minutes, 44 minutes, 45 minutes, 46 minutes, 47 minutes, 48 minutes, 49 minutes, 50 minutes, 51 minutes, 52 minutes, 53 minutes, 54 minutes, 55 minutes, 56 minutes, 57 minutes, 58 minutes, 59 minutes, or 60 minutes. In some aspects, the liquid solution of the ECM is treated with ultrasonic pulses for a total time as listed herein. Therefore, in some aspects, the liquid (e.g., buffered saline solution) solution of the ECM is treated with pulses, such as pulse lengths of at least about 30 seconds, such as lengths of about 30 seconds, about 40 seconds, or about 60 seconds. The liquid (e.g., buffered saline solution) solution of the ECM can be treated with ultrasound 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, so that the total time of the treatment is 60 seconds to one hour, or any one of the total times listed.The liquid solution of the ECM can be processed for 20 seconds, 21 seconds, 22 seconds, 23 seconds, 24 seconds, 25 seconds, 26 seconds, 27 seconds, 28 seconds, 29 seconds, 30 seconds, 31 seconds, 32 seconds, 33 seconds, 34 seconds, 35 seconds, 36 seconds, 37 seconds, 38 seconds, 39 seconds, 40 seconds, 41 seconds, 42 seconds, 43 seconds, 44 seconds, 45 seconds, 46 seconds, 47 seconds, 48 seconds, 49 seconds, 50 seconds, 51 seconds, 52 seconds, 53 seconds, 54 seconds, 55 seconds, 56 seconds, 57 seconds, 58 seconds, 59 seconds or 60 seconds. The liquid (e.g., buffered saline solution) solution of the ECM can be processed for at least 30 seconds. Typically, if a variety of therapeutic methods are used, they will be performed in less than 1 hour. Exemplary methods are 30 seconds of ultrasonic pulses, followed by 30 to 45 seconds without treatment, followed by another treatment. The treatment is applied 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more. An exemplary non-limiting method is 6 30 second ultrasound pulses, such as about 20kHz ultrasound pulses, followed by a 45 second rest, repeated 6 times, for a total of 3 minutes of ultrasound treatment.
[0187] The amplitude of the ultrasound is about 20 μm to 320 μm. Typically, the amplitude is measured from the center of the probe used to generate the ultrasound. The amplitude of the vibrating surface of the probe is the distance between the positions of the probe in the fully extended and fully retracted states, in micrometers (μm). In some aspects, the amplitude is about 30 μm to about 200 μm. In other aspects, the amplitude is about 36 μm to about 180 μm. The amplitude may be about 30μm, 40μm, 50μm, 60μm, 70μm, 80μm, 90μm, 100μm, 110μm, 120μm, 130μm, 140μm, 150μm, 160μm, 170μm, 180μm, 190μm, 200μm, 210μm, 220μm, 230μm, 240μm, 250μm, 260μm, 270μm, 280μm, 290μm or 300μm. In some aspects, the amplitude can be about 30-40 μm, 40-50 μm, 50-60 μm, 60-70 μm, 70-80 μm, 80-90 μm, 90-100 μm, 100-110 μm, 110-120 μm, 120-130 μm, 130-140 μm, 140-150 μm, 150-160 μm, 160-1 In one non-limiting example, the ultrasound has a frequency of about 20 kHz and an amplitude of about 36 μm to 180 μm. In another non-limiting example, the ultrasound has a frequency of about 20 kHz and an amplitude of about 36 μm to about 180 μm, and the treatment is about 1 minute, 2 minutes, 3 minutes, 4 minutes or 5 minutes in total, for example, about 3 minutes. The ultrasonic treatment can last for about 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 11 minutes, 12 minutes, 13 minutes, 14 minutes, 15 minutes, 16 minutes, 17 minutes, 18 minutes, 19 minutes or 20 minutes. The ultrasonic treatment can be about 30 seconds to about 5 minutes. The ultrasonic treatment can be, for example, between about 1 to about 5 minutes. The ultrasonic treatment can be about 1 minute to about 10 minutes. The ultrasonic treatment can be, for example, between 1 minute to about 20 minutes. In more aspects, the ultrasonic treatment can be less than about 1 hour, less than about 30 minutes, less than about 20 minutes or less than about 10 minutes. In some aspects, the ultrasonic treatment can last at least 30 seconds.In other aspects, the ultrasonic treatment can be from about 10 minutes to about 24 hours, such as about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours or 24 hours. In some aspects, the ultrasonic treatment can be up to 48 hours.
[0188] In some aspects, the liquid solution of the ECM is treated with ultrasound at a temperature range of about 30°C to about 43°C. In one aspect, the liquid solution of the ECM is treated with ultrasound at a temperature range of about 35°C to about 40°C. In one aspect, the liquid solution of the ECM is treated with ultrasound at a temperature range of about 36°C to about 38°C. In another aspect, the liquid solution of the ECM is treated with ultrasound at a temperature range of about 37°C or higher, for example, a temperature of about 37°C to about 55°C, for example, about 37C to about 50°C, for example, about 37°C to about 45°C, for example, about 37°C to about 40°C. The liquid solution of the ECM is treated with ultrasound at a temperature of about 37°C, 38°C, 39°C, 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, 47°C, 48°C, 49°C, 50°C, 51°C, 52°C, 53°C, 54°C or 55°C. In other aspects, the liquid solution of ECM is treated with ultrasound at a temperature greater than about 38°C, such as about 38°C to about 50°C, such as about 38°C to about 45°C, such as about 38°C to about 40°C.
[0189] In some aspects, an acoustic ECM hydrogel is produced by ultrasonic treatment. The acoustic ECM hydrogel typically undergoes a phase transition from sol to gel at around 37°C, and thus transitions to a liquid phase at above 37°C and to a gel phase at below 37°C. At 37°C, the acoustic ECM hydrogel is sufficiently viscous, similar to a gel; however, when the temperature rises above 37°C, the gel transitions to a sol. When the temperature drops below 37°C, the acoustic ECM hydrogel forms a gel (sol-to-gel transition). Therefore, in some aspects, after ultrasonic treatment, the acoustic ECM hydrogel is cooled to a temperature below 37°C, for example, from about 4°C to about 36°C. The acoustic ECM hydrogel can be cooled to room temperature, typically about 25°C. In some aspects, the acoustic ECM hydrogel is cooled to about 15°C to about 25°C. The acoustic ECM hydrogel can be cooled to about 23°C to about 27°C. The acoustic ECM hydrogel can be cooled to about 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, 11°C, 12°C, 13°C, 14°C, 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C or 30°C to induce the gel phase.
[0190] In some aspects, exogenous MBV can be added to the ECM solution before sonication. In other aspects, exogenous MBV can be added to the acoustic ECM hydrogel after sonication. The exogenous MBV can be added to the ECM hydrogel before the hydrogel is transformed into a gel (e.g., when it is in a liquid phase); thus, in one aspect, exogenous MBV is added to the acoustic ECM hydrogel at a temperature greater than 37°C to produce a composition comprising an acoustic hydrogel disclosed herein (containing exogenous MBV). On the other hand, the exogenous MBV is added to the acoustic ECM hydrogel during the gel stage of the acoustic ECM hydrogel, for example, at a temperature below 37°C. For example, disclosed herein is an acoustic ECM hydrogel comprising exogenous MBV.
[0191] In some aspects, an acoustic mammalian ECM hydrogel is disclosed, wherein the hydrogel is thermoreversible, wherein the hydrogel is in a solid (gel) phase at a temperature below about 37°C and in a liquid (sol) phase at a temperature above 37°C. The acoustic hydrogel can be prepared using any of the methods disclosed herein. In some aspects, the storage modulus (G') of the acoustic ECM hydrogel is about one order of magnitude higher than the loss modulus (G"). In other aspects, the viscosity of the acoustic ECM hydrogel is at a temperature of about 15 to about 37°C, for example, at about 15°C, 15°C, 16°C, 17°C, 18°C, 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, In one aspect, the acoustic ECM hydrogel has a viscosity that decreases with increasing stress at room temperature and / or at about 23°C to about 27°C and / or about 15°C to about 25°C. In one aspect, the transition of the acoustic ECM hydrogel from gel to sol is at about 37°C, so that the hydrogel can be used as a submucosal pad because it is viscous enough at body temperature.
[0192] These acoustic ECM hydrogels can be made from any mammalian ECM disclosed above. In a specific non-limiting example, the ECM is a human ECM. In other non-limiting examples, the ECM is a bladder ECM, a small intestinal submucosal ECM, an esophageal ECM, or a dermal ECM. In one aspect, the ECM is a bladder ECM. In another aspect, the ECM is a dermal ECM. In another aspect, the ECM is an esophageal ECM. The source of the ECM can be, for example, pig, cow, or sheep.
[0193] In some aspects, the acoustic ECM hydrogel includes an ECM with a concentration of about 25 mg / ml to about 600 mg / ml. In other aspects, the acoustic ECM hydrogel includes an ECM with a concentration of about 20 mg / ml to about 600 mg / ml, about 25 mg / ml to about 300 mg / ml, about 25 mg / ml to about 200 mg / ml, and about 25 mg / ml to about 150 mg / ml. In more aspects, the ECM includes an ECM with a concentration of about 50 mg / ml to 600 mg / ml in a liquid (e.g., in a buffer). The ECM concentration of the acoustic ECM hydrogel can also be about 50 mg / ml to about 300 mg / ml, about 50 mg / ml to about 200 mg / ml, about 50 mg / ml to about 150 mg / ml, about 50-100 mg / ml, or about 100-150 mg / ml. In some non-limiting examples, the acoustic ECM hydrogel comprises a concentration of about 20 mg / ml, 25 mg / ml, 30 mg / ml, 35 mg / ml, 40 mg / ml, 45 mg / ml, 50 mg / ml, 55 mg / ml, 60 mg / ml, 65 mg / ml, 70 mg / ml, 75 mg / ml, 80 mg / ml, 85 mg / ml, 90 mg / ml, 95 mg / ml, 100 mg / ml, 105 mg / ml. / ml, 110mg / ml, 115mg / ml, 120mg / ml, 125mg / ml, 130mg / ml, 135mg / ml, 140mg / ml, 150mg / ml, 155mg / ml, ECM at 160mg / ml, 165mg / ml, 170mg / ml, 175mg / ml, 180mg / ml, 185mg / ml, 190mg / ml, 195mg / ml and 200mg / ml.In some non-limiting examples, the acoustic ECM hydrogel comprises a concentration of about 20-25 mg / ml, 25-30 mg / ml, 30-35 mg / ml, 35-40 mg / ml, 40-45 mg / ml, 45-50 mg / ml, 50-55 mg / ml, 55-60 mg / ml, 60-65 mg / ml, 65-70 mg / ml, 70-75 mg / ml, 75-80 mg / ml, 80-85 mg / ml, 85-90 mg / ml, 90-95 mg / ml, 95-100 mg / ml, 100-105 mg / ml, 105-110 mg / ml, 110- 115mg / ml, 115-120mg / ml, 120-125mg / ml, 125-130mg / ml, 130-135mg / ml, 135-140mg / ml, 140-145mg / ml, 145-150mg / ml, 150-155mg / ml, 155-160mg / ml, 160-165mg / ml, 165-170mg / ml, 170-175mg / ml, 175-180mg / ml, 180-185mg / ml, 185-190mg / ml, 190-195mg / ml and 195-200mg / mL of ECM. Exemplary non-limiting concentrations of ECM also include about 25mg / ml, 100mg / ml and 150mg / ml. In one non-limiting example, the acoustic ECM hydrogel comprises an ECM at a concentration of about 25 mg / ml to about 150 mg / ml. In one aspect, the ECM concentration is about 100 mg / ml.
[0194] In some aspects, when the concentration of ECM is about 150 mg / mL, the acoustic ECM hydrogel has a viscosity of about 1400 Pa*s at 15° C. and a viscosity of about 400 Pa*s at 25° C. In other aspects, when the concentration of ECM is about 150 mg / mL, the acoustic ECM hydrogel has a storage modulus of about 2700 Pa*s at 15° C., about 800 Pa*s at 25° C., and 600 Pa*s at 37° C.
[0195] The liquid phase acoustic ECM hydrogel can be placed in a three-dimensional mold before cooling, or it can be spread on The acoustic ECM hydrogel can be configured to form a film on the sheet. The high concentration of ECM in the acoustic ECM hydrogel (50 to 600 mg / ml) can form a very thin sheet, such as a sheet as thin as 4 microns. The acoustic ECM hydrogel can be configured to any size greater than 4 microns and any two-dimensional or three-dimensional shape. In some aspects, a sheet with a thickness of about 4 to about 10 microns is formed, for example, a thickness of about 4 microns, 5 microns, 6 microns, 7 microns, 8 microns, 9 microns or 10 microns. The acoustic ECM hydrogel can form any three-dimensional shape, including but not limited to cylinders, spheres, ellipsoids, discs, sheets, cubes, cuboids, cones, triangles or rectangular prisms, as well as hollow spheres, hollow ellipsoids and open hollow cylinders, etc. The acoustic ECM hydrogel can also be used as an injection, for example by placing it in a syringe and squeezing it out of the syringe in a gel phase or a sol phase.
[0196] In some aspects, the mammal acoustic ECM hydrogel includes a concentration greater than about 0.1 mg / ml dissolved ECM. The mammal acoustic ECM gel may include a concentration of about 0.1 mg / ml to about 1,000 mg / ml dissolved ECM. Suitable concentrations also include about 1 mg / ml to about 1,000 mg / ml, 1 mg / ml to about 500 mg / ml, 1 mg / ml to about 300 mg / ml, 1 mg / ml to about 200 mg / ml, about 1 mg / ml to about 100 mg / ml, about 10 mg / ml to about 100 mg / ml, about 10 mg / ml to about 200 mg / ml, about 100 mg / ml to about 500 mg / ml, about 50 mg / ml to about 150 mg / ml, about 20 mg / ml to about 70 mg / ml, about 4 mg / ml to about 20 mg / ml, or about 40 mg / ml to about 66 mg / ml dissolved ECM. The mammalian acoustic ECM hydrogel may include an ECM dissolved in the liquid (e.g., buffer) at a concentration of about 10 mg / ml to about 500 mg / ml. The mammalian acoustic ECM hydrogel may include 10 mg / ml, 25 mg / ml, 30 mg / ml, 35 mg / ml, 40 mg / ml, 45 mg / ml, 50 mg / ml, 55 mg / ml, 60 mg / ml, 65 mg / ml, 70 mg / ml, 75 mg / ml, 80 mg / ml, 85 mg / ml, 90 mg / ml, 95 mg / ml, 100 mg / ml, 105 mg / ml, 11 In one non-limiting example, the mammal acoustic ECM hydrogel comprises an ECM dissolved at a concentration of about 20 mg / ml to about 70 mg / ml. In one non-limiting example, the mammal acoustic ECM hydrogel comprises an ECM dissolved at a concentration of about 40 mg / ml or about 66 mg / ml. In one non-limiting example, the mammalian acoustic ECM hydrogel comprises a dissolved ECM at a concentration of about 10 mg / ml to about 100 mg / ml. In one non-limiting example, the mammalian acoustic ECM hydrogel comprises a dissolved ECM at a concentration of about 50 mg / ml to about 150 mg / ml.In one non-limiting example, the mammalian acoustic ECM hydrogel comprises a dissolved ECM at a concentration of about 10 mg / ml to about 200 mg / ml. In one non-limiting example, the mammalian acoustic ECM hydrogel comprises a dissolved ECM at a concentration of about 10 mg / ml to about 500 mg / ml.
[0197] Exemplary concentrations include about 20 mg / ml, 40 mg / ml, 66 mg / ml, 70 mg / ml, and 150 mg / ml dissolved ECM. In one non-limiting example, the mammalian acoustic ECM hydrogel includes about 20 mg / ml to about 70 mg / ml dissolved ECM. In one non-limiting example, the mammalian acoustic ECM hydrogel includes about 40 mg / ml or about 66 mg / ml dissolved ECM.
[0198] In some aspects, the mammal acoustic ECM hydrogel includes an ECM dissolved at a concentration of about 25 mg / ml to about 600 mg / ml. In other aspects, the mammal acoustic ECM gel includes an ECM dissolved at a concentration of about 20 mg / ml to about 600 mg / ml, about 25 mg / ml to about 500 mg / ml, about 25 mg / ml to about 400 mg / ml, about 25 mg / ml to about 300 mg / ml, about 25 mg / ml to about 200 mg / ml, and about 25 mg / ml to about 150 mg / ml. In more aspects, the mammal acoustic ECM gel includes an ECM dissolved at a concentration of about 50 mg / ml to 600 mg / ml. The mammal acoustic ECM gel includes an ECM dissolved at a concentration of about 50 mg / ml to about 300 mg / ml, about 50 mg / ml to about 200 mg / ml, about 50 mg / ml to about 150 mg / ml, about 50-100 mg / ml, or about 100-150 mg / ml. In some non-limiting examples, the mammalian acoustic ECM hydrogel comprises a concentration of about 20-25 mg / ml, 25-30 mg / ml, 30-35 mg / ml, 35-40 mg / ml, 40-45 mg / ml, 45-50 mg / ml, 50-55 mg / ml, 55-60 mg / ml, 60-65 mg / ml, 65-70 mg / ml, 70-75 mg / ml, 75-80 mg / ml, 80-85 mg / ml, 85-90 mg / ml, 90-95 mg / ml, 95-100 mg / ml, 100-105 mg / ml, 105-110 mg / ml, 110 -115mg / ml, 115-120mg / ml, 120-125mg / ml, 125-130mg / ml, 130-135mg / ml, 135-140mg / ml, 140-145mg / ml, 145-150mg / ml, 150-155mg / ml, 155-160mg / ml, 160-165mg / ml, 165-170mg / ml, 170-175mg / ml, 175-180mg / ml, 180-185mg / ml, 185-190mg / ml, 190-195mg / ml and 195-200mg / mL dissolved ECM.
[0199] In some aspects, a composition comprising the mammal acoustic ECM hydrogel and trehalose is prepared. In more aspects, the composition used includes trehalose from about 0.1 mg / ml to about 700 mg / ml. In some aspects, the composition includes about 1 mg / ml trehalose to about 700 mg / ml trehalose. In other aspects, the composition includes trehalose from 50 mg / ml to about 500 mg / ml. In other aspects, the composition includes about 10 mg / ml trehalose to about 600 mg / ml, about 10 mg / ml to about 500 mg / ml, about 10 mg / ml to about 400 mg / ml, about 10 mg / ml to about 300 mg / ml, about 10 mg / ml to about 200 mg / ml, or about 10 mg / ml to about 100 mg / ml trehalose. In other aspects, the composition may include about 0.1 to about 100 mg / ml trehalose, about 0.1 to about 10 mg / ml trehalose or about 0.1 to about 1 mg / ml trehalose. In more aspects, the composition may include about 50mg / ml to about 400mg / ml trehalose, about 50mg / ml to about 300mg / ml trehalose, about 50mg / ml to about 200mg / ml trehalose, or about 50mg / ml to about 100mg / ml trehalose. In some aspects, the composition includes about 20mg / ml to about 70mg / ml trehalose. In some aspects, the composition includes about 10mg / ml to about 100mg / ml trehalose. In some aspects, the composition includes 15-30mg / ml trehalose. In some aspects, the composition includes 60-70mg / ml trehalose. In some aspects, the composition includes 20mg / ml trehalose. In some aspects, the composition includes 66mg / ml trehalose. In other aspects, the composition may include about 1 mg / ml, 2 mg / ml, 3 mg / ml, 4 mg / ml, 5 mg / ml, 6 mg / ml, 7 mg / ml, 8 mg / ml, 9 mg / ml, 10 mg / ml, 20 mg / ml, 30 mg / ml, 40 mg / ml, 50 mg / ml, 60 mg / ml, 66 mg / ml, 70 mg / ml, 80 mg / ml, 90 mg / ml, 100 mg / ml, 200 mg / ml, 300 mg / ml, 400 mg / ml, 500 mg / ml or 600 mg / ml of trehalose. In other aspects, the composition comprises about 100 mg / ml to about 700 mg / ml trehalose, for example about 100 mg / ml, 150 mg / ml, 200 mg / ml, 250 mg / ml, 300 mg / ml, 350 mg / ml, 400 mg / ml, 450 mg / ml, 500 mg / ml, 550 mg / ml or 600 mg / ml of trehalose.In further aspects, the composition can include about 0.1 mg / ml, 0.2 mg / ml, 0.3 mg / ml, 0.4 mg / ml, 0.5 mg / ml, 0.6 mg / ml, 0.7 mg / ml, 0.8 mg / ml, 0.9 mg / ml, or 1 mg / ml of trehalose.
[0200] In more aspects, the composition includes the mammalian acoustic ECM hydrogel (including dissolved ECM), additionally crushed mammalian ECM and optional trehalose. The crushed ECM is not sonicated and is not dissolved in the hydrogel. The crushed ECM is a unique additive to the composition that also includes the mammalian ECM hydrogel. The composition may include about 1 to about 30% of crushed ECM, weight / volume (w / v), which is not dissolved in the acoustic ECM hydrogel. Without being bound by theory, the crushed ECM typically has intact collagen particles, while the acoustic ECM hydrogel has collagen that has been ultrasonically destroyed, thereby increasing the soluble collagen content (Hussey et al., ultrasonic cavitation to prepare ECM hydrogels Acta Biomater. 2020 May; 108: 77-86, incorporated herein by reference in its entirety). Therefore, the acoustic ECM hydrogel composition containing additionally crushed mammalian ECM includes intact collagen and destroyed collagen.
[0201] The composition may include about 5% to about 30% w / v, about 10% to about 30%, about 15% to about 30%, about 20% to about 30%, about 25% to about 30%, about 1% to about 20%, about 5% to about 20%, about 10% to about 20%, about 15% to about 20%, about 10% to about 20%, or about 15% to about 20% of pulverized ECM (w / v). The composition may include about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25% or 30% pulverized ECM (w / v). The composition may include no more than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25% or 30% pulverized ECM (w / v). The composition can include at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or 30% pulverized ECM (w / v).
[0202] The pulverized ECM can be from the same species as the mammalian acoustic ECM hydrogel. In a specific non-limiting example, the mammalian acoustic ECM hydrogel and the pulverized ECM are both porcine. In other non-limiting examples, the mammalian acoustic ECM hydrogel and the pulverized ECM are both human.
[0203] The pulverized ECM can be from the same or different tissue as the mammalian acoustic ECM hydrogel. In one aspect, the mammalian acoustic ECM hydrogel and the pulverized ECM are from the same tissue. In one aspect, the mammalian acoustic ECM hydrogel and the pulverized ECM are dermal ECM. In one aspect, the mammalian acoustic ECM hydrogel and the pulverized ECM are porcine dermal ECM.
[0204] The composition can be sterilized before being applied to a subject. The composition can be sterilized using any method known to those skilled in the art, including filtration and radiation. In some respects, the composition is sterilized with ionizing radiation (such as electron beam or gamma radiation). The composition can be sterilized using gamma radiation, for example, the composition uses 10 to 50kGy radiation sterilization, such as 15 to 45kGy radiation, 20 to 40kGy radiation or 10 to 30kGy radiation sterilization. In some non-limiting examples, the composition is sterilized using 10kGy, 15kGy, 20kGy, 25kGy, 30kGy, 35kGy, 40kGy, 45kGy or 50kGy radiation. Typically, the composition is sterilized enough time to achieve the absence of detectable live pathogens, such as but not limited to viruses and bacteria.
[0205] Enzymatic ECM hydrogel
[0206] Methods for preparing ECM hydrogels are disclosed, for example, in U.S. Pat. No. 8,361,503, the contents of which are incorporated herein by reference for all purposes. Any type of extracellular matrix tissue can be used to prepare hydrogels useful in the methods disclosed herein (see U.S. Pat. Nos. 4,902,508; 4,956,178; 5,281,422; 5,352,463; 5,372,821; 5,554,389; 5,573,784; 5,645,860; 5,771,969; 5,753,267; 5,762,966; 5,8 In certain aspects, the ECM is isolated from a vertebrate, such as, but not limited to, a warm-blooded mammalian vertebrate, including, but not limited to, humans, monkeys, horses, pigs, cows, and sheep. In specific non-limiting examples, the ECM is porcine or human.
[0207] The ECM can be derived from any organ or tissue, including but not limited to the bladder, intestine, liver, esophagus and dermis. For example, the ECM can be derived from the bladder, small intestine, heart, dermis, liver, kidney, uterus, brain, blood vessels, lungs, bones, muscles, pancreas, placenta, stomach, spleen, colon, adipose tissue and / or esophagus. The ECM can be obtained from cell culture. In one aspect, the ECM is isolated from the bladder. On the other hand, the ECM is isolated from the esophagus. The ECM may or may not include a basement membrane portion of the ECM. In some aspects, the ECM includes at least a portion of the basement membrane.
[0208] In some aspects, as described in U.S. Pat. No. 8,361,503 (incorporated herein by reference), bladder ECM (e.g., porcine bladder ECM) is prepared by abrading bladder tissue with a scalpel handle and moistened gauze using a longitudinal wiping motion to remove the outer layers of both the serosa and the muscularis. After eversion of the tissue segment, the luminal portion of the mucosa is peeled off from the underlying tissue using the same wiping motion. In some aspects, perforation of the submucosal layer can be prevented. After removing these tissues, the resulting ECM consists primarily of the submucosal layer. Wolf et al., Biomaterials 33:7028-7038, 2012 (incorporated herein by reference) discloses the production of hydrogels from decellularized dermal ECM. For example, methods for producing ECM from esophageal tissue are disclosed in Badylak et al. J Pediatr Surg. 35(7):1097-103, 2000 and Badylak et al., J Surg Res. 2005 September; 128(1):87-97, 2005, both of which are incorporated herein by reference. US Patent No. 6,893,666 discloses the production of ECM from bladder, skin, esophagus and small intestine.
[0209] Commercially available ECM preparations can also be used in the methods, devices and compositions described herein. In one aspect, the ECM is derived from the small intestinal submucosa or SIS. Commercially available preparations include, but are not limited to, SURGISIS TM 、SURGISIS-ES TM 、STRATASIS TM and STRATASIS-ES TM (Cook Urological Inc.; Indianapolis, Ind.) and GRAFTPATCH TM (Organogenesis Inc.; Canton Mass.). In another aspect, the ECM is derived from the dermis. Commercially available preparations include, but are not limited to, PELVICOL TM (Permacol TM For sale; Bard, Covington, Ga.), REPLIFORM TM (Microvasive; Boston, Mass.) and ALLODERM TM (LifeCell; Branchburg, NJ). In another aspect, the ECM is derived from the bladder. Commercially available preparations include, but are not limited to, UBM (Acell Corporation; Jessup, Md.).
[0210] The tissue used to prepare the ECM can be obtained in a variety of ways, and once obtained, multiple parts of the obtained tissue can be used. ECM has also been prepared from the esophagus and small intestine, and hydrogels have been prepared using the ECM, see, for example, Keane et al., Tissue Eng. Part A, 21 (17-18): 2293-2300, 2015, incorporated herein by reference. The esophageal ECM can be prepared by mechanically separating the mucosa and submucosa from the muscularis externa, digesting the mucosa in a buffer including trypsin, and then exposing to sucrose, TRITON-X The SIS can be prepared by mechanically removing the superficial mucosa, superficial serosa and superficial muscularis externa from the intact small intestine, leaving the submucosa, muscularis mucosa and basal dense layer intact. The SIS is then treated with peracetic acid. Keane et al provide an exemplary protocol. For example, as disclosed in Wolf et al, J Biomed Mater Res A. 2013. 35(25): 6838–49. PMID: 23873846. PMCID: 3808505 (incorporated herein by reference), a dermal hydrogel can be produced.
[0211] In one aspect, the ECM is separated from the porcine bladder obtained to prepare bladder matrix (UBM). Excess connective tissue and residual urine are removed from the bladder. Serosa, outer muscularis, submucosa and most of the muscularis mucosa can be removed by a combination of mechanical abrasion or enzymatic treatment, hydration and abrasion. Mechanical removal of these tissues can be achieved by using the abrasion of longitudinal wiping action to remove the outer layer (particularly the abluminal smooth muscle layer), or even the luminal part (epithelial layer) of the mucosa. Mechanical removal of these tissues is by removing mesenteric tissue with, for example, Adson-Brown forceps and Metzenbaum scissors, and using a scalpel handle or other hard objects wrapped in moist gauze to carry out longitudinal wiping action, thereby wiping off the muscularis and submucosa to complete. The epithelial cells of mucosa can also be dissociated by soaking the tissue in a de-epithelialization solution (such as, but not limited to, hypertonic saline). The resulting UBM, comprising the basement membrane of the mucosa and adjacent lamina propria, is further treated with peracetic acid, lyophilized, and powdered as described in US Pat. No. 8,361,503, incorporated herein by reference.
[0212] Dermis slices can be used to prepare the enzymatic ECM hydrogel, see PCT Application No. 2015 / 15164728, incorporated herein by reference. In a specific non-limiting example, the dermis can be decellularized at room temperature with 0.25% trypsin / 1% TritonX-100 (i.e., without SDS) on a vortex oscillator at 300 RPM in the following solutions: 0.25% trypsin for 6 hours, l×; deionized water, 15 minutes, 3×; 70% ethanol, 10 to 12 hours, l×; 3% H 2 O 2 , 15 minutes, lx, deionized water, 15 minutes, 2x; 1% Triton X-100 in 0.26% EDTA / 0.69% Tris, 6 hours, lx, then overnight, lx; deionized water, 15 minutes, 3x; 0.1% peracetic acid / 4% ethanol, 2 hours, lx; PBS, 15 minutes, 2x; and finally deionized water, 15 minutes, 2x. The dermal sheets were then lyophilized and subsequently granulated using a Waring blender and a Wiley Mill with a #20 mesh screen.
[0213] In some aspects, epithelial cells can be peeled off by first soaking the tissue in a de-epithelialization solution (e.g., hypertonic saline, such as, but not limited to, 1.0N saline) for a period of 10 minutes to 4 hours. Epithelial cells can be effectively removed from the basement membrane below by being exposed to a hypertonic saline solution. The remaining tissue after the initial stripping procedure includes the tissue layer of the epithelial basement membrane and the epithelial basement membrane abaxial cavity. Next, the tissue is further processed to remove most of the abaxial cavity tissue, but the epithelial basement membrane is not removed. By the combination of mechanical abrasion or enzymatic treatment, hydration and abrasion, outer serosal (outer serosal), adventitial (adventitial), smooth muscle tissue, submucosal layer and most of the muscularis mucosa are removed from the remaining de-epithelialization tissue.
[0214] ECM can be sterilized by many standard techniques, including but not limited to exposure to peracetic acid, low-dose gamma radiation, gas plasma sterilization, ethylene oxide treatment or electron beam treatment. More generally, sterilization of ECM is performed by soaking in 0.1% (v / v) peracetic acid, 4% (v / v) ethanol and 95.9% (v / v) sterile water for two hours. Peracetic acid residues are removed by washing twice with PBS (pH=7.4) for 15 minutes and twice with sterile water for 15 minutes. ECM materials can be sterilized by propylene oxide or ethylene oxide treatment, gamma radiation treatment (0.05 to 4 mRad), gas plasma sterilization, peracetic acid sterilization or electron beam treatment. ECM can also be sterilized by glutaraldehyde treatment, which crosslinks the protein material, but this treatment greatly changes the material, causing it to be slowly absorbed or not absorbed at all, and triggering a different type of host remodeling, which is more similar to scar tissue formation or encapsulation rather than constructive remodeling. The cross-linking of the protein material can also be induced by carbodiimide or dehydrogenation heat method or photooxidation method. As disclosed in U.S. Pat. No. 8,361,503, the ECM is sterilized by immersion in 0.1% (v / v) peracetic acid (a), 4% (v / v) ethanol and 96% (v / v) sterile water for 2 hours. The ECM material is then washed twice with PBS (pH=7.4) for 15 minutes, and twice with deionized water for 15 minutes.
[0215] After isolating the tissue of interest, decellularization is performed by various methods, such as, but not limited to, exposure to hypertonic saline, peracetic acid, TRITON- Or other detergents. Sterilization and decellularization can be performed simultaneously. For example, but not limited to, sterilization with peracetic acid as described above can also be used to decellularize the ECM. The decellularized ECM can then be dried, or lyophilized (freeze-dried) or air-dried. The dried ECM can be pulverized by methods including but not limited to tearing, grinding, cutting, grinding and shearing. The pulverized ECM can also be further processed into a powder by methods such as but not limited to grinding or grinding in a frozen or freeze-dried state. In order to prepare dissolved ECM tissue, the pulverized ECM is digested with an acidic solution of an acidic protease to form a digestion solution. The acidic protease can be trypsin and / or pepsin, for example, or a combination thereof.
[0216] In one aspect, the decellularized ECM material is partially digested by the acidic protease. In one example, the decellularized ECM material is not completely digested compared to a 0.01M HCl solution of 1mg / mL pepsin digesting 1mg / mL freeze-dried powdered ECM material for 48 hours. In another example, the decellularized ECM material is not completely digested compared to a 0.01M HCl solution of 1mg / mL pepsin digesting 10mg / mL freeze-dried powdered ECM material for 48 hours. On the other hand, the digestibility of hyaluronic acid in the ECM material is less than 50%, 40%, 30%, 25%, 20% or 10% compared to undigested ECM material, see PCT application number WO 2015 / 164728, incorporated herein by reference.
[0217] The digestion solution of ECM is usually kept under constant stirring for a certain period of time at room temperature. The ECM digest can be used immediately, or it can be stored at -20°C, or frozen at a temperature such as, but not limited to, -20°C or -80°C. Thus, the ECM digest can be maintained in a dissolved state. For example, a method of maintaining a hydrogel in a dissolved state is disclosed in PCT Application No. PCT / US16 / 52261, filed on September 10, 2016 (incorporated herein by reference).
[0218] Once the ECM is dissolved (usually substantially completely dissolved), the pH of the solution is raised to between 7.2 and 7.8, and according to one aspect, to pH 7.4. The pH can be raised to about 7.2, 7.3, 7.4, 7.5, 7.6, 7.7 or 7.8. A base (e.g., a base containing hydroxide ions, including NaOH) can be used to increase the pH of the solution. Similarly, a buffer (e.g., an isotonic buffer, including but not limited to phosphate buffered saline (PBS)) can be used to bring the solution to a target pH, or to help maintain the pH and ionic strength of the gel at a target level, such as physiological pH and ionic conditions. This forms a "pre-gel" solution, i.e., a dissolved ECM hydrogel. The neutralized digestion solution (pre-gel, i.e., a dissolved ECM hydrogel) can gel at a lower critical solution temperature, see PCT Publication No. 2015 / 164728, incorporated herein by reference.
[0219] The ECM hydrogel forms a gel when the temperature is increased (sol to gel transition). The lower critical solution temperature (LCST) of the reverse gel is the temperature at which the reverse gel polymer is soluble in its solvent (e.g., water or an aqueous solvent). When the temperature rises above the LCST of the reverse gel, a hydrogel is formed. The general concept of polymer reverse gelation and its relationship to the LCST are well known in the chemical field. The ECM gel described herein is prepared, for example, from a decellularized intact ECM as described below, by digesting the ECM material with an acidic protease, neutralizing the material to form a pregel, and raising the temperature of the pregel to above the LCST of the pregel to gel the pregel, for example to form a hydrogel. The transition temperature of the acidic protease digestion from solution to gel is generally in the range of 10°C to 40°C, and any increment or range therebetween, for example, 20°C to 35°C. For example, the pregel can be heated to 37°C to form a hydrogel. For example, a pregel.
[0220] Thus, the ECM may generally be derived from mammalian tissue, such as, but not limited to, one of the bladder, esophagus, or small intestine. In a specific non-limiting example, the ECM is derived from the bladder. According to one aspect, the decellularized ECM material prepared from the tissue is not dialyzed prior to partial or complete digestion with the acidic protease, and / or the decellularized ECM material prepared from the tissue is not dialyzed after digestion with the acidic protease and prior to gelation of the neutralized and digested ECM material.
[0221] In one non-limiting aspect, the ECM is freeze-dried and pulverized. The ECM is then dissolved with an acidic solution of an acidic protease to produce a digested ECM, such as a bladder ECM. The acidic protease may be, but is not limited to, pepsin or trypsin, or a combination thereof. The ECM can then be dissolved at an acidic pH (e.g., greater than about pH 2, or between pH and 4) suitable for or most suitable for the enzyme, such as in a 0.01M HCl solution. The ECM is typically dissolved for about 12 to about 48 hours under mixing (stirring, agitating, blending, blending, rotating, tilting, etc.), depending on the tissue type (e.g., see the example below). The ECM hydrogel is prepared by the following steps: (i) pulverizing the extracellular matrix, (ii) dissolving intact, non-dialyzed or non-crosslinked extracellular matrix by digestion with an acidic solution of an acidic protease to produce a digestion solution, (iii) raising the pH of the digestion solution to a pH between 7.2 and 7.8 to produce a neutralized digestion solution (pre-gel solution), and (iv) gelling the solution.
[0222] Thus, disclosed are compositions of ECM enzymatically digested with an acidic protease in an acidic solution, containing exogenous MBV. When neutralized (e.g., to a pH of 7.0-7.8), and when heated to about 37°C, the composition forms a gel and the protease is inactivated. In one aspect, the exogenous MBV is not derived from bone or cardiac tissue. In another aspect, the concentration of exogenous MBV in the composition is greater than 5 mg / mL.
[0223] Also disclosed are compositions of ECM enzymatically digested in a neutral solution (e.g., pH 7.0-7.8), wherein the solution contains an inactivated acidic protease, such as inactivated pepsin and / or trypsin, or another inactivated acidic protease whose active form is suitable for digesting ECM; and the composition also contains exogenous MBV. A gel is formed when the solution is heated to about 37°C. In one aspect, the exogenous MBV is not derived from bone or cardiac tissue. In another aspect, the concentration of exogenous MBV in the composition is greater than 5 mg / mL. The acidic protease can be inactivated or inactivated due to, for example, a change in pH.
[0224] On the other hand, the ECM hydrogel can be centrifuged and the soluble fraction collected. Exemplary methods for fractionation of ECM hydrogels are disclosed in, for example, PCT Publication No. WO 2015 / 164728, which is incorporated herein by reference. The method disclosed in the PCT publication includes partially or completely digesting a decellularized ECM material prepared from a tissue with an acidic protease (e.g., pepsin); neutralizing the digested ECM material to a pH of 7.0-8.0, 7.2-7.8, or 7.4; gelling the neutralized, digested ECM material at a temperature above its lower critical solution temperature; centrifuging the gelled ECM material to produce a precipitate and a supernatant; and separating the supernatant and the precipitate, thereby separating the structural fraction and the soluble fraction of the ECM material.
[0225] When the ECM hydrogel is exposed to a temperature above the lower critical solution temperature, such as a temperature of about 37°C, the gel is formed. The ECM hydrogel in "pre-gel" form (dissolved ECM hydrogel) can be frozen and stored at a temperature such as, but not limited to, -20°C or -80°C. The ECM hydrogel in "pre-gel" form can be stored at room temperature, such as about 25°C. In some non-limiting examples, the ECM hydrogel is in the pre-gel form when it is below 37°C, such as 25°C, 24°C, 23°C, 22°C, 21°C, 20°C, 19°C, 18°C, 17°C, 16°C, 15°C, 14°C, 13°C, 12°C, 11°C, 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4°C. The ECM hydrogel can be stored frozen, so it can be stored below 0°C. As used herein, the term "pre-gel form" or "pre-gel" refers to the ECM hydrogel in which the pH is increased but has not yet gelled. For example, but not limited to, the pH of the ECM hydrogel in pre-gel form is between 7.2 and 7.8. In some aspects, the dissolved ECM hydrogel is used in the method disclosed herein. For example, the PCT application number PCT / US16 / 52261 submitted on September 10, 2016 (incorporated herein by reference) discloses a method for keeping the hydrogel in dissolved form. In some aspects, the ECM composition prepared by any method described herein is absorbed or otherwise dispersed on or in a biocompatible substrate. Non-limiting examples of biocompatible substrates include: meshes, nonwoven decellularized tissues, polymer compositions, polymer structures, cell growth scaffolds, implants, orthopedic implants and intraocular lenses, sutures, intravascular implants, stents and grafts. The compositions described herein can be applied to or incorporated into nonwoven materials (e.g., bandages), sutures, implants (e.g., ceramic, metal, or polymer implants (e.g., prostheses, artificial or otherwise modified blood vessels, valves, intraocular lenses, or tissue implants)) by any suitable method. As used herein, the term "coat" and related cognates (e.g., "coated" and "coating") refer to a process consisting of covering an inorganic structure partially or completely with the composition herein. For example, but not limited to, coating an inorganic structure with a dissolved fraction can include methods such as pouring, embedding, layering, dipping, and spraying. Ultrasonic treatment can be used to assist in coating the inorganic structure.
[0226] The composition used includes an ECM hydrogel, i.e., an "enzymatic" ECM hydrogel containing exogenous MBV. Exogenous MBV is added to enrich the biological activity of the ECM hydrogel and improve its therapeutic efficacy of reducing inflammation and enhancing tissue growth and repair when applied to or implanted into a subject. The enzymatic ECM hydrogel is made of dissolved ECM. In order to prepare the dissolved ECM tissue, the crushed ECM is digested with an acidic solution of an acidic protease to form a digestion solution. As used herein, the term "acidic protease" refers to an enzyme that cleaves peptide bonds, wherein the peptide bond cleavage activity of the enzyme is enhanced at acidic pH. For example, but not limited to, acidic proteases may include pepsin and trypsin. In one aspect, the ECM is lyophilized before crushing.
[0227] The digestion solution of ECM is usually stirred constantly for a certain period of time at room temperature. The ECM digest can be used immediately, or stored at -20°C or frozen at, for example, but not limited to, -20°C or -80°C. In order to form a "pre-gel" solution, the pH of the digestion solution is increased to between 7.2 and 7.8. The pH can be increased by adding one or more alkalis or isotonic buffer solutions (for example, but not limited to NaOH or PBS at pH 7.4). The method usually does not include a dialysis step before gelation, thereby obtaining a more complete ECM-like matrix, which usually gels more slowly at 37°C than similar collagen or dialyzed ECM preparations. Therefore, the gel is more suitable for injection into the patient's body, and because many natural soluble factors (for example, but not limited to cytokines) are retained, more natural ECM properties are also retained.
[0228] As used herein, the term "isotonic buffer solution" refers to a solution buffered to a pH between 7.2 and 7.8, with a balanced salt concentration to promote an isotonic environment. As used herein, the term "base" refers to any compound or compound solution having a pH greater than 7. For example, but not limited to, the base is an alkaline hydroxide or an aqueous solution of an alkaline hydroxide. In certain aspects, the base is NaOH or a solution of NaOH in PBS.
[0229] At this point, this "pre-gel" solution can be incubated at a suitably warm temperature (for example, but not limited to, at about 37°C) to gel. The pre-gel can be frozen and stored at, for example, but not limited to, -20°C or -80°C. As used herein, the term "pre-gel solution" or "pre-gel" refers to a digestion solution with an increased pH. For example, but not limited to, the pH of the pre-gel is between 7.2 and 7.8. The ECM hydrogel composition of the present invention may include an inactivated acidic protease. The pH of the ECM hydrogel composition of the present invention may be between 7.2 and 7.8. The "pre-gel" may contain exogenous MBV. In one aspect, the exogenous MBV is not derived from cardiac or bone ECM.
[0230] The ECM hydrogel, the digestion solution or the pre-gel may contain ECM dissolved at a concentration between 1 mg / mL and 500 mg / mL. In some aspects, the amount of ECM dissolved in the ECM hydrogel, the digestion solution or the pre-gel is between 1 mg / mL and 400 mg / mL, for example, 1 mg / mL to 350 mg / mL, or 1 mg / mL to 300 mg / mL, or 1 mg / mL to 250 mg / mL, or 1 mg / mL to 200 mg / mL, or 1 mg / mL to 150 mg / mL, or 1 mg / mL to 100 mg / mL, or 1 mg / mL to 50 mg / mL, or 5 mg / mL to 250 mg / mL, or 20 mg / mL to 200 mg / mL, or 5 mg / mL to 200 mg / mL, or 5 mg / mL to 100 mg / mL. In more aspects, the amount of dissolved ECM in the ECM hydrogel, the digestion solution or pre-gel is between about 5 mg / ml to about 50 mg / ml, for example, about 10 mg / ml to about 50 mg / ml, about 20 mg / ml to about 50 mg / ml, about 30 mg / ml to about 50 mg / ml, about 40 mg / ml to about 50 mg / ml, about 5 mg / ml to about 40 mg / ml, about 5 mg / ml to about 30 mg / ml, about 5 mg / ml to about 20 mg / ml, or about 5 mg / ml to about 10 mg / ml. For example, the ECM hydrogel, the digestion solution or the pre-gel may contain a concentration of about 5 mg / ml, 10 mg / ml, 15 mg / ml, 20 mg / ml, 25 mg / ml, 30 mg / ml, 35 mg / ml, 40 mg / ml, 45 mg / ml, 50 mg / ml, 60 mg / ml, 65 mg / ml, 70 mg / ml, 75 mg / ml, 80 mg / ml, 85 mg / ml, 90 mg / ml, 95 mg / ml, 100 mg / ml, 150 mg / ml, 200 mg / ml, 250 mg / ml, 300 mg / ml, 350 mg / ml, 400 mg / ml, 450 mg / ml or 500 mg / ml dissolved ECM. In a non-limiting example, the amount of the ECM dissolved in the ECM hydrogel, the digestion solution or the pre-gel is between 10 mg / ml and 30 mg / ml. In another non-limiting example. The amount of ECM dissolved in the ECM hydrogel, the digestion solution or the pre-gel is between 1 mg / mL and 20 mg / mL. In another non-limiting example, the amount of ECM dissolved in the ECM hydrogel, the digestion solution or the pre-gel is between 4 mg / mL and 20 mg / mL. In another non-limiting example, the amount of ECM dissolved in the ECM hydrogel, the digestion solution or the pre-gel is between 1 mg / mL and 50 mg / mL.In some aspects, the amount of dissolved ECM in the ECM hydrogel, the digestion solution, or the pre-gel is about 5 to about 100 mg / mL, such as 50 to 100 mg / mL, 25 to 75 mg / mL, 60 to 80 mg / mL, 40 to 60 mg / mL, 50 to 80 mg / mL, or about 30 to about 60 mg / mL.
[0231] Other considerations
[0232] In some aspects, the disclosed compositions are absorbed or otherwise dispersed onto or in a biocompatible substrate. Non-limiting examples of biocompatible substrates include: meshes, nonwoven decellularized tissues, polymer compositions, polymer structures, cell growth scaffolds, implants, orthopedic implants and intraocular lenses, sutures, intravascular implants, stents, and grafts. In some aspects, the substrate is synthetic. In other aspects, the substrate is natural. The compositions described herein can be applied to nonwoven materials (e.g., bandages), sutures, implants (e.g., ceramic, metal, or polymer implants (e.g., prostheses, artificial or otherwise modified blood vessels, valves, intraocular lenses, or tissue implants)) by any suitable method, or incorporated therein. As used herein, the term "coat" and related homologues (e.g., "coated" and "coating") refer to a process in which an inorganic structure is partially or completely covered by a composition described herein. For example, but not limited to, coating an inorganic structure with the disclosed liquid composition can include methods such as pouring, embedding, layering, dipping, spraying.
[0233] In another aspect, the disclosed composition is applied in a liquid phase to a biocompatible structural material (e.g., a metal, an inorganic calcium compound (e.g., calcium hydroxide, calcium phosphate, or calcium carbonate), or a ceramic composition). Non-limiting examples of suitable metals are cobalt-chromium alloys, stainless steel alloys, titanium alloys, tantalum alloys, titanium-tantalum alloys, which may include non-metallic components and metal components (e.g., molybdenum, tantalum, niobium, zirconium, iron, manganese, chromium, cobalt, nickel, aluminum, and lanthanum), including but not limited to various grades of CP Ti (commercially pure titanium) or Ti 6A1 4V (90% wt. Ti, 6% wt. Al, and 4% wt. V), stainless steel 316, Nitinol (nickel-titanium alloy), and hydroxyapatite-coated titanium alloys. Metals are useful for their high strength, flexibility, and biocompatibility. Metals can also be formed into complex shapes, and many metals can withstand corrosion in biological environments, reduce wear, and do not cause damage to tissues. Other compositions include ceramics, calcium compounds, such as, but not limited to, aragonite. Combinations of metals, ceramics, and / or other materials may also be used.
[0234] Any useful agent can be mixed into any composition described herein, delivered together, used together or combined in other ways. For example, but not limited to, useful agents include interferons, interleukins, chemokines, monokines, hormones, coagulants, chemotherapeutic drugs and antibiotics.
[0235] Antibiotics or antimicrobial agents may be added to the composition to reduce the likelihood of infection at the treatment site. A variety of antibiotics are well known, including those that target the bacterial cell wall (e.g., penicillins and cephalosporins) or those that target the cell membrane (e.g., polymyxins), or those that interfere with essential bacterial enzymes (e.g., quinolones and sulfonamides). Antibiotics include, but are not limited to, clindamycin, erythromycin, tetracycline, minocycline, doxycycline, penicillin, ampicillin, carbenicillin, methicillin, cephalosporin, vancomycin and bacitracin, streptomycin, gentamicin, chloramphenicol, fusidic acid, ciprofloxacin and other quinolones, sulfonamides, trimethoprim, dapsone, isoniazid, teicoplanin, avoparcin, dalfopristin, vilgemycin, cefotaxime, ceftriaxone, piperacillin, ticarcillin, cefepime, cefpirome, rifampicin, pyrazinamide, ciprofloxacin, levofloxacin, enrofloxacin, amikacin, netikacin, imipenem, meropenem, linezolid, pharmaceutically acceptable salts thereof and prodrugs thereof. Antibacterial agents also include cyclic lipopeptides (e.g., daptomycin), glycylcyclines (e.g., tigecycline) and oxazolidinones (e.g., linezolid). Antibiotic can be narrow spectrum or broad spectrum antibiotic.Described antibiotic can target gram-negative bacteria or gram-positive bacteria.Topical antibiotic can include, for example macrolide antibiotic (for example erythromycin), sulfonamide antibiotic (for example sulfadiazine), cyclopeptide (for example bacitracin, polymyxin), pseudomonas acid (for example mupirocin), aminoglycoside (for example neomycin) or quinolone (for example ciprofloxacin or ofloxacin), nitroimidazole (for example metronidazole) or drug combination (for example bacteriocin / polymyxin or neomycin / polymyxin B / bacitracin).
[0236] Additionally, a local anesthetic may be added to the composition to minimize discomfort, such as lidocaine.Any suitable additive may be used so long as it is compatible with the composition and the particular patient and disease state being treated.
[0237] In some aspects, the composition, e.g., a sterilized composition, can be injected through a 5Fr / 16G catheter. In one aspect, the composition can be injected through a 5Fr / 16G catheter at room temperature or at room temperature and about 37°C.
[0238] How to use
[0239] Macrophages have been shown to be important regulators of normal healing and normal tissue development after injury. The disclosed compositions can reproduce the effects of the entire ECM on macrophage phenotype, thereby increasing M2-like, regulatory, or pro-remodeling macrophages. Therefore, any of the compositions disclosed herein can be used to change the phenotype of macrophages, such as for inducing regulatory M2 macrophages. For example, ECM hydrogels, whether acoustic ECM hydrogels or enzymatic ECM hydrogels, can be combined with exogenous MBVs to provide a composition for changing the phenotype of macrophages.
[0240] In some aspects, methods of inducing M2 macrophages in the subject by administering a therapeutically effective amount of a composition disclosed herein are disclosed. In other aspects, methods of reducing M1 (pro-inflammatory) macrophages in the subject are disclosed. The method comprises administering a therapeutically effective amount of a disclosed composition, thereby inhibiting M1 macrophages in the subject. The subject may be any subject of interest, including human subjects and animal subjects.
[0241] The disclosed compositions enhance hemostasis at the lesion of the subject. Therefore, methods for accelerating wound coagulation and / or reducing wound bleeding time are also disclosed. In some aspects, hemostasis is induced within about 10 to about 100 seconds, such as about 10 seconds, 20 seconds, 30 seconds, 40 seconds, 50 seconds, 60 seconds, 70 seconds, 80 seconds, 90 seconds or 100 seconds after applying the acoustic ECM hydrogel containing exogenous MBV to the subject. The disclosed compositions can be used to treat stroke.
[0242] In some aspects, a therapeutically effective amount of the composition can be topically applied to a subject's site to induce hemostasis. The subject may have a wound. The wound may be an external wound, or an internal wound that is not visible from the outside of the patient. The disclosed composition can be used as a hemostatic agent for any type of wound. The method may include selecting any one of the subjects of interest, such as a subject with any wound.
[0243] In some aspects, a method for treating a subject suffering from inflammation or having a wound is disclosed. The method includes applying the composition of a therapeutically effective amount topically to the inflammation or wound. In some aspects, the inflammation or wound is in the stomach, such as an ulcer. In some aspects, the inflammation or wound is in the throat, such as an ulcer. The composition disclosed herein can be applied locally (e.g., topical application, injection), or applied to the inflammation, wound or inflammation site of the stomach or ulcer by injection or by enteral administration. In some non-limiting examples, the subject suffers from an inflammatory condition, such as, but not limited to, inflammatory bowel disease, ulcerative colitis, Crohn's disease or rheumatoid arthritis. The method can include applying the ECM hydrogel to a tissue surface.
[0244] For example, a method for treating inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease) in a subject by administering to the subject an effective amount of an ECM hydrogel composition containing an exogenous MBV disclosed herein. The composition can be administered to a subject, such as a human subject, for example, by enema, by oral administration, by local administration in the intestine (e.g., local injection), or by systemic administration (e.g., by intravenous administration). For example, administration can be enteral administration, such as oral administration. For example, it can be directly administered to the intestine by enema. The amount of the composition administered is sufficient to reduce intestinal inflammation associated with inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease). For example, the amount of the composition administered reduces intestinal inflammation compared to the level of inflammation before the administration of the composition. For example, the composition can be administered to the subject weekly, every other week, monthly, every two months, or every three months. The method can also reduce symptoms associated with inflammatory bowel disease.
[0245] The disclosed compositions and methods can be used to treat Crohn's disease. The disclosed methods and compositions can be used to treat various types of Crohn's disease, including ileocolic Crohn's disease, Crohn's colitis, gastroduodenal Crohn's disease and jejunoileitis. Crohn's disease caused by a certain agent can be treated, such as Crohn's disease caused by immune system dysfunction (such as autoimmunity or innate immune impairment), genetic factors, intestinal bacterial changes and environmental factors. A variety of techniques can be used to identify subjects with Crohn's disease. For example, detection of Crohn's disease can include endoscopy (such as colonoscopy), imaging (such as using barium tracking X-rays, CT scans and MRI scans) and blood tests (such as to determine iron, vitamin D or vitamin B12 deficiency; erythrocyte sedimentation rate (ESR); and C-reactive protein levels). The method of applying the composition disclosed herein can reduce the severity or frequency of Crohn's disease attacks. These methods can also make Crohn's disease clinically relieved and endoscopically relieved. For example, in some aspects, compared with the score before treatment, the application of the disclosed composition reduces the Crohn's disease activity index (CDAI). In one aspect, the patient has a CDAI score reduced to less than 150 and experiences relief. On the other hand, the patient has a CDAI score reduced to less than 450 or lower (450 or higher represents a serious disease). On the other hand, the patient has a decline of at least 70 CDAI points (indicating a therapeutic response) because of receiving treatment according to the disclosed method. For example, on the other hand, the patient has a decline of at least 70 CDAI points (indicating a therapeutic response) because of treatment from the application of the disclosed composition, and the decline is maintained in 1 month, 2 months or 3 months or longer after application. In one aspect, the subject has a CDAI score decline since the application of the disclosed composition, and the decline is maintained in 1 month, 2 months or 3 months after application. In one aspect, the subject's CDAI score is reduced in 1 month, 2 months or 3 months treated with the disclosed composition. In one aspect, the efficacy of the treatment of Crohn's disease exceeds the duration of the course of treatment, for example, more than one month, two months, three months, four months, five months, six months or longer.
[0246] The disclosed composition can be used to treat a subject suffering from ulcerative colitis. A variety of techniques can be used to identify subject ulcerative colitis. For example, the detection of ulcerative colitis can include a complete blood count (e.g., to identify anemia or thrombocytosis), electrolyte or renal function tests (e.g., to identify hypokalemia, hypomagnesemia, or prerenal failure), liver function tests (e.g., to identify primary sclerosing cholangitis), X-rays, urinalysis, stool culture (e.g., to identify parasites or infectious pathogens), erythrocyte sedimentation rate or C-reactive protein measurement (e.g., to identify inflammation), or sigmoidoscopy (e.g., to identify colorectal ulcers). In some instances, the clinical colitis activity index can be used to assess the severity of ulcerative colitis. In some aspects, the disclosed composition is administered orally. The disclosed composition can be topically applied to, for example, the gut or bowel, for example, by enteral or enema or injection. The method can reduce the severity or frequency of ulcerative colitis attacks. The method can also cause clinical remission and endoscopic remission of ulcerative colitis. For example, in some aspects, compared with the score before treatment, the disclosed composition is applied to reduce the Mayo score or ulcerative colitis disease activity index (UCDAI) of ulcerative colitis. In one aspect, the patient has a Mayo score reduced to 2 points or less, and experiences remission. On the other hand, the patient has a Mayo score reduced to 5 points or less. On the other hand, the patient has a Mayo score reduced to less than 10 points. In one aspect, the subject is treated with the disclosed composition within a certain period of time, such as 1 month, 2 months or 3 months after application, and there is a reduction in Mayo score or UCDAI score. In one aspect, the efficacy of treating ulcerative colitis exceeds the duration of the course of treatment, for example, more than one month, two months, three months, four months, five months, six months or longer from the time of treatment.
[0247] The disclosed compositions can effectively increase the number, ratio or proportion of M2 macrophages in the gastrointestinal tract of a subject compared to M1 macrophages to treat inflammatory bowel diseases, such as Crohn's disease or ulcerative colitis. For example, when a subject is treated with the disclosed compositions, the number, ratio or proportion of M2 macrophages to M1 macrophages in the gastrointestinal tract (e.g., colon) of the subject increases. This increase can occur within at least one week, two weeks, or one month, for example, from the start of administration of the compositions disclosed herein.
[0248] Thus, for example, when treated with the compositions and methods disclosed herein, the histopathological evaluation of the subject's gastrointestinal tissue (e.g., colon tissue) will show less phenotypic characteristics of inflammation and disease characteristics (e.g., mucosal rupture, loss of confluent epithelial cells, increased cell mass in the lamina propria and submucosal layer) and more phenotypic characteristics of healthy intestinal tissue (e.g., colon tissue) characteristics (e.g., intact muscularis mucosa, the presence of healthy confluent mucosal epithelial cells and normal cell mass in the lamina propria and submucosal layer). In other non-limiting examples, the subject is an organ transplant recipient, a subject with graft-versus-host disease, a subject with myocardial infarction, or a subject with a wound, such as, but not limited to, a subject with a surgical wound or a non-surgical traumatic wound. Therefore, a method of accelerating wound healing and / or enhancing hemostasis in an individual in need is disclosed, comprising administering a therapeutically effective amount of a composition as disclosed herein. Administration can be topical administration to the site of the wound or transplant.
[0249] The composition can be applied to any wound site to enhance hemostasis and / or promote wound healing. The wound can be a wound on the skin or a wound on any surface (including but not limited to the eyes). A method for wounds caused by ischemia and ischemic damage (e.g., chronic venous leg ulcers caused by venous circulatory system reflux obstruction and / or insufficiency) is also provided. Therefore, the method of the present invention can utilize topical dermal administration or ocular administration.
[0250] Typically, in these applications, the composition is formulated for topical administration. The hydrogel can be applied to the tissue surface of any organ. For example, the composition disclosed herein can be applied to the esophagus to treat esophagitis. After applying the disclosed composition to a subject suffering from esophagitis, for example, applying to the esophagus, the inflammation of the esophagus can be reduced. In addition, compared with M1 macrophages, the disclosed composition can effectively increase the number, ratio or proportion of M2 macrophages in the subject's esophagus to treat esophagitis. For example, when treating a subject with the disclosed composition, the number, ratio or ratio of M2 macrophages in the subject's esophageal tissue is increased relative to that of M1 macrophages. This increase can occur, for example, within at least one week, two weeks or one month from the time of applying the composition disclosed herein.
[0251] Disclosed herein are topical compositions for healing wounds (e.g., dermal wounds). These treatable wounds may be superficial wounds, or may be deep wounds, involving damage to the dermis and epidermis of the skin. The wound may be a surgical wound. Therefore, a method for promoting wound healing in a subject and / or promoting blood coagulation (enhancing hemostasis) in the subject is provided.
[0252] The composition can be applied directly to the target site, for example in the form of a topical preparation (e.g., a sheet, a plug), or as part of a dressing or bandage. Bandages and wound dressings can contain the composition. These can be prepared by applying the composition to a bandage or wound dressing together with any other desired additives. These sheets, plugs, bandages or dressings can be used to shorten clotting time and / or accelerate wound healing. The acoustic hydrogel can be applied to the target site by injection to promote wound healing, for example, as a solid in a gel phase, or the temperature can be raised to above 37° C. before application so that the hydrogel is applied in a liquid phase.
[0253] The composition can be applied once. Alternatively, depending on the nature of the wound, the acoustic ECM hydrogel can be applied to the affected area periodically, typically about 1 to 10 times per day, for example, over a period of about 3 to 14 days. In some cases, it may be necessary to apply the composition indefinitely. For example, an ECM hydrogel combined with an exogenous MBV, whether an acoustic ECM hydrogel or an enzymatic ECM hydrogel, can be applied locally (e.g., topically) to the subject's body tissue, whether the tissue is external tissue (e.g., skin) or internal tissue (e.g., colon, small intestine, esophagus, throat, or stomach).
[0254] In some aspects, the composition enhances hemostasis and / or promotes wound healing by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 100%, or at least 200% compared to a control (e.g., a standard value, a wound healing rate or hemostasis rate achieved without treatment, or a wound healing rate or hemostasis rate achieved with ECM hydrogel treatment alone or MBV treatment alone).
[0255] The disclosed compositions can also be used to treat surgical wounds and other intentional interventions in which the compositions can be applied immediately after surgery is completed. Methods are provided for stimulating wound healing and enhancing hemostasis at wound sites, including surgical wounds, excisional wounds, deep wounds involving dermal and epidermal damage, eye tissue wounds, dental tissue wounds, oral wounds, diabetic ulcers, dermal ulcers, elbow ulcers, arterial ulcers, venous stasis ulcers, and burns caused by thermal exposure or chemicals.
[0256] The subject can be any mammalian subject of interest, including a human subject or an animal subject. The subject can be a child subject or an adult subject, such as a young subject, a middle-aged subject or an elderly subject. In humans, an adult subject is greater than 18 years old, a young subject is about 18 to about 35 years old, a middle-aged subject is generally considered to be about 35 to about 55 years old, and an advanced age (or elderly) human subject is more than about 55 years old (e.g., more than 60 years old, more than 65 years old, more than 70 years old, more than 75 years old or more than 80 years old).
[0257] The subject can heal wounds at a normal speed, or may have a healing disorder. Many discomforts and conditions can cause healing disorders. These include diabetes (e.g., type II diabetes), steroids and other drug treatments, and ischemic obstruction or damage (e.g., ischemic obstruction or damage in peripheral vascular disease or traumatic vascular occlusion). The conditions that induce abnormal wound healing include, but are not limited to, uremia, malnutrition, vitamin deficiency, obesity, infection, immunosuppression, and complications associated with systemic treatment with steroids, radiotherapy, antitumor drugs, and antimetabolites. It has been shown that the steroids that cause wound healing disorders include cortisone, hydrocortisone, dexamethasone, and methylprednisolone. Nonsteroidal compounds (e.g., octreotide acetate) have also been shown to cause wound healing disorders (Waddell et al., Am.Surg.63:446 449,1997).
[0258] The subject may have a coagulation disorder, or be taking an anticoagulant (such as but not limited to warfarin or ) treatment. The subject may suffer from factor II, V, VII, X or XII deficiency. The subject may suffer from hemophilia A, hemophilia B, von Willebrand disease, fibrinogen or prothrombin deficiency or structural abnormalities. Therefore, in certain aspects, these subjects are selected for treatment.
[0259] Also provided herein is a method for enhancing the adhesion of skin grafts to wound beds and stimulating the re-epithelialization of the wound beds. The types of grafts include, but are not limited to, autologous skin grafts, artificial skin, allografts, autologous dermal grafts, autologous epidermal grafts, avascular grafts, cloth-cloth grafts, bone grafts, embryonic grafts, skin grafts, delayed grafts, dermal grafts, epidermal grafts, fascia grafts, full-thickness skin grafts, allogeneic grafts, xenografts, homologous grafts, hyperplastic grafts, corneal lamellar grafts, mesh grafts, mucosal grafts, Ao-Ti two-grafts, retinal grafts, patch grafts, pedicle grafts, penetrating corneal grafts, split-layer skin grafts, and thick split-layer skin grafts. The method includes applying a therapeutically effective amount of the composition disclosed herein to the subject with the transplant, thereby enhancing the adhesion and acceptability of the transplant, and controlling or eliminating bacterial growth. In some aspects, the cells or tissues treated with the composition are transplanted into the subject. In one specific non-limiting example, the composition is applied to a graft, such as a skin graft, prior to transplantation.
[0260] Also provided are methods for treating blisters and burns caused by abrasion or chemical injury. These methods include treating the skin or internal organs. These methods include treating ovarian damage (e.g., due to chemotherapy drug treatment or cyclophosphamide treatment); radiation or chemotherapy-induced cystitis; or high-dose chemotherapy-induced intestinal damage. The method comprises administering to the subject a therapeutically effective amount of a composition as disclosed herein to promote healing of blisters or burns and reduce or eliminate bacterial growth.
[0261] Provided are methods for promoting the healing of anastomotic wounds and other wounds caused by individual surgical procedures. These methods include applying an effective amount of the composition disclosed herein after and / or during anastomotic surgery or other surgery. Anastomosis is the connection of two tubular structures, for example, when the middle section of the intestine is removed and the rest is connected together to reconstruct the intestine. Unlike skin healing, the healing process of anastomotic wounds is usually invisible. In addition, wound healing, at least in the gastrointestinal tract, proceeds rapidly without complications; however, complications usually require correction by additional surgery (Thornton and Barbul, Surg. Clin. North Am. 77: 549 573 (1997)). The method may include selecting a subject who needs anastomotic wound healing. The subject may be a subject with a wound healing disorder due to one of the above-mentioned conditions, or may be a subject with normal wound healing, such as a subject who does not suffer from any of the above-mentioned conditions.
[0262] In some aspects, the composition is used to treat or prevent surgical adhesions, for example, to form scar tissue bands that bind tissues or organs that are not normally connected. The composition comprising an ECM hydrogel (containing exogenous MBV) disclosed herein can be arranged on a tissue surface or between tissues that do not require adhesion, for example, by local application or injection during surgery. The surgery can be an abdominal surgery, such as a hernia operation, a cesarean section, an appendectomy, or a resection of any part of the gastrointestinal tract (e.g., the colon, rectum, or anus). For example, the disclosed composition is applied to the abdominal wall and tissues or organs that cause hernias, such as the small intestine, large intestine, or stomach. The disclosed composition is applied to the uterus and surrounding tissues to prevent adhesions after cesarean section.
[0263] In some aspects, the composition is sterilized. Sterilization is important to ensure that the composition is sufficiently free of pathogen contamination and suitable for medical use (e.g., implantation in humans or animals). Although other sterilization methods known in the art may also be suitable, such as gamma radiation, ethylene oxide, supercritical CO 2 , hydrogen peroxide gas plasma or ozone methods may be suitable for sterilization. Gamma sterilization is an acceptable sterilization method.
[0264] Use as a submucosal liner
[0265] Endoscopy is the examination of the interior of hollow organs or cavities in the body without invasive surgery, using an instrument called an endoscope. Endoscopy can be used for surgical procedures, such as cauterizing bleeding vessels, removing polyps, adenomas and small tumors, taking biopsies or removing foreign bodies. Endoscopic procedures can be performed in the gastrointestinal tract, respiratory tract, ear, urinary tract, female reproductive system, and through small incisions in normally closed body cavities, such as the abdomen or pelvis (laparoscopy), inside joints (arthroscopy), and chest organs (thoracoscopy and mediastinoscopy). Endoscopy can be performed in the upper or lower gastrointestinal tract. An endoscope is a lighted instrument, usually fiberoptic, flexible or rigid, tubular instrument, used to view the interior of a hollow organ or part (such as the bladder, esophagus, stomach or intestine) for diagnostic or therapeutic purposes, and it usually has one or more working channels to enable instruments (such as forceps, electric scalpel, endoscopic injection needle or scissors) to pass through or to facilitate the removal of biological specimens. It includes a suitable light and imaging device at its distal portion and can be inserted through a natural opening of the body, such as the mouth, anus, ear, nose, or through a small surgical incision. In view of the wide variety of body organs or cavities that can be examined by endoscopic surgery, there are several types of specialized endoscopes, such as laryngoscopes, thoracoscopes, angioscopes, colonoscopes, enteroscopes, sigmoidoscopes, rectoscopes, proctoscopes, anoscopes, arthroscopes, rhinoscopes, laparoscopes, hysteroscopes, encephaloscopes, nephroscopes, esophagoscopes, bronchoscopes, gastroscopes, amniographs, cystoscopes.
[0266] Endoscopic surgery is widely used in the gastrointestinal tract, including the upper and lower GI tract. For example, endoscopic surgery can be used to examine the mucosa that covers the gastrointestinal lumen and detect large and small pathological lesions, such as inflammatory tissue, polyps, pseudopolyps, serrated lesions, adenomas, ulcers, dysplasia, pre-neoplasia and neoplasia, and tumors. Endoscopic surgery can be used to biopsy and remove pathological lesions (polyps, adenomas, dysplasia, pre-neoplasia and neoplasia, tumors). Surgical interventions include two endoscopic resection procedures that are commonly used during gastrointestinal endoscopy to remove pathological lesions: endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). Both techniques enable minimally invasive treatment of gastrointestinal polyps, adenomas, dysplasia, and early cancers with minimal risk of lymph node metastasis.
[0267] Disclosed herein is a method for dissecting mucosa and submucosa from the muscularis propria of a subject's organ region. The organ may be in the gastrointestinal tract, such as the esophagus, duodenum, stomach, small intestine, large intestine (colon) or rectum. The organ may be a bladder, oral respiratory system organ (lung, throat (pharynx), tongue, nasal passage, sinus), skin or uterus and vagina. Examples of specific tissues are respiratory epithelium, nasal epithelium, dermal tissue or epidermal tissue and uterine epithelium. An exemplary organ is the esophagus. Another exemplary organ is the colon. The method may be used for any organ with mucosa and submucosa, wherein superficial lesions, such as malignant lesions or premalignant lesions, may be formed.
[0268] These methods include injecting a composition of a disclosed ECM hydrogel (containing exogenous MBV) submucosally into an organ of the subject, thereby forming a cushion between the submucosal layer and the underlying muscularis propria of the organ region. In one aspect, the organ is not the esophagus. In another aspect, the organ is the esophagus. In another aspect, the organ is the large intestine (colon). The method can be endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD).
[0269] EMR is an endoscopic technique used to remove sessile or flat tumors confined to the superficial layers (mucosa and submucosa) of the gastrointestinal (GI) tract. EMR is typically used to remove lesions smaller than 2 cm or to remove larger lesions piecemeal. EMR also plays an important role in evaluating the resected specimen for accurate pathological staging. In contrast to polypectomy, EMR involves lifting the lesion from the muscle layer by injecting a fluid agent, usually a normal saline (NS) solution, into the submucosa. EMR can also be used to obtain specimens for accurate histopathological staging to determine the risk of lymph node metastasis. EMR helps to completely remove the affected mucosa by resecting the middle or deeper portions of the submucosa of the intestinal wall. Various EMR techniques have been described, and four methods involving snare resection are commonly used: (1) injection and cutting method; (2) injection, lift, and cut method; (3) transparent cap-assisted EMR (EMRC); and (4) EMR with ligature (EMRL). In the injection and cut technique, the diseased mucosa is lifted from the muscle layer, captured, tightened using an electrosurgical snare, and then excised by creating a submucosal fluid cushion of an ECM hydrogel composition containing exogenous MBV. However, injection into the thin submucosal layer is a delicate process, the injected solution tends to dissipate rapidly, flat, depressed lesions are difficult to capture with a snare compared to protruding lesions, and large or poorly located lesions may be difficult to remove (Uraoka et al., Drug Design, Development and Therapy 2008: 2 131-138). Injection-assisted EMR is often used to treat large, flat colon polyps.
[0270] Endoscopic submucosal dissection (ESD) was developed specifically for the removal of larger lesions. The use of an electrosurgical knife to dissect the lesion directly along the submucosal layer allows for en bloc removal of even large lesions. ESD is expected to replace conventional surgery in the treatment of certain stages of cancer, but because ESD has a higher complication rate of perforation and bleeding than conventional EMR, it requires a higher degree of endoscopic skill and experience than EMR. Many electrosurgical knives can be used for ESD, such as insulated-tip diathermy knives, needle knives, hook knives, spiral retractable knives (flex knives), triangular knives, flush knives, splash-proof needles, and small-caliber tip transparent hoods. These knives can be used with a high-frequency electrosurgical current (HFEC) generator. ESD is characterized by three steps: (1) injecting material (e.g., ECM hydrogel containing exogenous MBV) to form a submucosal pad to elevate the lesion from the muscle layer; (2) making a circumferential cut in the mucosa surrounding the lesion; and (3) stripping the submucosal connective tissue beneath the lesion (see Kakushima et al., Wold J. Gstroenterol. 14(9):2962-2967, 2008, incorporated herein by reference). Various submucosal injection solutions have been developed and demonstrated satisfactory results for use during EMR, but the introduction of longer ESD procedures requires longer-lasting solutions to aid in identifying the cut line during submucosal stripping (Uraoka et al., Drug Design, Development and Therapy 2008:2 131-138). The method disclosed herein meets this need.
[0271] Submucosal injection is used for EMR because injecting fluid into the submucosal pad is beneficial for separating the tissue to be removed before capturing the target lesion, such as removing it with a snare, thereby reducing the risk of thermal damage and perforation and bleeding, while also facilitating resection. Submucosal injection plays an important role in EMR surgery because the solution must remain in place for a sufficient time and needs to be formed into a hemispherical shape to facilitate snare removal. In addition, a sufficiently high submucosal lift enables safe submucosal cutting during ESD surgery (Uraoka et al., Drug Design, Development and Therapy 2008: 2 131-138). In addition, since the surgery causes inflammation, any padding retained at the surgical site should have anti-inflammatory properties. The disclosed ECM hydrogel composition including exogenous MBV will reduce stenosis and promote re-epithelialization. The method disclosed now also meets this need.
[0272] In some aspects, the disclosed composition has anti-inflammatory properties, and is cheap, non-toxic, easy to inject and provides a high and lasting submucosal pad. The composition is applied to the injection site with its gel state to form a pad. The pad can be peeled off during the operation so that some hydrogels remain on the underlying muscularis propria, thereby helping to heal. The disclosed composition is conducive to the closure of the wound by removing the mucosa / submucosal layer that is removed. In some aspects, the operation is ESD. In other aspects, the operation is EMR.
[0273] Normal saline (NS) and diluent solutions (e.g., ELEVIEW TM , see U.S. Pat. No. 9,226,996, incorporated herein by reference) have been used as submucosal pads for endoscopic resection, but the inherent characteristics of these solutions make it difficult to manufacture an appropriate submucosal fluid pad, maintain the desired height, and keep the pad in the desired position due to the rapid dispersion of the solutions. In addition, in ESD, once the mucosa / submucosa is removed, these agents will not remain on the underlying muscularis propria. In addition, these agents do not assist in the healing process, such as by reducing inflammation. These needs are met using the disclosed compositions including ECM hydrogels (containing exogenous MBV).
[0274] The compositions disclosed herein (e.g., ECM hydrogels incorporating MBV) can be used in any ESD or ESR. As disclosed in U.S. Pat. No. 9,364,580 (incorporated herein by reference), an endoscopic injection needle is a device that can be long (up to about 230 cm) and includes a relatively long catheter, in which an internal injection tube with a distal injection needle is slidably arranged. A proximal actuation handle is coupled to the catheter and the injection tube so that one moves relative to the other when necessary. A fluid passage to the injection tube is usually provided by a leer connector on the handle. An endoscopic injection needle device is usually delivered to the injection site through the working channel of the endoscope. In order to protect the lumen of the endoscope working channel from damage, before the device is inserted into the endoscope, the handle of the infusion needle device is manipulated to retract the distal injection needle into the lumen of the catheter. This prevents the sharp tip of the injection needle from being exposed when the device moves through the lumen of the endoscope. When the distal end of the endoscopic injection needle device is located at the injection site, the handle is manipulated again to move the injection needle distally out of the lumen of the catheter. When advanced to the most distal position, the length of the exposed portion of the injection needle is about 4-6 mm.
[0275] After puncturing the injection site, the composition comprising the ECM hydrogel (e.g., enzymatically or acoustically produced ECM hydrogel) and MBV (typically contained in a 5 ml to 10 ml syringe with a luer-lock fitting connected to the handle of the injection needle) can be delivered to the injection site, e.g., between the submucosal layer and the underlying muscularis propria, via the injection tube and the injection needle.
[0276] Injection needles and other accessories commonly used during endoscopic surgery, such as snares, clamping devices, biopsy forceps, etc., for polypectomy, pass through one or more specific channels of the endoscope, commonly referred to as working channels or operating channels. Depending on the type of endoscope used in GI endoscopy (e.g., gastroscope, enteroscope, colonoscope, duodenoscope, sigmoidoscope, etc.), the inner diameter of the working channel can vary significantly. However, the inner diameter of the working channel of the most commonly used endoscopes for GI endoscopy ranges from about 2 mm to about 5 mm. Typically, endoscope accessory manufacturers produce accessories with an outer diameter that enables them to fit all working channels. In some aspects, the outer diameter of the endoscopic injection needle, catheter ranges from 1.9 mm to 2.3 mm, such as about 1.9 cm, 2.0 cm, 2.1 cm, 2.2 cm or 2.3 cm. Therefore, considering that the internal injection tube is accommodated in the external catheter, its inner diameter is generally 1 mm or less. The disclosed ECM hydrogel in gel or liquid form can easily pass through these catheters.
[0277] The composition comprising the ECM hydrogel and exogenous MBV can be used in endoscopic resection surgery by drawing a certain volume of the hydrogel from its main container through a syringe, and injecting a suitable volume of the hydrogel directly under the superficial mucosal layer through an endoscopic injection needle inserted into the working channel of the endoscope to deposit the composition into the submucosal layer, which becomes a cushion when in place: the elevation of the mucosal surface allows the endoscopist to easily resect mucosal lesions found during the performance of endoscopic surgery, even if the lesions are flat and therefore do not protrude into the intestinal cavity, esophageal cavity or gastric cavity. At body temperature, the acoustic ECM hydrogel is a viscous but flowable gel that transitions to a liquid phase and can be easily injected under the superficial mucosal layer to form a cushion for this surgery. Because the gel-sol transition takes time, the cushion remains in place for a sufficient time to perform the resection. Enzymatic ECM hydrogels containing exogenous MBV are also suitable for such endoscopic surgeries because they begin to solidify at body temperature, thus providing adequate support for the resected tissue and remaining in place to promote healing of the resected site.
[0278] The presence of at least one dye in the padding can help the endoscopist observe the structures (e.g., submucosal layer and outer muscle wall) below the mucosa, thereby reducing the risk that the endoscopist may cause damage to the structures during the resection operation. The use of the dye can observe the padding cavity and mucosal base. Removing lesions from the mucosal surface produces mucosal wounds. The durability of the padding produced by the injected volume of the pharmaceutical composition enables endoscopic resection surgery to be performed without re-injection. The acoustic ECM hydrogel is injected submucosally into the area of interest (e.g., lesion or tumor area) of the subject's organ to form a padding between the submucosal layer at the organ area and the underlying muscularis propria. The padding can be peeled off so that a portion of the composition remains on the underlying muscularis propria and helps the healing process.
[0279] The disclosed methods are for use in the esophagus. In one non-limiting example, the method comprises a method of stripping esophageal cancer or adenocarcinoma from the esophagus. In another non-limiting example, the method comprises stripping mucosa and submucosa from the esophagus of a subject with Barrett's esophagus. In these aspects, the ECM hydrogel can be made of bladder ECM, small intestinal submucosal (SIS) ECM, esophageal ECM, tracheal ECM, liver ECM, or dermal ECM.
[0280] The disclosed method is also used for other organs. The organ can be any organ of interest, such as an organ of the gastrointestinal tract. The organ can be in the upper gastrointestinal tract, such as the pharynx, tongue or oral cavity. The organ can be a bladder, vagina or uterus. In some aspects, the organ is a colon, duodenum, stomach, cecum, colon, sigmoid colon, rectum, small intestine or large intestine. In a non-limiting example, the organ is a stomach, small intestine or large intestine, and the method includes a method for stripping cancer or adenocarcinoma from the stomach. In other non-limiting examples, the organ is a colon, and wherein the method includes stripping polyps or cancers from the colon. In these aspects, the composition can include an acoustic ECM hydrogel, which can be a bladder acoustic ECM hydrogel, a small intestinal submucosal acoustic ECM hydrogel, an esophageal acoustic ECM hydrogel, a tracheal acoustic ECM hydrogel, a liver acoustic ECM hydrogel or a dermal acoustic ECM hydrogel. The source of the MBV can be the same or different.
[0281] The composition comprising the ECM hydrogel and exogenous MBV as disclosed herein is maintained at or below a temperature to allow it to gel for application as a submucosal pad.
[0282] The composition comprising the ECM hydrogel (e.g., acoustic hydrogel) and exogenous MBV can be maintained at, for example, about 4°C or about room temperature before administration. In one aspect, the acoustic ECM hydrogel can be applied at a temperature of, for example, from 4°C to below 37°C, or 4°C to 25°C. In one aspect, the composition is applied at a temperature below 37°C. An effective amount of the composition as a gel is then used. The composition comprising the ECM hydrogel and exogenous MBV remains as a gel in a subject's tissue at a temperature of approximately 37°C. In one aspect, the acoustic ECM hydrogel (with the exogenous MBV) has a gel to sol transition temperature of about 37°C, so the composition can be used as a submucosal pad because it has sufficient viscosity at body temperature.
[0283] In some aspects, the concentration of ECM in the hydrogel is 25 mg / ml to about 200 mg / ml, for example, about 25 mg / ml to about 100 mg / ml. In other aspects, the concentration of ECM in the hydrogel is about 50 to about 150 mg / ml, for example, about 75 to about 125 mg / ml, for example, about 75 mg / ml, 80 mg / ml, 85 mg / ml, 90 mg / ml, 95 mg / ml, 100 mg / ml, 105 mg / ml, 110 mg / ml, 115 mg / ml, 120 mg / ml or 125 mg / ml. In a specific non-limiting example, the ECM concentration in the hydrogel is about 100 mg / ml.
[0284] The composition may be provided in lyophilized form at room temperature, cold (eg, about 4°C), or frozen (eg, about -20°C), and reconstituted just prior to administration to the anatomical area of interest of the subject.
[0285] The disclosed methods are used for any subject, including human subjects and animal subjects. The subject can be of any age. The subject can be an adult or a teenager. In one aspect, a composition comprising an ECM hydrogel is injected into the target tissue of an organ to form a cushion, and then an endoscopic surgical procedure, such as a resection, is optionally performed on it. The ECM can be from the same species as the subject being treated, or can be from a different species. In some aspects, the subject is a human, and the ECM hydrogel / MBV is derived from human ECM or porcine ECM. In other aspects, the ECM hydrogel / MBV is derived from non-human primates, dogs, cats, horses or cattle. The ECM can also be from a commercial source. In some aspects, the ECM hydrogel / MBV can be derived from any mammalian tissue, such as, but not limited to, porcine tissue or human tissue, and in some non-limiting examples, can be derived from the bladder, small intestine or esophagus.
[0286] The disclosed methods are invasive because they require injection, and the mucosa and submucosal layer are peeled off from the muscularis propria of the intestinal organ area of the subject. In some aspects, the composition is not applied to the surface of the organ (e.g., gastrointestinal organ, e.g., esophagus). The disclosed methods can be used for the esophagus, but can also be used for other tissues. In other aspects, the composition is applied to the organ surface.
[0287] Any of the methods disclosed herein may include injecting a pharmaceutical composition comprising an ECM hydrogel and exogenous MBV submucosally into the subject's organ to form a cushion between the submucosal layer and the underlying muscularis propria of the organ region. The composition gels and peels the mucosa and submucosal layer from the underlying muscularis propria, and inhibits inflammation in the subject's organ region. The composition as a gel can be administered endoscopy or by catheter. In some aspects, the organ is the esophagus, colon, stomach, cecum, colon, sigmoid colon, rectum, small intestine, or large intestine. The composition, as a gel or sol, can also be administered endoscopy or by catheter.
[0288] In some aspects, the resection procedure is an endoscopic mucosal resection or endoscopic submucosal dissection of the esophagus, and the method comprises a method of dissecting esophageal cancer or adenocarcinoma from the esophagus. In more aspects, the method comprises dissecting mucosa and submucosa from the esophagus of a patient suffering from dysplasia. In more aspects, the method comprises dissecting mucosa and submucosa from the esophagus of a subject suffering from Barrett's esophagus.
[0289] In some aspects, the resection procedure is an endoscopic mucosal resection or endoscopic submucosal dissection. In other aspects, the organ is the stomach, small intestine or large intestine, and the method comprises a method of dissecting a polyp, a cancer or an adenocarcinoma from the colon. In more aspects, the method comprises dissecting the mucosa and submucosa from an organ of a patient suffering from dysplasia. In a specific non-limiting example, the method comprises dissecting a polyp or a cancer from the colon.
[0290] The method may also include performing an endoscopic resection on the liner. In some aspects, the method includes separating the liner so that the hydrogel remains on the underlying muscularis propria of the esophagus, and removing the mucosa and submucosa from the esophageal region. In some non-limiting examples, the portion of the hydrogel liner that remains on the underlying muscularis propria downregulates pro-inflammatory macrophage activation in the esophagus.
[0291] The following examples are provided to illustrate specific features of certain aspects of the disclosure, but the scope of the claims should not be limited to those features exemplified.
[0292] Example
[0293] Example 1: Treatment of ulcerative colitis
[0294] To demonstrate the effectiveness of the combined use of ECM hydrogel and MBV, a study was performed to evaluate colon healing after DSS-induced ulcerative colitis in rats.
[0295] Overview of Study Design
[0296] The study population was 15 female Sprague-Dawley rats. The rats were randomly divided into a healthy control group (N=3) or a dextran sulfate sodium (DSS)-treated group (N=12). The animals exposed to DSS were further divided into 5 subgroups: (1) untreated control group (N=3), (2) MBV enema group (N=2), ECM hydrogel enema group (N=2), MBV injected into the dermis ECM acoustic hydrogel enema group (N=2) and multiple MBV intravenous injection group (N=3).
[0297] Table 1. Experimental groups and descriptions
[0298]
[0299] Ulcerative colitis (UC) was induced in rats by exposing them to 5.5% dextran sodium sulfate (DSS) in drinking water ad libitum for 6 days prior to treatment. Animals were evaluated for weight loss, food and water consumption, stool consistency, and fecal blood content throughout disease induction. Figure 1 The animals were treated with the indicated regimen and their colons were removed on day 4 for histological analysis.
[0300] Detailed procedures
[0301] Animals and Housing: Animal studies were conducted in accordance with all regulations for humane handling of experimental animals established by the Institutional Animal Care and Use Committee of the University of Pittsburgh. Female Sprague-Dawley rats, 8-12 weeks of age, were obtained from a certified supplier (Jackson Labs). After shipment, the rats were acclimated for 7-10 days. The animals were housed under standard laboratory conditions with a temperature of 21-23°C and a 12-h dark / light cycle. The rats had free access to food and water. At the time of study, the animals were housed individually to collect appropriate data.
[0302] Preparation and administration of dextran sulfate sodium: Dextran sulfate sodium (DSS) salt (molecular weight 36,000-50,000) was obtained from MP Biomedical. A 5.5% DSS solution was prepared in autoclaved tap water and administered ad libitum for 6 days.
[0303] MBV Isolation: Porcine bladder extracellular matrix (ubECM) powder was obtained from ECM Therapeutics (Warrendale, PA). The UBM-ECM powder was enzymatically digested (0.05 mg / mL Liberase, 5 mM CaCl) at 37 °C. 2 The enzymatically digested ECM was centrifuged at 10,000×g for 30 min at 4°C. The supernatant was ultracentrifuged at 28,000×g for 70 min. The precipitate was washed once with PBS and then resuspended in particle-free 1×PBS. The average particle size and concentration of the MBV suspension were determined by nanoparticle tracking analysis (NTA) using NanoSight NS500. The MBV suspension (238 nm, 1.10×10 12 Particles / mL) were stored at -20°C until use.
[0304] MBV enema: Increase the volume of MBV suspension to 5 mL with 1X PBS and place in a 5 mL syringe to a concentration of 1.38 × 10 11 particles / mL, or 6.9×10 per enema 11 Particles.
[0305] Dermal ECM Acoustic Hydrogel Enema: Dermal ECM powder was provided by ECM Therapeutics (Warrendale, PA). A 50 mg / mL dermal ECM powder in PBS solution was prepared by sonicating the ECM at 40% amplitude for 5 minutes. The solution was then added to a 5-mL syringe and placed at 4°C. The syringe containing the 5-mL volume of dermal ECM acoustic hydrogel was stored at 4°C until use.
[0306] MBV-infused dermal ECM acoustic hydrogel enema: Dermal ECM powder was provided by ECM Therapeutics (Warrendale, PA). A 50 mg / mL dermal ECM powder solution in PBS was prepared and sonicated at 40% amplitude for 5 min. After cooling at room temperature for 5-10 min, 5 mL of MBV suspension was added to 35 mL of sonicated solution and mixed gently to a MBV concentration of 1.38 × 10 11 The solution was then added to a 5 mL syringe and allowed to gel, resulting in 6.9 × 10 particles / mL per enema. 11 The syringes containing the hydrogels were stored at 4 °C until use.
[0307] MBV intravenous injection: 300 μL of MBV suspension in 1× PBS solution was placed in a 1 mL syringe, and each injection contained 1.10×10 12Particles / mL or 3.3×10 11 Particles.
[0308] Enema delivery: Rats were anesthetized with 0.5-5% isoflurane by inhalation and placed in a flexible Winged infusion catheter (Terumo, OD = 2 mm) for enema ( Figure 2A -C). The enema solution was administered along the length of the colon using a syringe attached to the catheter; specifically, starting from 8 cm all the way to the anus while gradually withdrawing the catheter, with a total infusion time of approximately 60 seconds. A total of 5 mL of the designated treatment material was contained in the syringe. The rate of enema delivery and the volume of enema material were designed to ensure complete coverage of the colon from proximal to distal locations. The treatment group received daily enemas for 4 days starting immediately after the removal of 5.5% DSS from the drinking water.
[0309] MBV injection delivery: Rats were anesthetized with 0.5-5% isoflurane by inhalation and a volume of 300 uL of material was administered into the caudal vein. Appropriate groups were injected immediately after the removal of 5.5% DSS from the drinking water and 2 days after the removal of DSS.
[0310] In vivo observations: Trained personnel recorded the following data daily: (1) food consumption, (2) water consumption, (3) animal weight, (4) stool consistency, and (5) presence of blood in the stool. Stools were scored based on consistency (0 = normal, 2 = loose, 4 = diarrhea) and the presence of blood (0 = none, 2 = occult blood, 4 = heavy bleeding). Occult blood was detected using the ColoScreen ES Lab Pack fecal occult blood test.
[0311] Colon removal plan: Figure 1 Animals were sacrificed on day 4 as indicated. According to the American Veterinary Medical Association (AVMA) guidelines, animals were sacrificed by CO inhalation. 2 Euthanasia was performed by cervical dislocation. After euthanasia, the colon was removed by a midline abdominal incision. The colon from the rectum to the cecum was longitudinally cut to expose the luminal surface, rinsed with PBS, and then the tissue was scored grossly. The removed colon was photographed and scored. The distal 8 cm of the colon was fixed in 10% neutral formalin fixative for 2 days, paraffin embedded and tissue sectioned (5 um). The samples were stained with hematoxylin and eosin, representative images were taken, and histological examination and scoring were performed.
[0312] Gross Scoring of Colonic Tissue: Colonic injury was grossly assessed according to the indices listed in Table 2. The scores were determined by investigators who were blinded to the treatment groups.
[0313] Table 2. Gross anatomy scoring criteria
[0314] score Appearance 0 normal 1 Local congestion, no ulcer 2 Inflammation, no ulcers 3 Ulcers and inflammation in one area 4 Ulcers and inflammation in two or more areas 5 Multiple ulcers extending more than 1 cm along the length of the colon 6-10 When the lesion extends > 2 cm along the colon, the score is increased by 1 point per cm.
[0315] Histological assessment: Microscopic analysis of the removed tissues was performed as described previously. H&E-stained sections were scored for colonic histomorphological changes as shown in Table 3. Separate scores were given for the degree of ulceration, mild mucosal inflammation, severe mucosal inflammation, mild submucosal inflammation, and severe submucosal inflammation for each tissue section. Scores were determined by investigators who were blinded to the treatment groups. In order to achieve uniformity in scoring, each scorer was provided with a guide document defining the scoring criteria and demonstrating examples.
[0316] Table 3. Histological scoring criteria for H&E stained sections
[0317]
[0318] Macrophage analysis by immunofluorescence staining: The excised colon was analyzed by immunofluorescence staining of macrophages. The slides were dewaxed by a series of xylene and ethanol washes followed by water washes. The slides were stained with citrate antigen retrieval buffer (10 mM citrate, pH 6.0) at high temperature in a microwave oven for 15 min and then in copper sulfate buffer (10 mM CuSO 4 , 50mM ammonium acetate) to facilitate antigen retrieval of tissue sections. Blocking solution (Pierce protein-free blocking buffer, 4% goat serum, 2% BSA, 0.1% Triton, 0.1% Tween; Pierce protein-free blocking buffer) was incubated on slides for 10 minutes. The tissues were then microwaved for 3 minutes at medium-low settings with primary antibodies (goat anti-CD206 1:100; rabbit anti-TNFα 1:100; mouse anti-CD68 1:100), incubated for 3 minutes, and then washed with TBS-T. Secondary antibodies (rabbit anti-goat HRP 1:100; goat anti-rabbit HRP 1:100; goat anti-mouse HRP 1:100) were microwaved for 3 minutes at medium-low settings with tissues and incubated for 3 minutes, then washed. Opal reagent (green, red, and blue 1:100 in appropriate dilutions) was incubated with tissues for 10 minutes in the dark, then washed. Antigen retrieval and antibody incubation were performed in duplicate for each staining. DRAQ5 was used as a nuclear marker. Tissue sections were then fixed with an antifade reagent and imaged.
[0319] Results - In vivo observation
[0320] Food and water consumption: From day -5 to day 4, the food and water consumed by each rat were measured daily ( Figure 3 ). Water intake appeared to increase in the disease-induced group on day 1 after the DSS water was removed and normal water was given. Overall, food consumption remained stable throughout the study.
[0321] Body weight changes: Rats were weighed once daily from day -6 to day 4. Individual rat weights were normalized to their starting weight on day -6 ( Figure 4 ). During the first three days of exposure of the rats to DSS, there appeared to be an overall loss of body weight. Overall, body weight appeared to stabilize once the DSS water was removed and treatment began.
[0322] Fecal hardness and blood content: Fecal hardness scores and blood scores were determined daily for each rat. In the scoring system for both indicators, higher scores indicate higher levels of disease. Individual rat scores for fecal hardness and blood content were normalized to the scores given on day 0 to determine changes from the end of disease induction to the end of treatment ( Figure 5 ). All treatment groups appeared to show a reduction in disease progression.
[0323] Clinical and histological findings
[0324] After removal, the length of the colon was measured from the cecum to the rectum as an indicator of disease activity, with shorter colons corresponding to more severe disease states. Overall, all animals given DSS appeared to have shorter colons than healthy controls, as expected. The colon was examined macroscopically for evidence of congestion, inflammation, and ulceration. Overall, as expected, Figure 6 As shown, the total scores of treated animals appeared to be lower than those of untreated animals.
[0325] Histological analysis is shown in Figures 7A-7G , and are discussed in detail below.
[0326] Normal healthy colon tissue: Fig. 7A and Figure 7G The colon tissue shown in (i) was obtained from a healthy animal and is characterized by a mucosa of uniform thickness with a confluent layer of epithelial cells. The lamina propria has a normal amount of cells and the underlying muscularis mucosa is well defined. The submucosa contains a normal number of monocytes, most of which are dormant macrophages. The deepest layer is a thick muscle layer, called the muscularis externa. This tissue section represents normal healthy colon tissue.
[0327] Diseased Colon: Figure 7B and Figure 7G(ii) The colon tissue shown was obtained from an animal treated with 5.5% DSS for 6 days, after which the animal received no therapeutic intervention. The mucosal morphology was significantly destroyed. There were small clusters of mucosal epithelial cells that were widely distributed, which was evidence of an attempt to regenerate the mucosal epithelium and restore the normal barrier function of the mucosal layer. Unlike normal, healthy colons, there was no confluent layer of epithelial cells. The cell mass of the lamina propria increased, indicating an inflammatory response of the host to tissue damage and invasion of toxic colonic contents. The muscularis mucosa, which normally separates the mucosa from the underlying submucosa, was significantly destroyed. The cell mass of the lamina propria and submucosa increased significantly, and two nodules of lymphocyte accumulation (black circular areas) could be seen in the submucosa of the diseased colon. The outer muscularis was normal (all samples were the same).
[0328] ECM hydrogel treatment group: Fig.7D and Figure 7G (iii) The colon tissue shown was obtained from an animal treated with an ECM acoustic hydrogel made of dermal ECM. The colon mucosa was partially restored, as evidenced by an increase in the number of mucosal epithelial cells compared to the diseased colon group. The cell mass of the lamina propria and submucosa was less than that of the diseased group, but not as low as that of the normal colon group. The muscularis mucosa was clearly visible and intact. This histological appearance represents partial healing of the colon mucosa.
[0329] MBV+saline treatment group: Figure 7C and Figure 7G As shown in (vi), the histological appearance of the colon tissue in this group was very similar to that of the ECM hydrogel-treated group. The colon mucosa was partially restored, the muscularis mucosa remained intact, and the number of macrophages contained in the submucosal layer increased slightly.
[0330] ECM hydrogel + MBV treatment group: Exemplary tissues of this group are as follows: Fig. 7E and Figure 7G (v) and showed significant and almost complete replacement of the mucosa, muscularis mucosa and submucosa. It was clearly different from the diseased colon group. The mucosal epithelial cell population was almost completely replaced, and the cell mass of the lamina propria and submucosa was close to normal. The muscularis mucosa was intact. Surprisingly and unexpectedly, the histological samples of the ECM hydrogel + MBV group were almost indistinguishable from normal, healthy colon mucosa, indicating that the combination of ECM hydrogel + MBV has a synergistic effect on the healing of colon tissue, which is not seen when ECM hydrogel or MBV (enema or intravenous administration) is used alone.
[0331] Summary: The group that did not receive ECM in any way had a markedly destructive outcome with minimal attempts at colon mucosal replacement and repair. All MBV groups showed partial replacement of the colon mucosa, while the disease-only group showed minimal replacement. The combination of ECM hydrogel and MBV induced an almost complete repair of the colon mucosa. The combination of IV MBV and ECM hydrogel significantly outperformed the results of all other MBV groups.
[0332] Further histological evaluation
[0333] Histological samples of the treated tissues were evaluated at higher magnification microscopy and macroscopic observation showed that the treated samples had less inflammation than the diseased samples. The mucosa of the treated animals qualitatively appeared healthier in terms of the presence and organization of the crypts. By macroscopic observation of the hematoxylin and eosin stained samples, the samples treated with the combination of ECM hydrogel and MBV ( Fig.11D ) showed a healthier mucosa and submucosa, with clearly organized intestinal crypts and minimal cellular infiltration. Fig.11A ), intestinal crypts were completely lost in many areas, whereas in treated samples ( Figures 11B-11E ) cells seem to begin to move towards a healthy ( Fig. 7A ) Common orientation and structural reorganization of the colonic mucosa and submucosa.
[0334] In addition, if Fig.11D As shown, compared with topical application of MBV+PBS ( Fig. 11C ) or topical application of ECM hydrogel alone ( Fig. 11B ), the effect of topical administration of MBV-infused ECM hydrogels to the rat colon improved the health of the mucosa and submucosa as demonstrated by histology, suggesting that the combination may have a synergistic effect on healing the colon.
[0335] MBV treatment was shown to modulate macrophages toward an M2 or pro-remodeling phenotype
[0336] MBV has previously been shown to modulate macrophages toward a pro-healing, anti-inflammatory phenotype. This was further demonstrated in the treatment of DSS-induced ulcerative colitis. Figures 12A-12EThe M2:M1 macrophage ratio throughout each tissue layer of the treated rats was further confirmed in the study. The data showed that systemic MBV administration or the ECM hydrogel-MBV enema combination significantly increased the M2:M1 ratio in colon tissue compared to ECM hydrogel enema alone or MBV enema alone. The M2:M1 ratio in colon tissue treated with MBV hydrogel enema was greater than the effect of colon tissue treated with MBV enema alone or hydrogel enema alone, even when the two were added together, suggesting that the combination of MBV and hydrogel has a synergistic effect on the regulation of macrophages in colon tissue toward the M2 phenotype, and therefore has a synergistic effect on the M2:M1 macrophage ratio. In addition to counting M2 and M1 cells throughout the colon ( Fig. 12A ), and also counted the various histological layers of colonic tissue (i.e., mucosa, muscularis, submucosa, see Fig. 12B , Fig. 12C and Fig.12D ) in the ECM hydrogels. Overall, the data showed that adding MBV to the ECM hydrogels had a synergistic effect on the M2:M1 ratio, rather than just an additive effect. In addition, systemic administration of MBV or administration of MBV in the ECM hydrogels significantly reduced the number of CD68+ cells ( Fig.12E ), indicating a decrease in the total number of macrophages in these tissues.
[0337] Summarize
[0338] As described above, disease progression during the study was followed by in vivo observations, including water consumption, food consumption, body weight, stool consistency, and the presence of blood in the stool. Successful challenge of DSS-induced ulcerative colitis in the test animals was confirmed by a decrease in body weight, an increase in stool consistency scores, and the presence of blood in the stool.
[0339] Overall, the data showed that ECM hydrogels supplemented with exogenous MBV improved healing rates in a DSS-induced ulcerative colitis (UC) rat model based on in vivo observations, histological analysis, and macrophage polarization analysis. In vivo observations showed faster recovery rates in all treatment groups compared to the disease controls. Gross scores and histology confirmed the in vivo observations, which showed lower severity of colonic disease both macroscopically and microscopically. The organization and density of the mucosa and submucosa in the treatment groups showed signs of improved healing rates through the presence of intestinal crypts, lower levels of inflammation, and higher levels of mucosal organization. Macrophages in the treatment groups showed a greater shift toward a remodeling phenotype compared to the disease group alone, further confirming the ability and results of improved healing rates due to treatment.
[0340] The results of the above studies suggest that MBV-infused ECM hydrogels have strong therapeutic potential in the treatment of intestinal inflammatory diseases, such as inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.
[0341] In view of the fact that the principles of the present invention can be applied to many possible aspects, it should be recognized that the aspects shown are merely examples of the present invention and should not be considered as limitations on the scope of the present invention. Instead, the scope of the present invention is defined by the following claims. Therefore, we claim all that is within the scope and spirit of these claims as our invention.
Claims
1. A composition comprising an extracellular matrix (ECM) hydrogel, the extracellular matrix (ECM) hydrogel comprising: a) dissolved extracellular matrix (ECM); and b) Exogenous matrix-bound nanovesicles (MBVs) derived from the extracellular matrix, wherein the MBVs do not express CD63 and CD81 or are CD63 lo CD81 lo , and wherein the MBV does not contain alkaline phosphatase, wherein the exogenous MBV is present in the ECM hydrogel at a concentration of at least about 1×10 5 Up to 1×10 20 particles / mL, and wherein the composition: i) is shear-thinning; ii) a storage modulus (G') of about 50 Pa to about 200 Pa and a loss modulus (G") of about 5 Pa to about 20 Pa at 37°C, and a G' to G" ratio of about 4:1 to about 15:1, and iii) The degradation rate was 50% within 24 hours to 14 days.
2. The composition of claim 1, wherein the ECM hydrogel is an acoustic hydrogel.
3. The composition of claim 1, wherein the ECM hydrogel is an enzymatic hydrogel.
4. A composition comprising: an acidic solution comprising exogenous acid proteases and dissolved extracellular matrix; and Exogenous MBV derived from extracellular matrix, wherein the MBV does not express CD63 and CD81 or CD63 lo CD81 lo , and wherein the MBV does not contain alkaline phosphatase, wherein the exogenous MBV is present in the composition at a concentration of at least about 1×10 5 About 1×10 20 Particles / mL, Wherein when the acidic solution is neutralized to a pH of about 7.0 to about 7.8, a gel is formed at a temperature above 25°C.
5. A composition comprising: dissolved extracellular matrix; Inactivated exogenous acid proteases; Exogenous MBV derived from extracellular matrix, wherein the MBV does not express CD63 and CD81 or CD63 lo CD81 lo , and wherein the MBV does not contain alkaline phosphatase, wherein the exogenous MBV is present in the composition at a concentration of at least about 1×10 5 Up to 1×10 20 Particles / mL, wherein the composition enters a liquid phase at a temperature below 25°C and enters a gel phase at a temperature above 25°C; wherein the pH of the composition is between about 7 and about 7.
8.
6. The composition of any one of claims 1-5, further comprising pulverized ECM.
7. The composition of any one of claims 1 to 6, wherein the exogenous MBV is present in the composition at a concentration of about 1×10 6 Up to 1×10 - .
8. The composition of any one of claims 1-3 or 6-7, wherein the dissolved ECM is present in the ECM hydrogel in an amount of 1 mg / mL to 500 mg / mL.
9. The composition of claims 4-7, wherein the solubilized ECM is present in the composition in an amount of 1 mg / mL to 500 mg / mL.
10. The composition of claim 9, wherein the solubilized ECM is present in an amount of 5 mg / mL to 50 mg / mL.
11. The composition of any one of claims 1-10, wherein the ECM hydrogel or dissolved ECM comprises intact ECM.
12. The composition of any one of claims 1-11, wherein the MBV is derived from the extracellular matrix of the bladder, small intestine, heart, dermis, liver, kidney, uterus, brain, blood vessels, lung, bone, muscle, pancreas, placenta, stomach, spleen, colon, adipose tissue, or esophagus.
13. The composition of any one of claims 1-11, wherein the MBV is not derived from bone ECM or cardiac ECM.
14. The composition of any one of claims 1-11, wherein the MBV is derived from the extracellular matrix of the bladder, small intestine, dermis, liver, kidney, uterus, brain, blood vessels, lung, muscle, pancreas, placenta, stomach, spleen, colon, adipose tissue, or esophagus.
15. The composition of any one of claims 1-11, wherein the MBV is derived from urinary bladder matrix (UBM), small intestinal submucosa (SIS), or urinary bladder submucosa (UBS).
16. The composition of any one of claims 1-15, wherein the MBV is derived from the extracellular matrix of a mammalian vertebrate selected from humans, monkeys, pigs, cows, or sheep.
17. The composition of any one of claims 1-16, wherein the ECM hydrogel is derived from the extracellular matrix of the bladder, small intestine, heart, dermis, liver, kidney, uterus, brain, blood vessels, lung, bone, muscle, pancreas, placenta, stomach, spleen, colon, adipose tissue, or esophagus.
18. The composition of any one of claims 1-16, wherein the ECM hydrogel is derived from urinary bladder matrix (UBM), small intestinal submucosa (SIS), or urinary bladder submucosa (UBS).
19. The composition according to any one of claims 4-18, wherein the acidic protease is pepsin or trypsin, or a combination thereof.
20. The composition of any one of claims 5-19, wherein the pH of the composition is about 7.
2.
21. The composition of any one of claims 5-19, wherein the pH of the composition ranges from 7.2 to 7.
4.
22. The composition of any one of claims 1-21, wherein the dissolved ECM is present in the composition in an amount between 10 mg / mL and 30 mg / mL.
23. The composition of any one of claims 1-22, wherein the exogenous MBV is present in the composition at a concentration of a) about 1×10 12 particles / mL; b) about 1×10 11 particles / mL; c) about 1×10 10 particles / mL; d) about 1×10 9 particles / mL; or about 1×10 8 About 1×10 11 .
24. The composition of any one of claims 1-23, formulated for topical administration or as an enema.
25. A method for treating a subject suffering from inflammatory bowel disease, comprising: Administering an effective amount of the composition of any one of claims 1-23 to the subject, thereby treating inflammatory bowel disease in the subject.
26. The method of claim 25, wherein the composition is administered to the intestinal tract of the subject by enema.
27. The method of claim 25, wherein the composition is administered orally.
28. The method of any one of claims 25-27, wherein the method reduces inflammation in the subject's colon.
29. The method of any one of claims 25-28, wherein the subject has ulcerative colitis.
30. The method of claim 29, wherein the subject's Mayo score or Ulcerative Colitis Disease Activity Index score is reduced after administration of the composition.
31. The method of claim 30, wherein the score decreases within 1 month, 2 months, 3 months or more from receiving the administration.
32. The method of any one of claims 25-31, wherein the subject has Crohn's disease.
33. The method of claim 32, wherein the subject's Crohn's Disease Activity Index score decreases after administration of the composition.
34. The method of claim 33, wherein the Crohn's Disease Activity Index score decreases within 1 month, 2 months, 3 months or more from receiving the composition.
35. A method for treating a subject suffering from esophageal inflammation, comprising: Administering an effective amount of the composition of any one of claims 1-24 to the esophagus of the subject, thereby treating esophageal inflammation in the subject.
36. The method of claim 35, wherein the composition is administered topically to the esophagus.
37. The method of any one of claims 25-36, wherein the subject is a human.
38. The method of any one of claims 25-34 or 37, wherein administering the composition to the subject increases the number of M2 macrophages compared to M1 macrophages in the subject's intestine.
39. The method of claim 38, wherein the subject's intestinal tract is the subject's colon.
40. The method of any one of claims 35-37, wherein administering the composition to the subject increases the number of M2 macrophages compared to M1 macrophages in the esophagus of the subject.
